Prolactin	O
and	O
dopamine	O
:	O
what	O
is	O
the	O
connection	O
?	O

A	O
review	O
article	O
.	O

Dopamine	O
(	O
DA	O
)	O
holds	O
a	O
predominant	O
role	O
in	O
the	O
regulation	O
of	O
prolactin	O
(	O
PRL	O
)	O
secretion	O
.	O

Through	O
a	O
direct	O
effect	O
on	O
anterior	O
pituitary	O
lactotrophs	O
,	O
DA	O
inhibits	O
the	O
basally	O
high	O
-	O
secretory	O
tone	O
of	O
the	O
cell	O
.	O

It	O
accomplishes	O
this	O
by	O
binding	O
to	O
D2	O
receptors	O
expressed	O
on	O
the	O
cell	O
membrane	O
of	O
the	O
lactotroph	O
,	O
activation	O
of	O
which	O
results	O
in	O
a	O
reduction	O
of	O
PRL	O
exocytosis	O
and	O
gene	O
expression	O
by	O
a	O
variety	O
of	O
intracellular	O
signalling	O
mechanisms	O
.	O

The	O
hypothalamic	O
dopaminergic	O
neurons	O
,	O
which	O
provide	O
DA	O
to	O
the	O
anterior	O
pituitary	O
gland	O
,	O
are	O
themselves	O
regulated	O
by	O
feedback	O
from	O
PRL	O
through	O
a	O
's	O
hort	O
-	O
loop	O
feedback	O
mechanism	O
'	O
.	O

A	O
variety	O
of	O
other	O
modulators	O
of	O
prolactin	O
secretion	O
act	O
at	O
the	O
hypothalamic	O
level	O
by	O
either	O
disinhibition	O
of	O
the	O
dopaminergic	O
tone	O
(	O
e.g.	O
serotonin	O
,	O
GABA	O
,	O
oestrogens	O
and	O
opioids	O
)	O
or	O
by	O
reinforcing	O
it	O
(	O
e.g.	O
substance	O
P	O
)	O
.	O

All	O
typical	O
antipsychotic	O
medications	O
are	O
associated	O
with	O
sustained	B
hyperprolactinaemia	I
due	O
to	O
their	O
high	O
affinity	O
for	O
the	O
D2	O
receptor	O
and	O
their	O
slow	O
dissociation	O
from	O
the	O
receptor	O
once	O
bound	O
,	O
but	O
atypicals	O
differ	O
quite	O
dramatically	O
in	O
their	O
propensity	O
to	O
cause	O
prolonged	O
high	O
prolactin	O
levels	O
.	O

Of	O
those	O
atypicals	O
that	O
are	O
associated	O
with	O
prolactin	O
elevation	O
,	O
the	O
main	O
causative	O
factor	O
appears	O
to	O
be	O
a	O
higher	O
peripheral	O
-	O
to	O
-	O
central	O
dopamine	O
receptor	O
potency	O
of	O
either	O
the	O
parent	O
drug	O
or	O
its	O
active	O
metabolite	O
(	O
e.g.	O
risperidone	O
,	O
9	O
-	O
hydroxy	O
-	O
risperidone	O
and	O
amisulpride	O
)	O
.	O

Antipsychotics	O
that	O
easily	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
exhibit	O
fast	O
dissociation	O
from	O
the	O
dopamine	O
receptor	O
once	O
bound	O
do	O
not	O
result	O
in	O
sustained	B
hyperprolactinaemia	I
.	O

Arsenic	O
upregulates	O
MMP	O
-	O
9	O
and	O
inhibits	O
wound	B
repair	O
in	O
human	O
airway	O
epithelial	O
cells	O
.	O

As	O
part	O
of	O
the	O
innate	O
immune	O
defense	O
,	O
the	O
polarized	O
conducting	O
lung	O
epithelium	O
acts	O
as	O
a	O
barrier	O
to	O
keep	O
particulates	O
carried	O
in	O
respiration	O
from	O
underlying	O
tissue	O
.	O

Arsenic	O
is	O
a	O
metalloid	O
toxicant	O
that	O
can	O
affect	O
the	O
lung	O
via	O
inhalation	O
or	O
ingestion	O
.	O

We	O
have	O
recently	O
shown	O
that	O
chronic	O
exposure	O
of	O
mice	O
or	O
humans	O
to	O
arsenic	O
(	O
10	O
-	O
50	O
ppb	O
)	O
in	O
drinking	O
water	O
alters	O
bronchiolar	O
lavage	O
or	O
sputum	O
proteins	O
consistent	O
with	O
reduced	O
epithelial	O
cell	O
migration	O
and	O
wound	B
repair	O
in	O
the	O
airway	O
.	O

In	O
this	O
report	O
,	O
we	O
used	O
an	O
in	O
vitro	O
model	O
to	O
examine	O
effects	O
of	O
acute	O
exposure	O
of	O
arsenic	O
(	O
15	O
-	O
290	O
ppb	O
)	O
on	O
conducting	O
airway	O
lung	O
epithelium	O
.	O

We	O
found	O
that	O
arsenic	O
at	O
concentrations	O
as	O
low	O
as	O
30	O
ppb	O
inhibits	O
reformation	O
of	O
the	O
epithelial	O
monolayer	O
following	O
scrape	O
wounds	O
of	O
monolayer	O
cultures	O
.	O

In	O
an	O
effort	O
to	O
understand	O
functional	O
contributions	O
to	O
epithelial	O
wound	B
repair	O
altered	O
by	O
arsenic	O
,	O
we	O
showed	O
that	O
acute	O
arsenic	O
exposure	O
increases	O
activity	O
and	O
expression	O
of	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-	O
9	O
,	O
an	O
important	O
protease	O
in	O
lung	O
function	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
MMP	O
-	O
9	O
in	O
arsenic	O
-	O
treated	O
cells	O
improved	O
wound	B
repair	O
.	O

We	O
propose	O
that	O
arsenic	O
in	O
the	O
airway	O
can	O
alter	O
the	O
airway	O
epithelial	O
barrier	O
by	O
restricting	O
proper	O
wound	B
repair	O
in	O
part	O
through	O
the	O
upregulation	O
of	O
MMP	O
-	O
9	O
by	O
lung	O
epithelial	O
cells	O
.	O

Stem	O
cell	O
mobilization	O
with	O
cyclophosphamide	O
overcomes	O
the	O
suppressive	O
effect	O
of	O
lenalidomide	O
therapy	O
on	O
stem	O
cell	O
collection	O
in	O
multiple	B
myeloma	I
.	O

A	O
total	O
of	O
28	O
treatment	O
-	O
na	O
?	O

ve	O
patients	O
with	O
stage	O
II	O
or	O
III	O
multiple	B
myeloma	I
(	O
MM	B
)	O
were	O
treated	O
with	O
the	O
combination	O
of	O
clarithromycin	O
,	O
lenalidomide	O
,	O
and	O
dexamethasone	O
(	O
BiRD	O
)	O
.	O

Stem	O
cells	O
were	O
collected	O
following	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
or	O
cyclophosphamide	O
(	O
Cy	O
)	O
plus	O
G	O
-	O
CSF	O
mobilization	O
at	O
maximum	O
response	O
.	O

Sufficient	O
stem	O
cells	O
for	O
2	O
autologous	O
stem	O
cell	O
transplants	O
were	O
collected	O
from	O
all	O
patients	O
mobilized	O
with	O
Cy	O
plus	O
G	O
-	O
CSF	O
,	O
versus	O
33	O
%	O
mobilized	O
with	O
G	O
-	O
CSF	O
alone	O
(	O
P	O
<	O
.0001	O
)	O
.	O

The	O
duration	O
of	O
prior	O
lenalidomide	O
therapy	O
did	O
not	O
correlate	O
with	O
success	O
of	O
stem	O
cell	O
harvests	O
(	O
P	O
=	O
.91	O
)	O
.	O

In	O
conclusion	O
,	O
Cy	O
can	O
be	O
added	O
to	O
G	O
-	O
CSF	O
for	O
stem	O
cell	O
mobilization	O
to	O
successfully	O
overcome	O
the	O
suppressive	O
effect	O
of	O
prior	O
treatment	O
with	O
lenalidomide	O
.	O

Fluctuating	O
functions	O
related	O
to	O
quality	O
of	O
life	O
in	O
advanced	O
Parkinson	O
disease	O
:	O
effects	O
of	O
duodenal	O
levodopa	O
infusion	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
fluctuations	O
in	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
and	O
motor	O
performance	O
in	O
patients	O
with	O
advanced	O
Parkinson	O
disease	O
(	O
PD	O
)	O
treated	O
with	O
continuous	O
daytime	O
duodenal	O
levodopa	O
/	O
carbidopa	O
infusion	O
or	O
conventional	O
therapy	O
.	O

METHODS	O
:	O
Of	O
18	O
patients	O
completing	O
a	O
6	O
-	O
week	O
trial	O
(	O
DIREQT	O
)	O
,	O
12	O
were	O
followed	O
for	O
up	O
to	O
6	O
months	O
and	O
assessed	O
using	O
electronic	O
diaries	O
and	O
the	O
PD	O
Questionnaire	O
-	O
39	O
(	O
PDQ	O
-	O
39	O
)	O
.	O

RESULTS	O
:	O
During	O
the	O
trial	O
and	O
follow	O
-	O
up	O
,	O
major	O
diurnal	O
fluctuations	O
were	O
observed	O
,	O
especially	O
for	O
hyperkinesia	B
,	O
'	O
off	O
'	O
time	O
,	O
ability	O
to	O
walk	O
and	O
depression	B
.	O

Duodenal	O
infusion	O
was	O
associated	O
with	O
significantly	O
more	O
favourable	O
outcomes	O
compared	O
with	O
conventional	O
treatment	O
for	O
satisfaction	O
with	O
overall	O
functioning	O
,	O
'	O
off	O
'	O
time	O
and	O
ability	O
to	O
walk	O
,	O
with	O
improved	O
outcomes	O
with	O
PDQ	O
-	O
39	O
.	O

CONCLUSIONS	O
:	O
Relative	O
to	O
conventional	O
treatment	O
,	O
infusion	O
therapy	O
may	O
stabilize	O
and	O
significantly	O
improve	O
motor	O
function	O
and	O
patient	O
's	O
QoL	O
.	O

The	O
potential	O
for	O
daily	O
fluctuation	O
in	O
PD	O
symptoms	O
means	O
single	O
measures	O
of	O
treatment	O
effectiveness	O
can	O
result	O
in	O
bias	O
in	O
effect	O
estimates	O
and	O
hence	O
repeated	O
measures	O
are	O
recommended	O
.	O

Apaziquone	O
for	O
non	B
-	I
muscle	I
invasive	I
bladder	I
cancer	I
:	O
a	O
critical	O
review	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
clinical	O
needs	O
in	O
non	B
-	I
muscle	I
invasive	I
bladder	I
cancer	I
(	O
NMIBC	B
)	O
and	O
review	O
the	O
potential	O
of	O
apaziquone	O
in	O
this	O
respect	O
.	O

METHODS	O
:	O
Epidemiology	O
and	O
clinical	O
practice	O
in	O
NMIBC	B
,	O
as	O
well	O
as	O
new	O
drugs	O
and	O
strategies	O
are	O
reviewed	O
.	O

RESULTS	O
:	O
Bladder	B
cancer	I
is	O
a	O
heterogeneous	O
and	O
frequent	O
disease	O
.	O

Clinical	O
risk	O
factors	O
help	O
in	O
determining	O
additional	O
therapy	O
after	O
initial	O
resection	O
.	O

However	O
,	O
current	O
treatments	O
have	O
clear	O
limitations	O
with	O
regard	O
to	O
efficacy	O
and	O
/	O
or	O
toxicity	O
.	O

New	O
drugs	O
and	O
strategies	O
have	O
been	O
tested	O
recently	O
and	O
are	O
in	O
(	O
pre	O
)	O
clinical	O
use	O
.	O

Intravesical	O
apaziquone	O
(	O
EOquin	O
)	O
is	O
a	O
new	O
drug	O
.	O

It	O
has	O
theoretical	O
advantages	O
for	O
intravesical	O
use	O
,	O
has	O
proven	O
safety	O
and	O
is	O
presently	O
under	O
further	O
clinical	O
evaluation	O
.	O

CONCLUSION	O
:	O
Apaziquone	O
is	O
a	O
promising	O
drug	O
for	O
intravesical	O
use	O
in	O
patients	O
with	O
NMIBC	B
.	O

Allopregnanolone	O
impairs	O
episodic	O
memory	O
in	O
healthy	O
women	O
.	O

OBJECTIVE	O
:	O
Allopregnanolone	O
is	O
an	O
endogenous	O
neuroactive	O
steroid	O
that	O
,	O
through	O
its	O
binding	O
to	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
A	O
receptor	O
,	O
has	O
GABA	O
-	O
active	O
properties	O
.	O

Animal	O
studies	O
indicate	O
that	O
allopregnanolone	O
administration	O
results	O
in	O
diminished	B
learning	I
and	O
memory	B
impairment	I
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
intravenously	O
administered	O
allopregnanolone	O
on	O
episodic	O
memory	O
,	O
semantic	O
memory	O
,	O
and	O
working	O
memory	O
in	O
healthy	O
women	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Twenty	O
-	O
eight	O
healthy	O
women	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
participants	O
were	O
scheduled	O
for	O
the	O
memory	O
tests	O
twice	O
in	O
the	O
follicular	O
phase	O
.	O

During	O
the	O
test	O
sessions	O
,	O
an	O
intravenous	O
allopregnanolone	O
and	O
placebo	O
infusion	O
were	O
administered	O
in	O
a	O
double	O
-	O
blinded	O
,	O
randomized	O
order	O
at	O
intervals	O
of	O
48	O
h	O
.	O

Before	O
and	O
10	O
min	O
after	O
the	O
allopregnanolone	O
/	O
placebo	O
injections	O
,	O
memory	O
tasks	O
were	O
performed	O
.	O

RESULTS	O
:	O
The	O
study	O
demonstrated	O
that	O
allopregnanolone	O
impaired	O
episodic	O
memory	O
in	O
healthy	O
women	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
pre	O
-	O
and	O
postallopregnanolone	O
injection	O
episodic	O
memory	O
scores	O
(	O
p	O
<	O
0.05	O
)	O
,	O
whereas	O
there	O
was	O
no	O
change	O
in	O
episodic	O
memory	O
performance	O
following	O
the	O
placebo	O
injections	O
.	O

There	O
was	O
also	O
a	O
significant	O
difference	O
between	O
allopregnanolone	O
and	O
placebo	O
postinjection	O
episodic	O
memory	O
scores	O
(	O
p	O
<	O
0.05	O
)	O
.	O

There	O
were	O
no	O
effects	O
of	O
allopregnanolone	O
on	O
the	O
semantic	O
memory	O
task	O
or	O
working	O
memory	O
task	O
.	O

CONCLUSION	O
:	O
Intravenous	O
allopregnanolone	O
impairs	O
episodic	O
memory	O
in	O
healthy	O
women	O
,	O
but	O
there	O
is	O
a	O
high	O
degree	O
of	O
individual	O
variability	O
.	O

Effect	O
of	O
carbocisteine	O
on	O
acute	O
exacerbation	O
of	O
chronic	B
obstructive	I
pulmonary	I
disease	I
(	O
PEACE	O
Study	O
)	O
:	O
a	O
randomised	O
placebo	O
-	O
controlled	O
study	O
.	O

BACKGROUND	O
:	O
Chronic	B
obstructive	I
pulmonary	I
disease	I
(	O
COPD	B
)	O
is	O
characterised	O
by	O
airflow	O
limitation	O
,	O
and	O
has	O
many	O
components	O
including	O
mucus	O
hypersecretion	O
,	O
oxidative	O
stress	O
,	O
and	O
airway	O
inflammation	O
.	O

We	O
aimed	O
to	O
assess	O
whether	O
carbocisteine	O
,	O
a	O
mucolytic	O
agent	O
with	O
anti	O
-	O
inflammatory	O
and	O
antioxidation	O
activities	O
,	O
could	O
reduce	O
the	O
yearly	O
exacerbation	O
rate	O
in	O
patients	O
with	O
COPD	B
.	O

METHODS	O
:	O
We	O
did	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
709	O
patients	O
from	O
22	O
centres	O
in	O
China	O
.	O

Participants	O
were	O
eligible	O
if	O
they	O
were	O
diagnosed	O
as	O
having	O
COPD	B
with	O
a	O
postbronchodilator	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV	O
(	O
1	O
)	O
)	O
to	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
ratio	O
(	O
FEV	O
(	O
1	O
)	O
/	O
FVC	O
)	O
of	O
less	O
than	O
0.7	O
and	O
an	O
FEV	O
(	O
1	O
)	O
between	O
25	O
%	O
and	O
79	O
%	O
of	O
the	O
predicted	O
value	O
,	O
were	O
aged	O
between	O
40	O
and	O
80	O
years	O
,	O
had	O
a	O
history	O
of	O
at	O
least	O
two	O
COPD	B
exacerbations	O
within	O
the	O
previous	O
2	O
years	O
,	O
and	O
had	O
remained	O
clinically	O
stable	O
for	O
over	O
4	O
weeks	O
before	O
the	O
study	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
1500	O
mg	O
carbocisteine	O
or	O
placebo	O
per	O
day	O
for	O
a	O
year	O
.	O

The	O
primary	O
endpoint	O
was	O
exacerbation	O
rate	O
over	O
1	O
year	O
,	O
and	O
analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

This	O
trial	O
is	O
registered	O
with	O
the	O
Japan	O
Clinical	O
Trials	O
Registry	O
(	O
http://umin.ac.jp/ctr/index/htm	O
)	O
number	O
UMIN	O
-	O
CRT	O
C000000233	O
.	O

FINDINGS	O
:	O
354	O
patients	O
were	O
assigned	O
to	O
the	O
carbocisteine	O
group	O
and	O
355	O
to	O
the	O
placebo	O
group	O
.	O

Numbers	O
of	O
exacerbations	O
per	O
patient	O
per	O
year	O
declined	O
significantly	O
in	O
the	O
carbocisteine	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
(	O
1.01	O
[	O
SE	O
0.06	O
]	O
vs	O
1.35	O
[	O
SE	O
0.06	O
]	O
)	O
,	O
risk	O
ratio	O
0.75	O
(	O
95	O
%	O
CI	O
0.62	O
-	O
0.92	O
,	O
p	O
=	O
0.004	O
)	O
.	O

Non	O
-	O
significant	O
interactions	O
were	O
found	O
between	O
the	O
preventive	O
effects	O
and	O
COPD	B
severity	O
,	O
smoking	O
,	O
as	O
well	O
as	O
concomitant	O
use	O
of	O
inhaled	O
corticosteroids	O
.	O

Carbocisteine	O
was	O
well	O
tolerated	O
.	O

INTERPRETATION	O
:	O
Mucolytics	O
,	O
such	O
as	O
carbocisteine	O
,	O
should	O
be	O
recognised	O
as	O
a	O
worthwhile	O
treatment	O
for	O
prevention	O
of	O
exacerbations	O
in	O
Chinese	O
patients	O
with	O
COPD	B
.	O

Induction	O
of	O
the	O
multixenobiotic	O
/	O
multidrug	O
resistance	O
system	O
in	O
various	O
cell	O
lines	O
in	O
response	O
to	O
perfluorinated	O
carboxylic	O
acids	O
.	O

The	O
multixenobiotic	O
resistance	O
(	O
closely	O
related	O
to	O
multidrug	O
resistance	O
)	O
system	O
controls	O
transport	O
across	O
the	O
plasma	O
membrane	O
as	O
a	O
defense	O
against	O
toxic	O
molecules	O
.	O

Multixenobiotic	O
resistance	O
system	O
consists	O
of	O
an	O
efflux	O
pump	O
,	O
ABCB1	O
(	O
also	O
named	O
P	O
-	O
glycoprotein	O
,	O
P	O
-	O
gp	O
)	O
,	O
and	O
/	O
or	O
a	O
molecule	O
of	O
the	O
ABCC	O
family	O
(	O
also	O
named	O
multiple	O
resistance	O
associated	O
protein	O
,	O
MRP	O
)	O
.	O

ABCB1	O
is	O
able	O
to	O
increase	O
efflux	O
of	O
many	O
low	O
-	O
molecular	O
foreign	O
molecules	O
.	O

Measuring	O
system	O
induction	O
may	O
be	O
used	O
as	O
a	O
biomarker	O
of	O
cell	O
/	O
organism	O
exposure	O
to	O
foreign	O
substances	O
.	O

Various	O
established	O
cell	O
lines	O
were	O
tested	O
for	O
constitutive	O
and	O
induced	O
multixenobiotic	O
resistance	O
proteins	O
by	O
Western	O
blotting	O
immunodetection	O
.	O

The	O
pumping	O
function	O
was	O
indirectly	O
assayed	O
with	O
Rhodamine	O
B	O
by	O
visualization	O
of	O
cell	O
fluorescence	O
in	O
the	O
presence	O
of	O
verapamil	O
.	O

Changes	O
in	O
ABC	O
proteins	O
were	O
measured	O
by	O
flow	O
cytometry	O
after	O
exposition	O
to	O
various	O
perfluorinated	O
carboxylic	O
acids	O
.	O

MCF7	O
and	O
HeLa	O
cells	O
were	O
found	O
to	O
contain	O
the	O
highest	O
constitutive	O
level	O
of	O
both	O
ABCB1	O
and	O
ABCC1	O
.	O

HEK293	O
exhibited	O
much	O
less	O
ABCB1	O
and	O
no	O
activity	O
of	O
pumping	O
out	O
Rhodamine	O
B	O
.	O

The	O
pumping	O
activity	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
amount	O
of	O
the	O
cell	O
-	O
type	O
specific	O
170	O
kDa	O
ABCB1	O
protein	O
.	O

An	O
8	O
-	O
day	O
exposure	O
to	O
10	O
(	O
-	O
4	O
)	O
M	O
perfluorononanoic	O
acid	O
resulted	O
in	O
about	O
2	O
-	O
2.5	O
-	O
fold	O
increase	O
of	O
ABCB1	O
level	O
.	O

That	O
was	O
confirmed	O
also	O
for	O
short	O
times	O
by	O
flow	O
cytometry	O
of	O
cells	O
exposed	O
to	O
perfluorinated	O
acids	O
and	O
its	O
natural	O
congeners	O
.	O

Both	O
ABCB1	O
-	O
and	O
ABCC1	O
-	O
related	O
fluorescence	O
increased	O
along	O
with	O
the	O
carbon	O
chain	O
in	O
acids	O
from	O
C	O
(	O
6	O
)	O
up	O
to	O
C	O
(	O
9	O
)	O
and	O
decreased	O
for	O
C	O
(	O
10	O
)	O
.	O

Measuring	O
of	O
multixenobiotic	O
resistance	O
changes	O
in	O
vitro	O
induced	O
by	O
chemicals	O
may	O
be	O
a	O
convenient	O
test	O
for	O
screening	O
for	O
their	O
potential	O
toxicity	O
.	O

Phase	O
I	O
/	O
II	O
study	O
of	O
biweekly	O
paclitaxel	O
and	O
radiation	O
in	O
androgen	O
-	O
ablated	O
locally	O
advanced	O
prostate	B
cancer	I
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
maximum	O
-	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
concurrent	O
paclitaxel	O
and	O
radiation	O
therapy	O
(	O
RT	O
)	O
in	O
patients	O
with	O
locally	O
advanced	O
prostate	B
cancer	I
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Eligible	O
patients	O
had	O
T2	O
-	O
4	O
tumors	B
with	O
Gleason	O
scores	O
greater	O
than	O
7	O
and	O
/	O
or	O
PSA	O
levels	O
greater	O
than	O
10	O
ng	O
/	O
mL	O
and	O
/	O
or	O
had	O
tumors	B
with	O
pathologic	O
stage	O
TxN1	O
.	O

Hormonal	O
ablation	O
was	O
initiated	O
3	O
months	O
before	O
RT	O
and	O
was	O
given	O
for	O
9	O
months	O
.	O

RT	O
was	O
delivered	O
daily	O
(	O
1.8	O
Gy	O
)	O
with	O
concurrent	O
twice	O
-	O
weekly	O
paclitaxel	O
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O

The	O
whole	O
pelvis	O
was	O
irradiated	O
to	O
39.6	O
Gy	O
.	O

The	O
radiation	O
dose	O
was	O
escalated	O
as	O
follows	O
:	O
63	O
Gy	O
,	O
66.6	O
Gy	O
,	O
70.2	O
Gy	O
,	O
and	O
73.8	O
Gy	O
.	O

The	O
last	O
RT	O
dose	O
level	O
was	O
fixed	O
at	O
73.8	O
Gy	O
.	O

RESULTs	O
:	O
Between	O
January	O
2000	O
and	O
October	O
2006	O
,	O
22	O
patients	O
were	O
enrolled	O
.	O

The	O
median	O
age	O
was	O
59	O
years	O
(	O
range	O
,	O
48	O
to	O
72	O
years	O
)	O
;	O
the	O
median	O
PSA	O
level	O
was	O
22.4	O
ng	O
/	O
mL	O
(	O
range	O
,	O
2.8	O
to	O
113	O
ng	O
/	O
mL	O
)	O
.	O

The	O
number	O
of	O
patients	O
per	O
stage	O
was	O
as	O
follows	O
:	O
three	O
with	O
T1	O
,	O
eight	O
with	O
T2	O
,	O
11	O
with	O
T3	O
,	O
and	O
five	O
with	O
pN1	O
=	O
5	O
.	O

No	O
grade	O
3	O
toxicities	O
occurred	O
at	O
63	O
Gy	O
.	O

Grade	O
3	O
diarrhea	B
occurred	O
in	O
three	O
patients	O
at	O
66.6	O
Gy	O
.	O

The	O
protocol	O
then	O
was	O
amended	O
to	O
treat	O
the	O
prostate	O
volume	O
first	O
followed	O
by	O
the	O
whole	O
pelvis	O
.	O

No	O
grade	O
3	O
toxicities	O
were	O
observed	O
at	O
70.2	O
Gy	O
.	O

One	O
patient	O
experienced	O
grade	O
3	O
diarrhea	B
at	O
73.8	O
Gy	O
.	O

Five	O
additional	O
patients	O
were	O
treated	O
to	O
73.8	O
Gy	O
without	O
grade	O
3	O
toxicity	O
,	O
which	O
established	O
the	O
MTD	O
for	O
combined	O
paclitaxel	O
and	O
RT	O
at	O
73.8	O
Gy	O
.	O

At	O
38	O
months	O
median	O
follow	O
-	O
up	O
(	O
range	O
,	O
9	O
to	O
87	O
months	O
)	O
,	O
21	O
(	O
95	O
%	O
)	O
of	O
22	O
patients	O
are	O
alive	O
.	O

Six	O
(	O
27	O
%	O
)	O
of	O
22	O
experienced	O
recurrence	O
.	O

CONCLUSION	O
:	O
Concurrent	O
biweekly	O
paclitaxel	O
with	O
RT	O
is	O
feasible	O
,	O
with	O
an	O
MTD	O
of	O
73.8	O
Gy	O
.	O

Recovery	O
of	O
gonadal	O
function	O
occurs	O
in	O
the	O
majority	O
of	O
patients	O
.	O

These	O
results	O
encourage	O
testing	O
in	O
a	O
phase	O
III	O
setting	O
.	O

Application	O
of	O
a	O
high	O
-	O
content	O
multiparameter	O
cytotoxicity	B
assay	O
to	O
prioritize	O
compounds	O
based	O
on	O
toxicity	O
potential	O
in	O
humans	O
.	O

Prioritization	O
of	O
compounds	O
based	O
on	O
human	O
hepatotoxicity	B
potential	O
is	O
currently	O
a	O
key	O
unmet	O
need	O
in	O
drug	O
discovery	O
,	O
as	O
it	O
can	O
become	O
a	O
major	O
problem	O
for	O
several	O
lead	O
compounds	O
in	O
later	O
stages	O
of	O
the	O
drug	O
discovery	O
pipeline	O
.	O

The	O
authors	O
report	O
the	O
validation	O
and	O
implementation	O
of	O
a	O
high	O
-	O
content	O
multiparametric	O
cytotoxicity	B
assay	O
based	O
on	O
simultaneous	O
measurement	O
of	O
8	O
key	O
cell	O
health	O
indicators	O
associated	O
with	O
nuclear	O
morphology	O
,	O
plasma	O
membrane	O
integrity	O
,	O
mitochondrial	O
function	O
,	O
and	O
cell	O
proliferation	O
.	O

Compounds	O
are	O
prioritized	O
by	O
(	O
a	O
)	O
computing	O
an	O
in	O
vitro	O
safety	O
margin	O
using	O
the	O
minimum	O
cytotoxic	O
concentration	O
(	O
IC	O
(	O
20	O
)	O
)	O
across	O
all	O
8	O
indicators	O
and	O
cell	O
-	O
based	O
efficacy	O
data	O
and	O
(	O
b	O
)	O
using	O
the	O
minimal	O
cytotoxic	O
concentration	O
alone	O
to	O
take	O
into	O
account	O
concentration	O
of	O
drug	O
in	O
tissues	O
.	O

Feasibility	O
data	O
using	O
selected	O
compounds	O
,	O
including	O
quinolone	O
antibiotics	O
,	O
thiazolidinediones	O
,	O
and	O
statins	O
,	O
suggest	O
the	O
viability	O
of	O
this	O
approach	O
.	O

To	O
increase	O
overall	O
throughput	O
of	O
compound	O
prioritization	O
,	O
the	O
authors	O
have	O
identified	O
the	O
higher	O
throughput	O
,	O
plate	O
reader	O
-	O
based	O
CyQUANT	O
assay	O
that	O
is	O
similar	O
to	O
the	O
high	O
-	O
content	O
screening	O
(	O
HCS	O
)	O
assay	O
in	O
sensitivity	O
of	O
measuring	O
inhibition	O
of	O
cell	O
proliferation	O
.	O

It	O
is	O
expected	O
that	O
the	O
phenotypic	O
output	O
from	O
the	O
multiparametric	O
HCS	O
assay	O
in	O
combination	O
with	O
other	O
highly	O
sensitive	O
approaches	O
,	O
such	O
as	O
microarray	O
-	O
based	O
expression	O
analysis	O
of	O
toxic	O
signatures	O
,	O
will	O
contribute	O
to	O
a	O
better	O
understanding	O
and	O
predictivity	O
of	O
human	O
hepatotoxicity	B
potential	O
.	O

Amended	O
final	O
report	O
of	O
the	O
safety	O
assessment	O
of	O
cocamidopropylamine	O
oxide	O
.	O

Cocamidopropylamine	O
Oxide	O
is	O
a	O
tertiary	O
amine	O
oxide	O
which	O
functions	O
as	O
a	O
hair	O
-	O
conditioning	O
agent	O
and	O
as	O
a	O
surfactant	O
,	O
currently	O
used	O
in	O
60	O
cosmetic	O
formulations	O
at	O
concentrations	O
between	O
0.07	O
%	O
and	O
4.0	O
%	O
.	O

In	O
an	O
earlier	O
safety	O
assessment	O
,	O
the	O
Cosmetic	O
Ingredient	O
Review	O
(	O
CIR	O
)	O
Expert	O
Panel	O
had	O
determined	O
that	O
the	O
available	O
data	O
were	O
insufficient	O
to	O
support	O
the	O
safety	O
of	O
this	O
ingredient	O
in	O
cosmetic	O
products	O
.	O

Additional	O
data	O
have	O
now	O
been	O
provided	O
and	O
reviewed	O
.	O

Cocamidopropylamine	O
Oxide	O
was	O
determined	O
to	O
have	O
an	O
acute	O
oral	O
LD	O
(	O
50	O
)	O
between	O
500	O
and	O
1000	O
mg	O
/	O
kg	O
day	O
(	O
-	O
1	O
)	O
using	O
rats	O
.	O

The	O
acute	O
dermal	O
LD	O
(	O
50	O
)	O
in	O
rats	O
was	O
>	O
2174	O
mg	O
/	O
kg	O
day	O
(	O
-	O
1	O
)	O
.	O

A	O
28	O
-	O
day	O
repeated	O
oral	O
dose	B
toxicity	I
study	O
in	O
rats	O
found	O
hemolytic	B
anemia	I
at	O
150	O
and	O
1000	O
mg	O
/	O
kg	O
day	O
(	O
-	O
1	O
)	O
,	O
with	O
a	O
no	O
observed	O
effect	O
level	O
(	O
NOEL	O
)	O
of	O
15	O
mg	O
/	O
kg	O
day	O
(	O
-	O
1	O
)	O
.	O

At	O
5	O
%	O
,	O
Cocamidopropylamine	O
Oxide	O
solution	O
was	O
not	O
a	O
primary	O
dermal	O
irritant	O
.	O

Application	O
of	O
81.5	O
%	O
Cocamidopropylamine	O
Oxide	O
to	O
rabbit	O
skin	O
caused	O
moderate	O
irritation	B
under	O
Draize	O
classification	O
scale	O
,	O
but	O
81.5	O
%	O
Cocamidopropylamine	O
Oxide	O
in	O
rabbit	O
eyes	O
caused	O
severe	O
irritation	B
.	O

A	O
maximization	O
study	O
classified	O
Cocamidopropylamine	O
Oxide	O
as	O
a	O
nonsensitizer	O
to	O
guinea	O
pig	O
skin	O
.	O

Cocamidopropylamine	O
Oxide	O
was	O
not	O
mutagenic	O
in	O
an	O
Ames	O
test	O
,	O
with	O
and	O
without	O
metabolic	O
activation	O
.	O

No	O
evidence	O
of	O
increased	O
chromosomal	O
aberrations	O
were	O
noted	O
in	O
human	O
lymphocytes	O
treated	O
with	O
81.5	O
%	O
Cocamidopropylamine	O
Oxide	O
.	O

In	O
a	O
clinical	O
study	O
,	O
7.5	O
%	O
Cocamidopropylamine	O
Oxide	O
was	O
not	O
a	O
sensitizer	O
,	O
although	O
it	O
did	O
produce	O
some	O
reactions	O
typical	O
of	O
mild	O
irritation	B
.	O

Although	O
the	O
impurities	O
,	O
amidoamine	O
and	O
dimethylaminopropylamine	O
,	O
have	O
been	O
implicated	O
in	O
contact	B
allergy	I
reactions	O
to	O
products	O
containing	O
cocamidopropylamine	O
betaine	O
,	O
clinical	O
testing	O
of	O
a	O
product	O
with	O
cocamidopropylamine	O
betaine	O
containing	O
these	O
impurities	O
,	O
at	O
levels	O
comparable	O
to	O
those	O
found	O
in	O
Cocamidopropylamine	O
Oxide	O
,	O
failed	O
to	O
produce	O
a	O
reaction	O
in	O
10	O
individuals	O
known	O
to	O
be	O
sensitive	O
to	O
cocamidopropylamine	O
betaine	O
.	O

Two	O
repeat	O
-	O
insult	O
patch	O
tests	O
using	O
a	O
facial	O
wash	O
with	O
1	O
%	O
raw	O
material	O
containing	O
35	O
%	O
to	O
36.5	O
%	O
Cocamidopropylamine	O
Oxide	O
did	O
not	O
find	O
evidence	O
of	O
dermal	B
sensitization	I
.	O

Tests	O
for	O
dermal	B
phototoxicity	I
and	O
photoallergenicity	B
with	O
the	O
same	O
facial	O
wash	O
product	O
also	O
did	O
not	O
produce	O
evidence	O
of	O
effect	O
.	O

The	O
CIR	O
Expert	O
Panel	O
recognizes	O
that	O
there	O
are	O
data	O
gaps	O
regarding	O
the	O
use	O
and	O
concentration	O
of	O
this	O
ingredient	O
.	O

However	O
,	O
the	O
overall	O
information	O
available	O
on	O
types	O
of	O
products	O
in	O
which	O
this	O
ingredient	O
is	O
used	O
and	O
at	O
what	O
concentration	O
indicate	O
a	O
pattern	O
of	O
use	O
,	O
which	O
was	O
considered	O
by	O
the	O
Expert	O
Panel	O
in	O
assessing	O
safety	O
.	O

Overall	O
,	O
these	O
data	O
demonstrate	O
that	O
Cocamidopropylamine	O
Oxide	O
has	O
low	O
toxicity	O
in	O
animal	O
and	O
in	O
vitro	O
tests	O
.	O

Although	O
there	O
are	O
no	O
available	O
carcinogenicity	B
data	O
,	O
the	O
available	O
genotoxicity	B
data	O
,	O
combined	O
with	O
the	O
absence	O
of	O
any	O
structural	O
alerts	O
,	O
suggest	O
no	O
carcinogenic	O
potential	O
.	O

The	O
Panel	O
noted	O
the	O
absence	O
of	O
reproductive	O
and	O
developmental	B
toxicity	I
data	O
.	O

Because	O
this	O
ingredient	O
has	O
a	O
highly	O
polarized	O
molecular	O
structure	O
,	O
the	O
Panel	O
considered	O
that	O
it	O
would	O
be	O
,	O
at	O
most	O
,	O
slowly	O
absorbed	O
.	O

Given	O
that	O
most	O
of	O
the	O
uses	O
and	O
the	O
highest	O
use	O
concentration	O
of	O
4	O
%	O
is	O
found	O
in	O
rinse	O
-	O
off	O
products	O
,	O
the	O
Panel	O
determined	O
that	O
the	O
available	O
data	O
suggest	O
that	O
Cocamidopropylamine	O
Oxide	O
is	O
safe	O
as	O
used	O
in	O
rinse	O
-	O
off	O
products	O
.	O

Although	O
dermal	O
penetration	O
may	O
be	O
slow	O
,	O
data	O
on	O
the	O
extent	O
of	O
dermal	O
penetration	O
of	O
Cocamidopropylamine	O
Oxide	O
are	O
needed	O
to	O
support	O
the	O
safety	O
of	O
leave	O
-	O
on	O
uses	O
.	O

If	O
there	O
is	O
significant	O
dermal	O
absorption	O
,	O
dermal	O
reproductive	O
and	O
developmental	B
toxicity	I
data	O
may	O
be	O
needed	O
.	O

Intravenous	O
fat	O
emulsion	O
:	O
a	O
potential	O
novel	O
antidote	O
.	O

Intravenous	O
fat	O
emulsions	O
(	O
IFE	O
)	O
are	O
traditionally	O
used	O
as	O
a	O
component	O
of	O
parenteral	O
nutrition	O
therapy	O
.	O

Recently	O
,	O
IFE	O
was	O
used	O
to	O
resuscitate	O
severe	O
local	B
anesthetic	I
drug	I
toxicity	I
.	O

This	O
review	O
focuses	O
on	O
the	O
potential	O
role	O
of	O
IFE	O
in	O
treatment	O
of	O
toxicity	O
due	O
to	O
local	O
anesthetics	O
and	O
other	O
lipid	O
-	O
soluble	O
drugs	O
.	O

The	O
general	O
properties	O
of	O
IFE	O
,	O
metabolic	O
fate	O
,	O
and	O
associated	O
adverse	O
events	O
are	O
described	O
.	O

Cases	O
of	O
local	B
anesthetic	I
toxicity	I
treated	O
with	O
IFE	O
are	O
presented	O
along	O
with	O
a	O
discussion	O
of	O
the	O
possible	O
antidotal	O
mechanisms	O
.	O

Initial	O
investigations	O
into	O
the	O
antidotal	O
use	O
of	O
IFE	O
for	O
lipophilic	O
central	O
nervous	O
and	O
cardiovascular	B
drug	I
toxicity	I
are	O
also	O
reviewed	O
.	O

The	O
use	O
of	O
ultrasound	O
and	O
micelles	O
in	O
cancer	B
treatment	O
.	O

The	O
high	O
toxicity	O
of	O
potent	O
chemotherapeutic	O
drugs	O
like	O
Doxorubicin	O
(	O
Dox	O
)	O
limits	O
the	O
therapeutic	O
window	O
in	O
which	O
they	O
can	O
be	O
applied	O
.	O

This	O
window	O
can	O
be	O
expanded	O
by	O
controlling	O
the	O
drug	O
delivery	O
in	O
both	O
space	O
and	O
time	O
such	O
that	O
non	O
-	O
targeted	O
tissues	O
are	O
not	O
adversely	O
affected	O
.	O

Recent	O
research	O
has	O
shown	O
that	O
ultrasound	O
(	O
US	O
)	O
can	O
be	O
used	O
to	O
control	O
the	O
release	O
of	O
Dox	O
and	O
other	O
hydrophobic	O
drugs	O
from	O
polymeric	O
micelles	O
in	O
both	O
time	O
and	O
space	O
.	O

It	O
has	O
also	O
been	O
shown	O
using	O
an	O
in	O
vivo	O
rat	O
tumor	O
model	O
that	O
Dox	O
activity	O
can	O
be	O
enhanced	O
by	O
ultrasound	O
in	O
one	O
region	O
,	O
while	O
in	O
an	O
adjacent	O
region	O
there	O
is	O
little	O
or	O
no	O
effect	O
of	O
the	O
drug	O
.	O

In	O
this	O
article	O
,	O
we	O
review	O
the	O
in	O
vivo	O
and	O
in	O
vitro	O
research	O
being	O
conducted	O
in	O
the	O
area	O
of	O
using	O
ultrasound	O
to	O
enhance	O
and	O
target	O
micellar	O
drug	O
delivery	O
to	O
cancerous	O
tissues	O
.	O

Additionally	O
,	O
we	O
summarize	O
our	O
previously	O
published	O
mathematical	O
models	O
that	O
attempt	O
to	O
represent	O
the	O
release	O
and	O
re	O
-	O
encapsulation	O
phenomena	O
of	O
Dox	O
from	O
Pluronic	O
P105	O
micelles	O
upon	O
the	O
application	O
of	O
ultrasound	O
.	O

The	O
potential	O
benefits	O
of	O
such	O
controlled	O
chemotherapy	O
compels	O
a	O
thorough	O
investigation	O
of	O
the	O
role	O
of	O
ultrasound	O
(	O
US	O
)	O
and	O
the	O
mechanisms	O
by	O
which	O
US	O
accomplishes	O
drug	O
release	O
and	O
/	O
or	O
enhances	O
drug	O
potency	O
.	O

Therefore	O
we	O
will	O
summarize	O
our	O
findings	O
related	O
to	O
the	O
mechanism	O
involved	O
in	O
acoustically	O
activated	O
micellar	O
drug	O
delivery	O
to	O
tumors	B
.	O

Drug	O
insight	O
:	O
aggrecanases	O
as	O
therapeutic	O
targets	O
for	O
osteoarthritis	B
.	O

In	O
healthy	O
cartilage	O
,	O
effective	O
weight	O
-	O
bearing	O
requires	O
a	O
high	O
concentration	O
of	O
intact	O
aggrecan	O
.	O

Degradation	O
and	O
loss	O
of	O
aggrecan	O
are	O
features	O
of	O
osteoarthritis	B
(	O
OA	B
)	O
.	O

It	O
is	O
unclear	O
whether	O
ADAMTS	O
-	O
4	O
,	O
ADAMTS	O
-	O
5	O
,	O
or	O
both	O
of	O
these	O
aggrecanases	O
from	O
the	O
ADAMTS	O
(	O
a	O
disintegrin	O
and	O
metalloproteinase	O
with	O
thrombospondin	O
motifs	O
)	O
enzyme	O
family	O
,	O
are	O
responsible	O
for	O
aggrecanolysis	O
in	O
human	O
OA	B
,	O
and	O
at	O
what	O
stage	O
of	O
disease	O
these	O
enzymes	O
are	O
active	O
.	O

Several	O
potential	O
disease	O
-	O
modifying	O
agents	O
for	O
OA	B
include	O
glucosamine	O
and	O
chondroitin	O
sulfate	O
,	O
diacerhein	O
,	O
and	O
pentosan	O
polysulfate	O
;	O
although	O
their	O
mechanisms	O
of	O
action	O
in	O
vivo	O
are	O
unknown	O
,	O
data	O
from	O
in	O
vitro	O
studies	O
and	O
animal	O
models	O
suggest	O
that	O
their	O
efficacy	O
might	O
be	O
partly	O
due	O
to	O
inhibition	O
of	O
proinflammatory	O
pathways	O
that	O
lead	O
to	O
downregulation	O
of	O
ADAMTS	O
enzymes	O
.	O

Some	O
histone	O
deacetylase	O
inhibitors	O
that	O
are	O
successfully	O
used	O
to	O
treat	O
cancer	B
can	O
block	O
ADAMTS	O
-	O
5	O
expression	O
;	O
however	O
,	O
these	O
inhibitors	O
will	O
only	O
be	O
considered	O
as	O
potential	O
therapies	O
for	O
OA	B
if	O
their	O
toxicity	O
is	O
markedly	O
reduced	O
.	O

ADAMTS	O
inhibitors	O
currently	O
in	O
development	O
are	O
expected	O
to	O
show	O
excellent	O
specificity	O
now	O
that	O
crystal	O
structures	O
for	O
several	O
ADAMTS	O
enzymes	O
are	O
available	O
to	O
guide	O
drug	O
design	O
.	O

ADAMTS	O
-	O
4	O
and	O
ADAMTS	O
-	O
5	O
are	O
appropriate	O
targets	O
for	O
OA	B
therapies	O
,	O
but	O
ultimately	O
,	O
inhibitors	O
of	O
these	O
enzymes	O
will	O
form	O
only	O
part	O
of	O
a	O
larger	O
arsenal	O
of	O
therapies	O
.	O

Long	O
-	O
term	O
clinical	O
and	O
surrogate	O
marker	O
effects	O
of	O
subcutaneous	O
intermittent	O
interleukin	O
-	O
2	O
without	O
antiretroviral	O
therapy	O
in	O
HIV	O
-	O
infected	O
patients	O
.	O

OBJECTIVES	O
:	O
Subcutaneous	O
administration	O
of	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
has	O
been	O
shown	O
to	O
increase	O
CD4	O
counts	O
in	O
HIV	O
-	O
infected	O
patients	O
.	O

It	O
remains	O
unclear	O
whether	O
this	O
effect	O
is	O
associated	O
with	O
a	O
clinical	O
benefit	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
conducted	O
a	O
long	O
-	O
term	O
follow	O
-	O
up	O
in	O
the	O
cohort	O
of	O
the	O
UK	O
-	O
Vanguard	O
study	O
in	O
which	O
three	O
groups	O
of	O
12	O
antiretroviral	O
-	O
naive	O
subjects	O
with	O
CD4	O
cell	O
counts	O
>	O
350	O
cells	O
/	O
mm	O
(	O
3	O
)	O
received	O
no	O
treatment	O
or	O
IL	O
-	O
2	O
at	O
either	O
4.5	O
or	O
7.5	O
MIU	O
twice	O
daily	O
in	O
5	O
day	O
cycles	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Mean	O
follow	O
-	O
up	O
was	O
376	O
weeks	O
.	O

IL	O
-	O
2	O
therapy	O
was	O
associated	O
with	O
a	O
higher	O
area	O
under	O
the	O
curve	O
of	O
CD4	O
cell	O
count	O
change	O
from	O
baseline	O
at	O
week	O
48	O
but	O
not	O
thereafter	O
.	O

HIV	O
-	O
RNA	O
levels	O
were	O
unaffected	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
was	O
initiated	O
after	O
a	O
mean	O
of	O
172	O
,	O
175	O
and	O
152	O
weeks	O
in	O
the	O
control	O
group	O
,	O
low	O
-	O
dose	O
and	O
high	O
-	O
dose	O
IL	O
-	O
2	O
treatment	O
group	O
,	O
respectively	O
,	O
a	O
statistically	O
non	O
-	O
significant	O
difference	O
.	O

There	O
was	O
a	O
tendency	O
to	O
start	O
HAART	O
soon	O
after	O
discontinuation	O
of	O
IL	O
-	O
2	O
therapy	O
which	O
may	O
have	O
been	O
triggered	O
by	O
the	O
steep	O
decay	O
of	O
CD4	O
counts	O
.	O

There	O
were	O
two	O
serious	O
adverse	O
events	O
in	O
the	O
control	O
group	O
,	O
seven	O
in	O
the	O
low	O
-	O
dose	O
IL	O
-	O
2	O
group	O
and	O
eight	O
in	O
the	O
high	O
-	O
dose	O
IL	O
-	O
2	O
group	O
.	O

No	O
pattern	O
of	O
disease	O
was	O
detected	O
,	O
making	O
an	O
association	O
with	O
IL	O
-	O
2	O
therapy	O
unlikely	O
.	O

CONCLUSIONS	O
:	O
We	O
could	O
detect	O
neither	O
a	O
benefit	O
of	O
IL	O
-	O
2	O
therapy	O
after	O
week	O
48	O
nor	O
delayed	O
initiation	O
of	O
HAART	O
.	O

This	O
is	O
currently	O
the	O
longest	O
follow	O
-	O
up	O
data	O
comparing	O
IL	O
-	O
2	O
therapy	O
with	O
no	O
therapy	O
in	O
antiretroviral	O
-	O
naive	O
HIV	O
-	O
infected	O
patients	O
and	O
does	O
not	O
show	O
a	O
persistent	O
benefit	O
of	O
the	O
intervention	O
.	O

Altered	O
first	O
-	O
pass	O
effects	O
in	O
a	O
liver	O
transplant	O
recipient	O
explained	O
intraindividual	O
variation	O
in	O
calcineurin	O
inhibitor	O
concentrations	O
:	O
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
The	O
significant	O
interindividual	O
and	O
intraindividual	O
variability	O
in	O
the	O
blood	O
concentrations	O
of	O
the	O
most	O
commonly	O
used	O
calcineurin	O
inhibitors	O
such	O
as	O
tacrolimus	O
and	O
cyclosporine	O
makes	O
the	O
exact	O
dosing	O
of	O
these	O
agents	O
in	O
transplant	O
recipients	O
very	O
challenging	O
.	O

As	O
both	O
of	O
these	O
drugs	O
have	O
narrow	O
therapeutic	O
index	O
and	O
are	O
metabolized	O
by	O
hepatic	O
and	O
intestinal	O
cytochrome	O
P450	O
3A	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
these	O
variations	O
are	O
secondary	O
to	O
varying	O
first	O
-	O
pass	O
effects	O
in	O
the	O
gut	O
and	O
the	O
liver	O
over	O
a	O
period	O
of	O
time	O
.	O

CASE	O
REPORT	O
:	O
A	O
liver	O
transplant	O
recipient	O
,	O
who	O
had	O
previously	O
presented	O
with	O
tacrolimus	B
toxicity	I
on	O
his	O
usual	O
dosing	O
regimen	O
and	O
intolerant	O
to	O
standard	O
doses	O
of	O
cyclosporine	O
,	O
was	O
selected	O
to	O
undergo	O
the	O
study	O
.	O

Oral	O
and	O
intravenous	O
midazolam	O
was	O
used	O
as	O
the	O
probe	O
to	O
measure	O
hepatic	O
and	O
intestinal	O
CYP3A4	O
activities	O
at	O
two	O
different	O
time	O
points	O
(	O
phases	O
one	O
and	O
two	O
)	O
.	O

Small	O
intestinal	O
biopsies	O
were	O
also	O
obtained	O
for	O
measuring	O
CYP3A4	O
activity	O
for	O
in	O
vitro	O
studies	O
.	O

On	O
serially	O
determining	O
the	O
patient	O
's	O
hepatic	O
and	O
intestinal	O
CYP3A	O
activities	O
,	O
we	O
concluded	O
that	O
the	O
variability	O
in	O
the	O
dosing	O
requirements	O
is	O
due	O
to	O
altered	O
first	O
-	O
pass	O
effects	O
in	O
the	O
intestine	O
.	O

DISCUSSION	O
:	O
Transplant	O
recipients	O
receive	O
multiple	O
medications	O
that	O
may	O
inhibit	O
or	O
induce	O
these	O
metabolizing	O
enzymes	O
,	O
which	O
eventually	O
determine	O
the	O
concentrations	O
of	O
these	O
narrow	O
therapeutic	O
agents	O
.	O

If	O
no	O
obvious	O
etiology	O
of	O
intolerance	O
to	O
calcineurin	O
inhibitors	O
in	O
a	O
transplant	O
recipient	O
is	O
identified	O
,	O
one	O
should	O
consider	O
altered	O
first	O
-	O
pass	O
effects	O
in	O
the	O
gut	O
and	O
the	O
liver	O
contributing	O
to	O
intraindividual	O
variations	O
in	O
the	O
blood	O
concentrations	O
.	O

AIDS	B
-	I
related	I
malignancies	I
:	O
state	O
of	O
the	O
art	O
and	O
therapeutic	O
challenges	O
.	O

Despite	O
the	O
impact	O
of	O
combination	O
antiretroviral	O
therapy	O
(	O
cART	O
)	O
on	O
HIV	O
-	O
related	O
mortality	O
,	O
malignancy	O
remains	O
an	O
important	O
cause	O
of	O
death	O
in	O
the	O
current	O
era	O
.	O

Although	O
the	O
advent	O
of	O
cART	O
has	O
resulted	O
in	O
reductions	O
in	O
the	O
incidence	O
of	O
Kaposi	B
's	I
sarcoma	I
and	O
non	B
-	I
Hodgkin	I
's	I
lymphoma	I
,	O
non	B
-	I
AIDS	I
-	I
defining	I
malignancies	I
present	O
an	O
increased	O
risk	O
for	O
HIV	O
-	O
infected	O
patients	O
,	O
characterized	O
by	O
some	O
common	O
clinical	O
features	O
,	O
generally	O
with	O
a	O
more	O
aggressive	B
behavior	I
and	O
a	O
more	O
advanced	O
disease	O
at	O
diagnosis	O
,	O
which	O
is	O
responsible	O
for	O
poorer	O
patient	O
outcomes	O
.	O

Specific	O
therapeutic	O
recommendations	O
are	O
lacking	O
for	O
these	O
new	O
nonopportunistic	O
malignancies	B
,	O
such	O
as	O
Hodgkin	B
's	I
lymphoma	I
,	O
anal	B
cancer	I
,	O
lung	B
cancer	I
,	O
hepatocarcinoma	B
,	O
and	O
many	O
others	O
.	O

Antiretroviral	O
agents	O
have	O
a	O
propensity	O
for	O
causing	O
drug	O
interactions	O
as	O
a	O
result	O
of	O
their	O
ability	O
to	O
either	O
inhibit	O
or	O
induce	O
the	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
enzyme	O
system	O
.	O

Because	O
many	O
antineoplastic	O
drugs	O
are	O
also	O
metabolized	O
by	O
the	O
CYP	O
system	O
,	O
coadministration	O
with	O
cART	O
could	O
result	O
in	O
either	O
drug	O
accumulation	O
with	O
increased	O
toxicity	O
,	O
or	O
decreased	O
efficacy	O
of	O
one	O
or	O
both	O
classes	O
of	O
drugs	O
.	O

Further	O
research	O
delineating	O
the	O
combined	O
safety	O
and	O
pharmacokinetics	O
of	O
antiretrovirals	O
and	O
antineoplastic	O
therapy	O
is	O
necessary	O
.	O

Special	O
considerations	O
of	O
these	O
AIDS	O
-	O
related	O
and	O
non	B
-	I
AIDS	I
-	I
related	I
malignancies	I
and	O
their	O
clinical	O
and	O
therapeutic	O
aspects	O
constitute	O
the	O
subject	O
of	O
this	O
review	O
.	O

Doxorubicin	O
,	O
cardiac	O
risk	O
factors	O
,	O
and	O
cardiac	B
toxicity	I
in	O
elderly	O
patients	O
with	O
diffuse	O
B	B
-	I
cell	I
non	I
-	I
Hodgkin	I
's	I
lymphoma	I
.	O

PURPOSE	O
:	O
Anthracycline	O
-	O
based	O
chemotherapy	O
,	O
which	O
improves	O
survival	O
for	O
patients	O
with	O
non	B
-	I
Hodgkin	I
's	I
lymphoma	I
,	O
is	O
often	O
withheld	O
from	O
elderly	O
patients	O
because	O
of	O
its	O
cardiotoxicity	B
.	O

We	O
studied	O
the	O
cardiac	O
effects	O
of	O
doxorubicin	O
in	O
a	O
population	O
-	O
based	O
sample	O
of	O
older	O
patients	O
with	O
diffuse	B
large	I
B	I
-	I
cell	I
lymphoma	I
(	O
DLBCL	B
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Among	O
patients	O
age	O
>	O
or	O
=	O
65	O
years	O
diagnosed	O
with	O
DLBCL	B
from	O
1991	O
to	O
2002	O
in	O
the	O
Surveillance	O
,	O
Epidemiology	O
,	O
and	O
End	O
Results	O
-	O
Medicare	O
database	O
,	O
we	O
developed	O
logistic	O
regression	O
models	O
of	O
the	O
associations	O
of	O
doxorubicin	O
with	O
demographic	O
,	O
clinical	O
,	O
and	O
cardiac	O
variables	O
.	O

We	O
then	O
developed	O
Cox	O
proportional	O
hazards	O
models	O
of	O
the	O
association	O
between	O
doxorubicin	O
and	O
subsequent	O
congestive	B
heart	I
failure	I
(	O
CHF	B
)	O
,	O
taking	O
predictors	O
of	O
CHF	B
into	O
account	O
.	O

RESULTS	O
:	O
Of	O
9,438	O
patients	O
with	O
DLBCL	B
,	O
3,164	O
(	O
42	O
%	O
)	O
received	O
doxorubicin	O
-	O
based	O
chemotherapy	O
.	O

Any	O
doxorubicin	O
use	O
was	O
associated	O
with	O
a	O
29	O
%	O
increase	O
in	O
risk	O
of	O
CHF	B
(	O
95	O
%	O
CI	O
,	O
1.02	O
to	O
1.62	O
)	O
;	O
CHF	B
risk	O
increased	O
with	O
number	O
of	O
doxorubicin	O
claims	O
,	O
increasing	O
age	O
,	O
prior	B
heart	I
disease	I
,	O
comorbidities	O
,	O
diabetes	B
,	O
and	O
hypertension	B
;	O
hypertension	B
intensified	O
the	O
effect	O
of	O
doxorubicin	O
on	O
risk	O
of	O
CHF	B
(	O
hazard	O
ratio	O
=	O
1.8	O
;	O
P	O
<	O
.01	O
)	O
.	O

In	O
the	O
8	O
years	O
after	O
diagnosis	O
,	O
the	O
adjusted	O
CHF	O
-	O
free	O
survival	O
rate	O
was	O
74	O
%	O
in	O
doxorubicin	O
-	O
treated	O
patients	O
versus	O
79	O
%	O
in	O
patients	O
not	O
treated	O
with	O
doxorubicin	O
.	O

CONCLUSION	O
:	O
Among	O
patients	O
receiving	O
chemotherapy	O
for	O
DLBCL	B
,	O
those	O
with	O
prior	B
heart	I
disease	I
were	O
less	O
likely	O
than	O
others	O
to	O
be	O
treated	O
with	O
doxorubicin	O
,	O
and	O
those	O
who	O
received	O
doxorubicin	O
were	O
more	O
likely	O
than	O
others	O
to	O
develop	O
CHF	B
.	O

Various	O
cardiac	O
risk	O
factors	O
increased	O
CHF	B
risk	O
,	O
but	O
only	O
hypertension	B
was	O
synergistic	O
with	O
doxorubicin	O
.	O

Doxorubicin	O
has	O
dramatically	O
improved	O
survival	O
of	O
DLBCL	B
patients	O
;	O
nonetheless	O
,	O
some	O
subgroups	O
may	O
benefit	O
from	O
efforts	O
to	O
reduce	O
doxorubicin	O
-	O
related	O
CHF	B
risk	O
.	O

A	O
high	O
throughput	O
in	O
vitro	O
analytical	O
approach	O
to	O
screen	O
for	O
oxidative	O
stress	O
potential	O
exerted	O
by	O
nanomaterials	O
using	O
a	O
biologically	O
relevant	O
matrix	O
:	O
human	O
blood	O
serum	O
.	O

Limited	O
studies	O
have	O
shown	O
that	O
selected	O
nanomaterials	O
(	O
NMs	O
)	O
impart	O
various	O
forms	O
of	O
toxicity	O
in	O
biological	O
systems	O
;	O
however	O
,	O
a	O
common	O
metric	O
to	O
screen	O
for	O
potential	O
toxicity	O
is	O
needed	O
.	O

This	O
study	O
optimized	O
and	O
utilized	O
a	O
'	O
Ferric	O
reducing	O
ability	O
of	O
serum	O
(	O
FRAS	O
)	O
'	O
assay	O
as	O
a	O
screening	O
tool	O
to	O
quantitate	O
the	O
degree	O
of	O
oxidative	O
damage	O
induced	O
by	O
NMs	O
on	O
human	O
blood	O
serum	O
.	O

Antioxidants	O
in	O
blood	O
protect	O
against	O
oxidative	O
damage	O
caused	O
by	O
free	O
radicals	O
via	O
chemical	O
quenching	O
and	O
will	O
decrease	O
when	O
exposed	O
to	O
oxidatively	O
stressful	O
materials	O
.	O

Using	O
this	O
approach	O
,	O
the	O
antioxidant	O
capacity	O
of	O
NM	O
treated	O
serum	O
was	O
significantly	O
decreased	O
by	O
nano	O
-	O
silver	O
,	O
a	O
series	O
of	O
nano	O
-	O
carbon	O
blacks	O
,	O
fullerene	O
soot	O
,	O
and	O
nano	O
-	O
TiO	O
(	O
2	O
)	O
(	O
anatase	O
,	O
p	O
<	O
0.05	O
)	O
,	O
but	O
not	O
with	O
nano	O
-	O
alumina	O
,	O
fullerite	O
,	O
purified	O
fullerene	O
,	O
fine	O
TiO	O
(	O
2	O
)	O
(	O
rutile	O
)	O
and	O
Min	O
-	O
U	O
-	O
Sil	O
5	O
.	O

Particle	O
surface	O
area	O
and	O
not	O
biological	O
particle	O
size	O
was	O
highly	O
associated	O
with	O
the	O
degree	O
of	O
oxidative	O
stress	O
observed	O
.	O

This	O
approach	O
appears	O
responsive	O
to	O
multiple	O
determinants	O
of	O
oxidative	O
damage	O
,	O
including	O
particle	O
chemistry	O
,	O
surface	O
area	O
and	O
impurities	O
,	O
and	O
may	O
be	O
a	O
valid	O
screening	O
method	O
to	O
determine	O
oxidative	O
damage	O
imparted	O
by	O
nanomaterials	O
.	O

Efficacy	O
and	O
safety	O
of	O
two	O
doses	O
of	O
pemetrexed	O
supplemented	O
with	O
folic	O
acid	O
and	O
vitamin	O
B12	O
in	O
previously	O
treated	O
patients	O
with	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
.	O

PURPOSE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
two	O
doses	O
of	O
pemetrexed	O
supplemented	O
with	O
folic	O
acid	O
and	O
vitamin	O
B	O
(	O
12	O
)	O
in	O
pretreated	O
Japanese	O
patients	O
with	O
advanced	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
(	O
NSCLC	B
)	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Patients	O
with	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
0	O
to	O
2	O
,	O
stage	O
III	O
or	O
IV	O
,	O
and	O
who	O
received	O
previously	O
one	O
or	O
two	O
chemotherapy	O
regimens	O
were	O
randomized	O
to	O
receive	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
pemetrexed	O
(	O
P500	O
)	O
or	O
1,000	O
mg	O
/	O
m	O
(	O
2	O
)	O
pemetrexed	O
(	O
P1000	O
)	O
on	O
day	O
1	O
every	O
3	O
weeks	O
.	O

The	O
primary	O
endpoint	O
was	O
response	O
rate	O
.	O

RESULTS	O
:	O
Of	O
the	O
216	O
patients	O
evaluable	O
for	O
efficacy	O
(	O
108	O
in	O
each	O
arm	O
)	O
,	O
response	O
rates	O
were	O
18.5	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
,	O
12.6	O
-	O
25.8	O
%	O
)	O
and	O
14.8	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
,	O
9.5	O
-	O
21.6	O
%	O
)	O
,	O
median	O
survival	O
times	O
were	O
16.0	O
and	O
12.6	O
months	O
,	O
1	O
-	O
year	O
survival	O
rates	O
were	O
59.2	O
%	O
and	O
53.7	O
%	O
,	O
and	O
median	O
progression	O
-	O
free	O
survival	O
were	O
3.0	O
and	O
2.5	O
months	O
for	O
the	O
P500	O
and	O
P1000	O
,	O
respectively	O
.	O

Cox	O
multiple	O
regression	O
analysis	O
indicated	O
that	O
pemetrexed	O
dose	O
was	O
not	O
a	O
significant	O
prognostic	O
factor	O
.	O

Drug	B
-	I
related	I
toxicity	I
was	O
generally	O
tolerable	O
for	O
both	O
doses	O
;	O
however	O
,	O
the	O
safety	O
profile	O
of	O
P500	O
showed	O
generally	O
milder	O
toxicity	O
.	O

Main	O
adverse	O
drug	O
reactions	O
of	O
severity	O
grade	O
3	O
or	O
4	O
were	O
neutrophil	B
count	I
decreased	I
(	O
20.2	O
%	O
)	O
and	O
alanine	B
aminotransferase	I
(	I
glutamine	I
pyruvic	I
transaminase	I
)	I
increased	I
(	O
15.8	O
%	O
)	O
in	O
P500	O
and	O
neutrophil	B
count	I
decreased	I
(	O
24.3	O
%	O
)	O
,	O
WBC	B
count	I
decreased	I
(	O
20.7	O
%	O
)	O
,	O
and	O
lymphocyte	B
count	I
decreased	I
(	O
18.0	O
%	O
)	O
in	O
P1000	O
.	O

One	O
drug	O
-	O
related	O
death	O
from	O
interstitial	B
lung	I
disease	I
occurred	O
in	O
the	O
P500	O
.	O

CONCLUSION	O
:	O
P500	O
and	O
P1000	O
are	O
similarly	O
active	O
with	O
promising	O
efficacy	O
and	O
acceptable	O
safety	O
outcomes	O
in	O
pretreated	O
patients	O
with	O
NSCLC	B
.	O

These	O
results	O
support	O
the	O
use	O
of	O
P500	O
as	O
a	O
second	O
-	O
and	O
third	O
-	O
line	O
treatment	O
of	O
NSCLC	B
.	O

Pharmacogenetics	O
of	O
analgesics	O
:	O
toward	O
the	O
individualization	O
of	O
prescription	O
.	O

The	O
use	O
of	O
analgesics	O
is	O
based	O
on	O
the	O
empiric	O
administration	O
of	O
a	O
given	O
drug	O
with	O
clinical	O
monitoring	O
for	O
efficacy	O
and	O
toxicity	O
.	O

However	O
,	O
individual	O
responses	O
to	O
drugs	O
are	O
influenced	O
by	O
a	O
combination	O
of	O
pharmacokinetic	O
and	O
pharmacodynamic	O
factors	O
that	O
can	O
sometimes	O
be	O
regulated	O
by	O
genetic	O
factors	O
.	O

Whereas	O
polymorphic	O
drug	O
-	O
metabolizing	O
enzymes	O
and	O
drug	O
transporters	O
may	O
affect	O
the	O
pharmacokinetics	O
of	O
drugs	O
,	O
polymorphic	O
drug	O
targets	O
and	O
disease	O
-	O
related	O
pathways	O
may	O
influence	O
the	O
pharmacodynamic	O
action	O
of	O
drugs	O
.	O

After	O
a	O
usual	O
dose	O
,	O
variations	O
in	O
drug	B
toxicity	I
and	O
inefficacy	O
can	O
be	O
observed	O
depending	O
on	O
the	O
polymorphism	O
,	O
the	O
analgesic	O
considered	O
and	O
the	O
presence	O
or	O
absence	O
of	O
active	O
metabolites	O
.	O

For	O
opioids	O
,	O
the	O
most	O
studied	O
being	O
morphine	O
,	O
mutations	O
in	O
the	O
ABCB1	O
gene	O
,	O
coding	O
for	O
P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
,	O
and	O
in	O
the	O
micro	O
-	O
opioid	O
receptor	O
reduce	O
morphine	O
potency	O
.	O

Cytochrome	O
P450	O
(	O
CYP	O
)	O
2D6	O
mutations	O
influence	O
the	O
analgesic	O
effect	O
of	O
codeine	O
and	O
tramadol	O
,	O
and	O
polymorphism	O
of	O
CYP2C9	O
is	O
potentially	O
linked	O
to	O
an	O
increase	O
in	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
-	O
induced	O
adverse	O
events	O
.	O

Furthermore	O
,	O
drug	O
interactions	O
can	O
mimic	O
genetic	O
deficiency	O
and	O
contribute	O
to	O
the	O
variability	O
in	O
response	O
to	O
analgesics	O
.	O

This	O
review	O
summarizes	O
the	O
available	O
data	O
on	O
the	O
pharmacokinetic	O
and	O
pharmacodynamic	O
consequences	O
of	O
known	O
polymorphisms	O
of	O
drug	O
-	O
metabolizing	O
enzymes	O
,	O
drug	O
transporters	O
,	O
drug	O
targets	O
and	O
other	O
nonopioid	O
biological	O
systems	O
on	O
central	O
and	O
peripheral	O
analgesics	O
.	O

Effect	O
of	O
repeated	O
doses	O
of	O
darunavir	O
plus	O
low	O
-	O
dose	O
ritonavir	O
on	O
the	O
pharmacokinetics	O
of	O
sildenafil	O
in	O
healthy	O
male	O
subjects	O
:	O
phase	O
I	O
randomized	O
,	O
open	O
-	O
label	O
,	O
two	O
-	O
way	O
crossover	O
study	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Darunavir	O
(	O
DRV	O
,	O
TMC114	O
)	O
is	O
a	O
novel	O
protease	O
inhibitor	O
administered	O
in	O
combination	O
with	O
low	O
-	O
dose	O
ritonavir	O
(	O
DRV	O
/	O
r	O
)	O
and	O
is	O
highly	O
active	O
against	O
both	O
wild	O
-	O
type	O
and	O
multidrug	O
-	O
resistant	O
HIV	O
-	O
1	O
strains	O
.	O

Sildenafil	O
is	O
an	O
oral	O
therapy	O
for	O
erectile	B
dysfunction	I
.	O

Concomitant	O
administration	O
of	O
protease	O
inhibitors	O
and	O
sildenafil	O
increases	O
sildenafil	O
plasma	O
concentrations	O
.	O

The	O
potential	O
for	O
a	O
pharmacokinetic	O
drug	O
interaction	O
exists	O
when	O
sildenafil	O
and	O
DRV	O
/	O
r	O
are	O
co	O
-	O
administered	O
,	O
as	O
these	O
drugs	O
are	O
primarily	O
metabolized	O
by	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
3A	O
,	O
and	O
darunavir	O
and	O
ritonavir	O
are	O
CYP3A	O
inhibitors	O
.	O

The	O
primary	O
objective	O
of	O
this	O
open	O
-	O
label	O
,	O
crossover	O
,	O
phase	O
I	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
multiple	O
doses	O
of	O
DRV	O
/	O
r	O
on	O
the	O
pharmacokinetics	O
of	O
sildenafil	O
and	O
its	O
active	O
metabolite	O
N	O
-	O
desmethyl	O
sildenafil	O
.	O

The	O
secondary	O
objective	O
was	O
to	O
assess	O
the	O
short	O
-	O
term	O
safety	O
and	O
tolerability	O
of	O
co	O
-	O
administration	O
of	O
sildenafil	O
and	O
DRV	O
/	O
r	O
.	O

METHODS	O
:	O
Sixteen	O
HIV	O
-	O
negative	O
healthy	O
male	O
subjects	O
were	O
randomized	O
to	O
one	O
of	O
two	O
sequences	O
.	O

In	O
two	O
sessions	O
each	O
subject	O
received	O
treatments	O
A	O
and	O
B	O
.	O

In	O
treatment	O
A	O
,	O
a	O
single	O
dose	O
of	O
sildenafil	O
100	O
mg	O
was	O
administered	O
.	O

In	O
treatment	O
B	O
,	O
the	O
subjects	O
received	O
DRV	O
/	O
r	O
400	O
/	O
100	O
mg	O
twice	O
daily	O
for	O
8	O
days	O
and	O
on	O
day	O
7	O
a	O
single	O
dose	O
of	O
sildenafil	O
25	O
mg	O
was	O
co	O
-	O
administered	O
.	O

Full	O
pharmacokinetic	O
profiles	O
of	O
sildenafil	O
,	O
N	O
-	O
desmethyl	O
sildenafil	O
,	O
darunavir	O
and	O
ritonavir	O
were	O
determined	O
.	O

Safety	O
and	O
tolerability	O
were	O
also	O
assessed	O
.	O

RESULTS	O
:	O
Sildenafil	O
exposure	O
(	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
[	O
AUC	O
]	O
)	O
was	O
comparable	O
between	O
the	O
two	O
treatments	O
despite	O
administration	O
of	O
a	O
lower	O
dose	O
of	O
sildenafil	O
(	O
25	O
mg	O
)	O
with	O
DRV	O
/	O
r	O
than	O
when	O
sildenafil	O
(	O
100	O
mg	O
)	O
was	O
administered	O
alone	O
.	O

When	O
sildenafil	O
25	O
mg	O
was	O
co	O
-	O
administered	O
with	O
DRV	O
/	O
r	O
,	O
the	O
sildenafil	O
maximum	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
was	O
38	O
%	O
lower	O
compared	O
with	O
Cmax	O
after	O
administration	O
of	O
sildenafil	O
alone	O
at	O
a	O
dose	O
of	O
100	O
mg	O
.	O

N	O
-	O
desmethyl	O
sildenafil	O
Cmax	O
and	O
AUC	O
from	O
the	O
time	O
of	O
administration	O
until	O
the	O
last	O
time	O
point	O
with	O
a	O
measurable	O
concentration	O
after	O
dosing	O
(	O
calculated	O
by	O
linear	O
trapezoidal	O
summation	O
[	O
AUClast	O
]	O
)	O
values	O
decreased	O
by	O
approximately	O
95	O
%	O
when	O
sildenafil	O
25	O
mg	O
was	O
co	O
-	O
administered	O
with	O
DRV	O
/	O
r	O
compared	O
with	O
sildenafil	O
100	O
mg	O
alone	O
.	O

Combined	O
treatment	O
with	O
DRV	O
/	O
r	O
and	O
sildenafil	O
was	O
generally	O
safe	O
and	O
well	O
tolerated	O
.	O

CONCLUSION	O
:	O
Sildenafil	O
exposure	O
is	O
increased	O
in	O
the	O
presence	O
of	O
DRV	O
/	O
r	O
.	O

In	O
this	O
setting	O
,	O
a	O
dose	O
adjustment	O
for	O
sildenafil	O
is	O
warranted	O
;	O
no	O
more	O
than	O
25	O
mg	O
of	O
sildenafil	O
is	O
recommended	O
over	O
a	O
48	O
-	O
hour	O
period	O
when	O
co	O
-	O
administered	O
with	O
DRV	O
/	O
r	O
.	O

Paternal	O
exposure	O
and	O
counselling	O
:	O
experience	O
of	O
a	O
Teratology	O
Information	O
Service	O
.	O

We	O
describe	O
paternal	O
exposure	O
and	O
counselling	O
in	O
a	O
selected	O
population	O
calling	O
to	O
an	O
Italian	O
Teratology	O
Information	O
Service	O
(	O
TIS	O
)	O
.	O

The	O
majority	O
of	O
callers	O
asked	O
for	O
paternal	O
drug	O
exposure	O
(	O
76	O
%	O
,	O
drugs	O
except	O
chemotherapy	O
)	O
and	O
treatment	O
for	O
cancer	B
(	O
17	O
%	O
,	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
)	O
.	O

Others	O
asked	O
for	O
exposure	O
to	O
diagnostic	O
radiations	O
(	O
4	O
%	O
)	O
,	O
recreational	O
drugs	O
(	O
2	O
%	O
)	O
and	O
occupational	O
chemicals	O
(	O
1	O
%	O
)	O
.	O

Among	O
paternal	O
drugs	O
neurological	O
compounds	O
,	O
immunosuppressive	O
drugs	O
and	O
antiviral	O
agents	O
were	O
the	O
main	O
reasons	O
for	O
calling	O
.	O

In	O
humans	O
,	O
there	O
are	O
no	O
evidences	O
of	O
birth	B
defects	I
after	O
paternal	O
exposures	O
,	O
but	O
to	O
minimize	O
any	O
possible	O
risk	O
,	O
counselling	O
in	O
men	O
exposed	O
to	O
radio	O
and	O
chemotherapy	O
should	O
recommend	O
delaying	O
conception	O
for	O
at	O
least	O
3	O
months	O
after	O
the	O
end	O
of	O
the	O
therapy	O
.	O

Male	O
patients	O
treated	O
with	O
drugs	O
,	O
whose	O
teratogenic	O
potential	O
has	O
been	O
well	O
assessed	O
or	O
suspected	O
for	O
maternal	O
exposure	O
,	O
should	O
be	O
advised	O
to	O
practice	O
effective	O
birth	O
control	O
during	O
therapy	O
and	O
up	O
to	O
one	O
or	O
two	O
cycles	O
of	O
spermatogenesis	O
and	O
to	O
avoid	O
semen	O
contact	O
with	O
vaginal	O
walls	O
during	O
first	O
trimester	O
of	O
pregnancy	O
.	O

A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
study	O
of	O
once	O
-	O
daily	O
dexmethylphenidate	O
in	O
children	O
with	O
attention	B
-	I
deficit	I
hyperactivity	I
disorder	I
:	O
rapid	O
onset	O
of	O
effect	O
.	O

BACKGROUND	O
:	O
Long	O
-	O
acting	O
methylphenidate	O
formulations	O
provide	O
control	O
of	O
attention	B
-	I
deficit	I
hyperactivity	I
disorder	I
(	O
ADHD	B
)	O
symptoms	O
for	O
up	O
to	O
12	O
hours	O
;	O
however	O
,	O
not	O
all	O
formulations	O
have	O
rapid	O
onset	O
of	O
therapeutic	O
effect	O
,	O
which	O
is	O
essential	O
for	O
providing	O
symptom	O
control	O
during	O
morning	O
hours	O
.	O

The	O
primary	O
objective	O
of	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
dexmethylphenidate	O
extended	O
release	O
(	O
ER	O
)	O
versus	O
placebo	O
by	O
measuring	O
the	O
change	O
from	O
pre	O
-	O
dose	O
to	O
0.5	O
hours	O
post	O
-	O
dose	O
on	O
the	O
Swanson	O
,	O
Kotkin	O
,	O
Agler	O
,	O
M	O
-	O
Flynn	O
and	O
Pelham	O
(	O
SKAMP	O
)	O
rating	O
scale	O
.	O

METHODS	O
:	O
Eighty	O
-	O
six	O
children	O
(	O
6	O
-	O
12	O
years	O
)	O
with	O
ADHD	B
diagnosed	O
using	O
the	O
DSM	O
-	O
IV	O
criteria	O
were	O
randomized	O
to	O
receive	O
dexmethylphenidate	O
ER	O
20	O
mg	O
/	O
day	O
or	O
placebo	O
,	O
sequentially	O
,	O
for	O
7	O
days	O
,	O
with	O
the	O
final	O
dose	O
administered	O
in	O
a	O
laboratory	O
classroom	O
setting	O
on	O
day	O
7	O
of	O
each	O
treatment	O
period	O
.	O

The	O
primary	O
efficacy	O
comparison	O
was	O
change	O
in	O
the	O
SKAMP	O
-	O
Combined	O
score	O
from	O
pre	O
-	O
dose	O
to	O
0.5	O
hours	O
post	O
-	O
dose	O
,	O
with	O
additional	O
secondary	O
assessments	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
and	O
8	O
hours	O
post	O
-	O
dose	O
.	O

Secondary	O
efficacy	O
measures	O
included	O
change	O
from	O
pre	O
-	O
dose	O
at	O
all	O
timepoints	O
in	O
the	O
SKAMP	O
-	O
Attention	O
and	O
SKAMP	O
-	O
Deportment	O
,	O
Math	O
Test	O
-	O
Attempted	O
and	O
Math	O
Test	O
-	O
Correct	O
scores	O
,	O
and	O
change	O
from	O
baseline	O
on	O
the	O
Conners	O
'	O
ADHD	B
/	O
DSM	O
-	O
IV	O
Scale	O
for	O
Parents	O
(	O
CADS	O
-	O
P	O
)	O
.	O

In	O
an	O
exploratory	O
analysis	O
,	O
a	O
daily	O
diary	O
card	O
was	O
completed	O
by	O
parents	O
on	O
the	O
children	O
's	O
in	O
-	O
home	O
behaviour	O
before	O
school	O
.	O

Safety	O
was	O
assessed	O
by	O
occurrence	O
of	O
adverse	O
events	O
,	O
monitoring	O
of	O
vital	O
signs	O
and	O
interpretation	O
of	O
ECGs	O
.	O

RESULTS	O
:	O
Significant	O
improvements	O
were	O
noted	O
at	O
0.5	O
hours	O
and	O
at	O
all	O
timepoints	O
post	O
-	O
dose	O
throughout	O
the	O
8	O
-	O
hour	O
laboratory	O
classroom	O
day	O
for	O
dexmethylphenidate	O
ER	O
vs	O
placebo	O
in	O
the	O
primary	O
outcome	O
measure	O
of	O
the	O
SKAMP	O
-	O
Combined	O
scores	O
(	O
p	O
<	O
0.001	O
)	O
,	O
as	O
well	O
as	O
SKAMP	O
-	O
Attention	O
,	O
SKAMP	O
-	O
Deportment	O
,	O
Math	O
Test	O
-	O
Attempted	O
and	O
Math	O
Test	O
-	O
Correct	O
scores	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
changes	O
from	O
baseline	O
in	O
CADS	O
-	O
P	O
scores	O
were	O
significantly	O
greater	O
with	O
dexmethylphenidate	O
ER	O
than	O
placebo	O
(	O
-	O
16.382	O
vs	O
-	O
4.622	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Responses	O
to	O
all	O
diary	O
questions	O
indicated	O
significant	O
improvement	O
with	O
dexmethylphenidate	O
ER	O
treatment	O
versus	O
placebo	O
(	O
all	O
p	O
<	O
0.001	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
abdominal	B
pain	I
(	O
dexmethylphenidate	O
ER	O
3.5	O
%	O
;	O
placebo	O
4.7	O
%	O
)	O
,	O
headache	B
(	O
dexmethylphenidate	O
ER	O
3.5	O
%	O
;	O
placebo	O
2.3	O
%	O
)	O
and	O
increased	B
appetite	I
(	O
dexmethylphenidate	O
ER	O
0	O
%	O
;	O
placebo	O
3.5	O
%	O
)	O
.	O

CONCLUSION	O
:	O
Compared	O
with	O
placebo	O
,	O
once	O
-	O
daily	O
dexmethylphenidate	O
ER	O
20	O
mg	O
provided	O
rapid	O
and	O
significant	O
improvement	O
at	O
0.5	O
hours	O
post	O
-	O
dose	O
in	O
attention	O
,	O
deportment	O
and	O
academic	O
performance	O
,	O
which	O
was	O
sustained	O
for	O
8	O
hours	O
post	O
-	O
dose	O
.	O

Overall	O
,	O
once	O
-	O
daily	O
dexmethylphenidate	O
ER	O
20	O
mg	O
was	O
well	O
tolerated	O
.	O

In	O
an	O
analysis	O
of	O
parental	O
assessment	O
of	O
diary	O
responses	O
,	O
children	O
appeared	O
more	O
organized	O
,	O
and	O
morning	O
preparation	O
for	O
school	O
was	O
smoother	O
and	O
less	O
frustrating	O
with	O
once	O
-	O
daily	O
dexmethylphenidate	O
ER	O
compared	O
with	O
placebo	O
.	O

Clostridium	O
perfringens	O
enterotoxin	O
in	O
antibiotic	B
-	I
associated	I
diarrhea	I
.	O

Clostridium	O
perfringens	O
type	O
A	O
is	O
associated	O
with	O
5	O
-	O
20	O
%	O
cases	O
of	O
antibiotic	B
-	I
associated	I
diarrhea	I
(	O
AAD	O
)	O
even	O
though	O
Clostridium	O
difficile	O
is	O
implicated	O
in	O
the	O
most	O
severe	O
cases	O
.	O

Fecal	O
specimens	O
from	O
one	O
hundred	O
hospitalized	O
patients	O
,	O
who	O
developed	O
diarrhea	B
regardless	O
of	O
antibiotic	O
intake	O
and	O
who	O
were	O
negative	O
for	O
C	O
.	O

difficile	O
toxin	O
assay	O
,	O
were	O
investigated	O
for	O
C	O
.	O

perfringens	O
enterotoxin	O
(	O
CPE	O
)	O
.	O

Simultaneously	O
,	O
cultures	O
were	O
set	O
up	O
for	O
other	O
possible	O
aetiological	O
factors	O
.	O

Ten	B
healthy	O
controls	O
were	O
also	O
similarly	O
investigated	O
.	O

CPE	O
was	O
positive	O
in	O
2	O
/	O
100	O
(	O
2	O
%	O
)	O
of	O
the	O
patients	O
and	O
the	O
samples	O
were	O
also	O
positive	O
for	O
the	O
organism	O
in	O
culture	O
.	O

Other	O
organisms	O
isolated	O
were	O
non	O
-	O
toxigenic	O
C	O
.	O

difficile	O
(	O
4	O
%	O
)	O
,	O
staphylococci	O
(	O
6	O
%	O
)	O
,	O
Candida	O
(	O
18	O
%	O
)	O
and	O
Klebsiella	O
pneumoniae	O
(	O
1	O
%	O
)	O
.	O

Stool	O
samples	O
from	O
healthy	O
controls	O
grew	O
mixed	O
growth	O
of	O
no	O
significance	O
and	O
CPE	O
was	O
negative	O
in	O
all	O
of	O
them	O
.	O

Detection	O
of	O
CPE	O
is	O
not	O
part	O
of	O
routine	O
laboratory	O
investigation	O
due	O
to	O
resource	O
implication	O
.	O

Criteria	O
for	O
initiating	O
investigations	O
have	O
to	O
be	O
therefore	O
established	O
by	O
understanding	O
the	O
true	O
burden	O
of	O
C	O
.	O

perfringens	O
-	O
associated	O
AAD	O
by	O
further	O
research	O
.	O

Should	O
we	O
abandon	O
corticosteroids	O
during	O
septic	B
shock	I
?	O

No	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
With	O
the	O
publication	O
of	O
the	O
results	O
of	O
the	O
recent	O
CORTICUS	O
trial	O
,	O
stress	O
(	O
'	O
low	O
'	O
)	O
doses	O
of	O
corticosteroids	O
for	O
the	O
treatment	O
of	O
vasopressor	O
-	O
dependent	O
septic	B
shock	I
in	O
adults	O
can	O
still	O
be	O
considered	O
controversial	O
.	O

The	O
purpose	O
of	O
this	O
narrative	O
review	O
is	O
to	O
elaborate	O
the	O
pros	O
and	O
cons	O
of	O
this	O
treatment	O
in	O
clinical	O
practice	O
and	O
to	O
formulate	O
clinical	O
and	O
research	O
directions	O
.	O

RECENT	O
FINDINGS	O
:	O
The	O
recent	O
CORTICUS	O
study	O
only	O
shows	O
a	O
beneficial	O
effect	O
of	O
stress	O
doses	O
of	O
corticosteroids	O
in	O
the	O
time	O
interval	O
to	O
shock	O
reversal	O
and	O
not	O
on	O
mortality	O
,	O
potentially	O
explained	O
by	O
an	O
increased	O
risk	O
for	O
superinfection	B
.	O

The	O
mortality	O
in	O
the	O
placebo	O
arm	O
was	O
relatively	O
low	O
and	O
lower	O
than	O
in	O
earlier	O
randomized	O
studies	O
in	O
which	O
stress	O
doses	O
of	O
corticosteroids	O
had	O
a	O
favorable	O
hemodynamic	O
effect	O
and	O
conferred	O
a	O
survival	O
benefit	O
in	O
septic	B
shock	I
.	O

SUMMARY	O
:	O
Treatment	O
by	O
stress	O
doses	O
of	O
corticosteroids	O
should	O
not	O
be	O
abandoned	O
during	O
septic	B
shock	I
.	O

Additional	O
studies	O
are	O
needed	O
,	O
however	O
,	O
to	O
better	O
delineate	O
the	O
patient	O
group	O
with	O
the	O
highest	O
likelihood	O
to	O
benefit	O
from	O
this	O
therapy	O
,	O
as	O
a	O
function	O
of	O
severity	O
of	O
illness	O
,	O
response	O
to	O
adrenocorticotrophic	O
hormone	O
testing	O
or	O
both	O
.	O

For	O
now	O
,	O
results	O
of	O
the	O
CORTICUS	O
study	O
should	O
not	O
change	O
current	O
clinical	O
practice	O
of	O
administering	O
200	O
-	O
300	O
mg	O
of	O
hydrocortisone	O
daily	O
(	O
in	O
divided	O
doses	O
)	O
in	O
case	O
of	O
fluid	O
and	O
vasopressor	O
-	O
insensitive	O
septic	B
shock	I
and	O
rapid	O
tapering	O
of	O
this	O
treatment	O
on	O
the	O
basis	O
of	O
a	O
hemodynamic	O
response	O
.	O

Inhibition	O
of	O
cell	O
-	O
cycle	O
progression	O
in	O
human	O
colorectal	O
carcinoma	O
Lovo	O
cells	O
by	O
andrographolide	O
.	O

In	O
recent	O
years	O
,	O
attention	O
has	O
been	O
focused	O
on	O
the	O
anti	O
-	O
cancer	O
properties	O
of	O
pure	O
components	O
,	O
an	O
important	O
role	O
in	O
the	O
prevention	O
of	O
disease	O
.	O

Andrographolide	O
(	O
Andro	O
)	O
,	O
the	O
major	O
constituent	O
of	O
Andrographis	O
paniculata	O
(	O
Burm	O
.	O
F	O
.	O
)	O

Nees	O
plant	O
,	O
is	O
implicated	O
towards	O
its	O
pharmacological	O
activity	O
.	O

To	O
investigate	O
the	O
mechanism	O
basis	O
for	O
the	O
anti	O
-	O
tumor	O
properties	O
of	O
Andro	O
,	O
Andro	O
was	O
used	O
to	O
examine	O
its	O
effect	O
on	O
cell	O
-	O
cycle	O
progression	O
in	O
human	O
colorectal	O
carcinoma	O
Lovo	O
cells	O
.	O

The	O
data	O
from	O
cell	O
growth	O
experiment	O
showed	O
that	O
Andro	O
exhibited	O
the	O
anti	O
-	O
proliferation	O
effect	O
on	O
Lovo	O
cells	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O

This	O
event	O
was	O
accompanied	O
the	O
arrest	O
of	O
the	O
cells	O
at	O
the	O
G1	O
-	O
S	O
phase	O
by	O
Andro	O
at	O
the	O
tested	O
concentrations	O
of	O
0	O
-	O
30	O
microM	O
.	O

Cellular	O
uptake	O
of	O
Andro	O
and	O
Andro	O
was	O
confirmed	O
by	O
capillary	O
electrophoresis	O
analysis	O
and	O
the	O
intracellular	O
accumulation	O
of	O
Andro	O
(	O
0.61	O
+	O
/	O
-	O
0.07	O
microM	O
/	O
mg	O
protein	O
)	O
was	O
observed	O
when	O
treatment	O
of	O
Lovo	O
cells	O
with	O
Andro	O
for	O
12h	O
.	O

In	O
addition	O
,	O
an	O
accumulation	O
of	O
the	O
cells	O
in	O
G1	O
phase	O
(	O
15	O
%	O
increase	O
for	O
10	O
microM	O
of	O
Andro	O
)	O
was	O
observed	O
as	O
well	O
as	O
by	O
the	O
association	O
with	O
a	O
marked	O
decrease	O
in	O
the	O
protein	O
expression	O
of	O
Cyclin	O
A	O
,	O
Cyclin	O
D1	O
,	O
Cdk2	O
and	O
Cdk4	O
.	O

Andro	O
also	O
inducted	O
the	O
content	O
of	O
Cdk	O
inhibitor	O
p21	O
and	O
p16	O
,	O
and	O
the	O
phosphorylation	O
of	O
p53	O
.	O

Further	O
immunoprecipitation	O
studies	O
found	O
that	O
,	O
in	O
response	O
to	O
the	O
treatment	O
,	O
the	O
formation	O
of	O
Cyclin	O
D1	O
/	O
Cdk4	O
and	O
Cyclin	O
A	O
/	O
Cdk2	O
complexes	O
had	O
declined	O
,	O
preventing	O
the	O
phosphorylation	O
of	O
Rb	O
and	O
the	O
subsequent	O
dissociation	O
of	O
Rb	O
/	O
E2F	O
complex	O
.	O

These	O
results	O
suggested	O
Andro	O
can	O
inhibit	O
Lovo	O
cell	O
growth	O
by	O
G1	O
-	O
S	O
phase	O
arrest	O
,	O
and	O
was	O
exerted	O
by	O
inducing	O
the	O
expression	O
of	O
p53	O
,	O
p21	O
and	O
p16	O
that	O
,	O
in	O
turn	O
,	O
repressed	O
the	O
activity	O
of	O
Cyclin	O
D1	O
/	O
Cdk4	O
and	O
/	O
or	O
Cyclin	O
A	O
/	O
Cdk2	O
,	O
as	O
well	O
as	O
Rb	O
phosphorylation	O
.	O

Impact	O
of	O
antioxidant	O
supplementation	O
on	O
chemotherapeutic	B
toxicity	I
:	O
a	O
systematic	O
review	O
of	O
the	O
evidence	O
from	O
randomized	O
controlled	O
trials	O
.	O

Much	O
debate	O
has	O
focused	O
on	O
whether	O
antioxidants	O
interfere	O
with	O
the	O
efficacy	O
of	O
cancer	B
chemotherapy	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
systematically	O
review	O
the	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
evidence	O
evaluating	O
the	O
effects	O
of	O
concurrent	O
use	O
of	O
antioxidants	O
with	O
chemotherapy	O
on	O
toxic	O
side	O
effects	O
.	O

We	O
performed	O
a	O
search	O
of	O
literature	O
from	O
1966	O
-	O
October	O
2007	O
using	O
MEDLINE	O
,	O
Cochrane	O
,	O
CinAhl	O
,	O
AMED	O
,	O
AltHealthWatch	O
and	O
EMBASE	O
databases	O
.	O

Randomized	O
,	O
controlled	O
clinical	O
trials	O
reporting	O
antioxidant	O
-	O
based	O
mitigation	O
of	O
chemotherapy	B
toxicity	I
were	O
included	O
in	O
the	O
final	O
tally	O
.	O

Searches	O
were	O
performed	O
following	O
a	O
standardized	O
protocol	O
for	O
systematic	O
reviews	O
.	O

Only	O
33	O
of	O
965	O
articles	O
considered	O
,	O
including	O
2,446	O
subjects	O
,	O
met	O
the	O
inclusion	O
criteria	O
.	O

Antioxidants	O
evaluated	O
were	O
:	O
glutathione	O
(	O
11	O
)	O
,	O
melatonin	O
(	O
7	O
)	O
,	O
vitamin	O
A	O
(	O
1	O
)	O
,	O
an	O
antioxidant	O
mixture	O
(	O
2	O
)	O
,	O
N	O
-	O
acetylcysteine	O
(	O
2	O
)	O
,	O
vitamin	O
E	O
(	O
5	O
)	O
,	O
selenium	O
(	O
2	O
)	O
,	O
L	O
-	O
carnitine	O
(	O
1	O
)	O
,	O
Co	O
-	O
Q10	O
(	O
1	O
)	O
and	O
ellagic	O
acid	O
(	O
1	O
)	O
.	O

The	O
majority	O
(	O
24	O
)	O
of	O
the	O
33	O
studies	O
included	O
reported	O
evidence	O
of	O
decreased	O
toxicities	O
from	O
the	O
concurrent	O
use	O
of	O
antioxidants	O
with	O
chemotherapy	O
.	O

Nine	O
studies	O
reported	O
no	O
difference	O
in	O
toxicities	O
between	O
the	O
2	O
groups	O
.	O

Only	O
1	O
study	O
(	O
vitamin	O
A	O
)	O
reported	O
a	O
significant	O
increase	O
in	O
toxicity	O
in	O
the	O
antioxidant	O
group	O
.	O

Five	O
studies	O
reported	O
the	O
antioxidant	O
group	O
completed	O
more	O
full	O
doses	O
of	O
chemotherapy	O
or	O
had	O
less	O
-	O
dose	O
reduction	O
than	O
control	O
groups	O
.	O

Statistical	O
power	O
and	O
poor	O
study	O
quality	O
were	O
concerns	O
with	O
some	O
studies	O
.	O

This	O
review	O
provides	O
the	O
first	O
systematically	O
reviewed	O
evidence	O
that	O
antioxidant	O
supplementation	O
during	O
chemotherapy	O
holds	O
potential	O
for	O
reducing	O
dose	O
-	O
limiting	O
toxicities	O
.	O

However	O
,	O
well	O
-	O
designed	O
studies	O
evaluating	O
larger	O
populations	O
of	O
patients	O
given	O
specific	O
antioxidants	O
defined	O
by	O
dose	O
and	O
schedule	O
relative	O
to	O
chemotherapy	O
are	O
warranted	O
.	O

Optimizing	O
docetaxel	O
chemotherapy	O
in	O
patients	O
with	O
cancer	B
of	I
the	I
gastric	I
and	I
gastroesophageal	I
junction	I
:	O
evolution	O
of	O
the	O
docetaxel	O
,	O
cisplatin	O
,	O
and	O
5	O
-	O
fluorouracil	O
regimen	O
.	O

Advanced	O
gastroesophageal	B
cancer	I
patients	O
are	O
often	O
treated	O
with	O
systemic	O
combination	O
chemotherapy	O
.	O

The	O
V	O
-	O
325	O
study	O
demonstrated	O
that	O
adding	O
docetaxel	O
(	O
D	O
)	O
to	O
a	O
frequently	O
used	O
regimen	O
of	O
cisplatin	O
and	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
provided	O
benefits	O
with	O
regard	O
to	O
overall	O
survival	O
,	O
response	O
rate	O
,	O
time	O
-	O
to	O
-	O
disease	O
progression	O
,	O
clinical	O
benefit	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

Although	O
the	O
DCF	O
regimen	O
provides	O
these	O
advantages	O
,	O
it	O
is	O
accompanied	O
by	O
an	O
increase	O
in	O
toxicity	O
compared	O
with	O
the	O
doublet	O
regimen	O
.	O

The	O
toxicity	O
profile	O
of	O
DCF	O
is	O
acceptable	O
only	O
with	O
appropriately	O
selected	O
patients	O
and	O
comprehensive	O
toxicity	O
management	O
strategies	O
.	O

The	O
objective	O
of	O
the	O
current	O
review	O
was	O
to	O
identify	O
trials	O
that	O
investigated	O
modifications	O
to	O
the	O
original	O
DCF	O
regimen	O
to	O
improve	O
its	O
toxicity	O
profile	O
and	O
summarize	O
response	O
rate	O
and	O
toxicities	O
.	O

An	O
attempt	O
was	O
also	O
made	O
to	O
summarize	O
ongoing	O
modifications	O
of	O
the	O
DCF	O
regimen	O
.	O

MEDLINE	O
,	O
major	O
meeting	O
proceedings	O
,	O
and	O
the	O
government	O
clinical	O
trials	O
website	O
were	O
searched	O
until	O
2007	O
.	O

The	O
modified	O
DCF	O
regimens	O
appear	O
to	O
improve	O
the	O
toxicity	O
profile	O
when	O
compared	O
with	O
the	O
original	O
DCF	O
regimen	O
.	O

The	O
docetaxel	O
-	O
based	O
triplet	O
combinations	O
appear	O
to	O
have	O
a	O
higher	O
response	O
rate	O
than	O
the	O
doublet	O
combinations	O
.	O

Many	O
institutions	O
and	O
cooperative	O
groups	O
continue	O
to	O
study	O
docetaxel	O
-	O
based	O
modifications	O
of	O
the	O
DCF	O
regimen	O
to	O
treat	O
patients	O
with	O
gastroesophageal	B
carcinoma	I
.	O

However	O
,	O
although	O
modified	O
DCF	O
reduces	O
the	O
frequency	O
of	O
severe	O
toxicities	O
previously	O
reported	O
with	O
DCF	O
,	O
considerably	O
more	O
advances	O
are	O
needed	O
to	O
improve	O
the	O
safety	O
,	O
survival	O
,	O
and	O
convenience	O
of	O
patients	O
with	O
advanced	O
gastroesophageal	B
cancer	I
.	O

Pentachlorophenol	O
decreases	O
ATP	O
levels	O
in	O
human	O
natural	O
killer	O
cells	O
.	O

Pentachlorophenol	O
(	O
PCP	O
)	O
is	O
used	O
as	O
a	O
wood	O
preservative	O
and	O
is	O
found	O
in	O
human	O
blood	O
and	O
urine	O
.	O

PCP	O
causes	O
significant	O
decreases	O
in	O
the	O
tumor	O
-	O
killing	O
(	O
lytic	O
)	O
function	O
of	O
human	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
,	O
a	O
critical	O
immune	O
defense	O
.	O

The	O
current	O
study	O
examined	O
the	O
association	O
between	O
decreased	O
lytic	O
function	O
and	O
decreased	O
ATP	O
levels	O
,	O
as	O
well	O
as	O
the	O
ability	O
of	O
antioxidants	O
(	O
vitamin	O
E	O
and	O
reduced	O
glutathione	O
)	O
to	O
prevent	O
PCP	O
-	O
induced	O
decreases	O
in	O
either	O
ATP	O
levels	O
or	O
lytic	O
function	O
.	O

Exposure	O
of	O
NK	O
cells	O
to	O
10	O
microm	O
PCP	O
decreased	O
ATP	O
levels	O
by	O
15	O
%	O
at	O
24	O
h	O
,	O
and	O
exposure	O
to	O
5	O
microm	O
PCP	O
decreased	O
ATP	O
levels	O
by	O
32	O
%	O
at	O
48	O
h	O
.	O

No	O
effects	O
were	O
seen	O
with	O
0.5	O
microm	O
at	O
48	O
h	O
or	O
with	O
5	O
microm	O
at	O
24	O
h	O
.	O

However	O
,	O
10	O
microm	O
PCP	O
decreased	O
lytic	O
function	O
by	O
69	O
%	O
at	O
24	O
h	O
and	O
5	O
microm	O
decreased	O
it	O
by	O
90	O
%	O
at	O
48	O
h	O
.	O

Even	O
0.5	O
microm	O
PCP	O
decreased	O
lytic	O
function	O
by	O
46	O
%	O
at	O
48	O
h	O
.	O

None	O
of	O
these	O
effects	O
were	O
prevented	O
by	O
pretreatment	O
with	O
1	O
mm	O
vitamin	O
E	O
or	O
reduced	O
glutathione	O
.	O

Using	O
dietary	O
exposure	O
and	O
physiologically	O
based	O
pharmacokinetic	O
/	O
pharmacodynamic	O
modeling	O
in	O
human	O
risk	O
extrapolations	O
for	O
acrylamide	B
toxicity	I
.	O

The	O
discovery	O
of	O
acrylamide	O
(	O
AA	O
)	O
in	O
many	O
common	O
cooked	O
starchy	O
foods	O
has	O
presented	O
significant	O
challenges	O
to	O
toxicologists	O
,	O
food	O
scientists	O
,	O
and	O
national	O
regulatory	O
and	O
public	O
health	O
organizations	O
because	O
of	O
the	O
potential	O
for	O
producing	O
neurotoxicity	B
and	O
cancer	B
.	O

This	O
paper	O
reviews	O
some	O
of	O
the	O
underlying	O
experimental	O
bases	O
for	O
AA	B
toxicity	I
and	O
earlier	O
risk	O
assessments	O
.	O

Then	O
,	O
dietary	O
exposure	O
modeling	O
is	O
used	O
to	O
estimate	O
probable	O
AA	O
intake	O
in	O
the	O
U	O
.	O

S	O
.	O

population	O
,	O
and	O
physiologically	O
based	O
pharmacokinetic	O
/	O
pharmacodynamic	O
(	O
PBPK	O
/	O
PD	O
)	O
modeling	O
is	O
used	O
to	O
integrate	O
the	O
findings	O
of	O
rodent	O
neurotoxicity	B
and	O
cancer	B
into	O
estimates	O
of	O
risks	O
from	O
human	O
AA	O
exposure	O
through	O
the	O
diet	O
.	O

The	O
goal	O
of	O
these	O
modeling	O
techniques	O
is	O
to	O
reduce	O
the	O
uncertainty	O
inherent	O
in	O
extrapolating	O
toxicological	O
findings	O
across	O
species	O
and	O
dose	O
by	O
comparing	O
common	O
exposure	O
biomarkers	O
.	O

PBPK	O
/	O
PD	O
modeling	O
estimated	O
population	O
-	O
based	O
lifetime	O
excess	O
cancer	B
risks	O
from	O
average	O
AA	O
consumption	O
in	O
the	O
diet	O
in	O
the	O
range	O
of	O
1	O
-	O
4	O
x	O
10	O
(	O
-	O
4	O
)	O
;	O
however	O
,	O
modeling	O
did	O
not	O
support	O
a	O
link	O
between	O
dietary	O
AA	O
exposure	O
and	O
human	O
neurotoxicity	B
because	O
marginal	O
exposure	O
ratios	O
were	O
50	O
-	O
300	O
lower	O
than	O
in	O
rodents	O
.	O

In	O
addition	O
,	O
dietary	O
exposure	O
modeling	O
suggests	O
that	O
because	O
AA	O
is	O
found	O
in	O
so	O
many	O
common	O
foods	O
,	O
even	O
big	O
changes	O
in	O
concentration	O
for	O
single	O
foods	O
or	O
groups	O
of	O
foods	O
would	O
probably	O
have	O
a	O
small	O
impact	O
on	O
overall	O
population	O
-	O
based	O
intake	O
and	O
risk	O
.	O

These	O
results	O
suggest	O
that	O
a	O
more	O
holistic	O
analysis	O
of	O
dietary	B
cancer	I
risks	O
may	O
be	O
appropriate	O
,	O
by	O
which	O
potential	O
risks	O
from	O
AA	O
should	O
be	O
considered	O
in	O
conjunction	O
with	O
other	O
risks	O
and	O
benefits	O
from	O
foods	O
.	O

Review	O
article	O
:	O
new	O
drug	O
formulations	O
,	O
chemical	O
entities	O
and	O
therapeutic	O
approaches	O
for	O
the	O
management	O
of	O
ulcerative	B
colitis	I
.	O

BACKGROUND	O
:	O
Treatment	O
options	O
for	O
ulcerative	B
colitis	I
(	O
UC	B
)	O
are	O
expanding	O
with	O
the	O
development	O
of	O
novel	O
drug	O
formulations	O
and	O
dosing	O
regimens	O
and	O
new	O
chemical	O
entities	O
.	O

Although	O
the	O
goals	O
of	O
medical	O
therapy	O
for	O
UC	B
remain	O
unchanged	O
,	O
that	O
is	O
to	O
induce	O
and	O
to	O
maintain	O
remission	O
,	O
focus	O
has	O
also	O
centred	O
on	O
improving	O
patient	O
compliance	O
,	O
modifying	O
the	O
natural	O
course	O
of	O
disease	O
and	O
healing	O
the	O
mucosa	O
.	O

AIM	O
:	O
To	O
examine	O
novel	O
formulations	O
,	O
new	O
chemical	O
entities	O
and	O
novel	O
therapeutic	O
approaches	O
to	O
the	O
management	O
of	O
UC	B
.	O

METHODS	O
:	O
Searches	O
for	O
all	O
studies	O
related	O
to	O
UC	B
treatment	O
in	O
Medline	O
and	O
abstracts	O
from	O
major	O
national	O
and	O
international	O
meetings	O
published	O
in	O
the	O
last	O
10	O
years	O
.	O

RESULTS	O
:	O
5	O
-	O
Aminosalicylic	O
acids	O
(	O
5	O
-	O
ASA	O
)	O
remain	O
the	O
standard	O
first	O
-	O
line	O
treatment	O
for	O
patients	O
with	O
mild	O
to	O
moderately	O
active	O
UC	B
.	O

New	O
formulations	O
with	O
altered	O
delivery	O
,	O
and	O
new	O
dosing	O
regimens	O
have	O
demonstrated	O
possible	O
improvements	O
in	O
efficacy	O
compared	O
with	O
historically	O
available	O
preparations	O
and	O
dosing	O
patterns	O
.	O

Once	O
-	O
daily	O
dosing	O
,	O
micropellet	O
formulations	O
,	O
and	O
high	O
-	O
dose	O
tablets	O
offer	O
enhanced	O
efficacy	O
and	O
improved	O
compliance	O
.	O

5	O
-	O
ASA	O
is	O
now	O
recognized	O
as	O
a	O
ligand	O
for	O
peroxisome	O
proliferator	O
activated	O
receptor	O
-	O
gamma	O
(	O
PPAR	O
-	O
gamma	O
)	O
and	O
it	O
has	O
a	O
role	O
as	O
a	O
chemo	O
-	O
preventive	O
agent	O
in	O
long	O
-	O
standing	O
UC	B
.	O

New	O
colonic	O
release	O
corticosteroid	O
formulations	O
help	O
to	O
limit	O
systemic	B
toxicity	I
;	O
turmeric	O
,	O
tacrolimus	O
and	O
infliximab	O
have	O
shown	O
promising	O
results	O
.	O

New	O
anti	O
-	O
inflammatory	O
targeted	O
therapies	O
include	O
an	O
anti	O
-	O
CD3	O
antibody	O
,	O
selective	O
integrin	O
blockers	O
,	O
anti	O
-	O
IL	O
-	O
2	O
antibody	O
and	O
PPAR	O
-	O
gamma	O
agonists	O
.	O

CONCLUSION	O
:	O
The	O
evolution	O
of	O
novel	O
oral	O
5	O
-	O
ASA	O
formulations	O
and	O
dosage	O
regimens	O
,	O
and	O
recent	O
development	O
of	O
new	O
molecules	O
have	O
expanded	O
the	O
therapeutic	O
armamentarium	O
of	O
UC	B
.	O

Dietary	O
flavonoids	O
inhibit	O
the	O
anticancer	O
effects	O
of	O
the	O
proteasome	O
inhibitor	O
bortezomib	O
.	O

Dietary	O
flavonoids	O
have	O
many	O
health	O
-	O
promoting	O
actions	O
,	O
including	O
anticancer	O
activity	O
via	O
proteasome	O
inhibition	O
.	O

Bor	O
-	O
tezomib	O
is	O
a	O
dipeptide	O
boronate	O
proteasome	O
inhibitor	O
that	O
has	O
activity	O
in	O
the	O
treatment	O
of	O
multiple	B
myeloma	I
but	O
is	O
not	O
effective	O
in	O
chronic	B
lymphocytic	I
leukemia	I
(	O
CLL	B
)	O
.	O

Although	O
CLL	B
cells	O
are	O
sensitive	O
in	O
vitro	O
to	O
bortezomib	O
-	O
induced	O
apoptosis	B
when	O
cultured	O
in	O
medium	O
,	O
the	O
killing	O
activity	O
was	O
blocked	O
when	O
cultured	O
in	O
50	O
%	O
fresh	O
autologous	O
plasma	O
.	O

Dietary	O
flavonoids	O
,	O
quercetin	O
and	O
myricetin	O
,	O
which	O
are	O
abundant	O
in	O
plasma	O
,	O
inhibited	O
bortezomib	O
-	O
induced	O
apoptosis	B
of	O
primary	O
CLL	B
and	O
malignant	O
B	O
-	O
cell	O
lines	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

This	O
inhibitory	O
effect	O
was	O
associated	O
with	O
chemical	O
reactions	O
between	O
quercetin	O
and	O
the	O
boronic	O
acid	O
group	O
,	O
-	O
RB	O
(	O
OH	O
)	O
2	O
,	O
in	O
bortezomib	O
.	O

The	O
addition	O
of	O
boric	O
acid	O
diminished	O
the	O
inhibitory	O
effect	O
of	O
both	O
quercetin	O
and	O
plasma	O
on	O
bortezomib	O
-	O
induced	O
apoptosis	B
.	O

The	O
protective	O
effect	O
was	O
also	O
reduced	O
when	O
myeloma	B
cell	O
lines	O
,	O
but	O
not	O
B	O
-	O
cell	O
lines	O
,	O
were	O
preincubated	O
with	O
quercetin	O
,	O
indicating	O
a	O
direct	O
effect	O
of	O
quercetin	O
on	O
myeloma	B
cells	O
.	O

At	O
high	O
doses	O
,	O
quercetin	O
itself	O
induced	O
tumor	O
cell	B
death	I
.	O

These	O
data	O
indicate	O
that	O
dietary	O
flavonoids	O
limit	O
the	O
efficacy	O
of	O
bortezomib	O
,	O
whereas	O
supplemental	O
inorganic	O
boric	O
acid	O
is	O
able	O
to	O
reverse	O
this	O
.	O

The	O
complex	O
interactions	O
between	O
quercetin	O
,	O
tumor	O
cells	O
,	O
and	O
bortezomib	O
mean	O
caution	O
is	O
required	O
when	O
giving	O
dietary	O
advice	O
to	O
patients	O
.	O

Nitrate	O
-	O
induced	O
toxicity	O
and	O
preconditioning	O
:	O
a	O
rationale	O
for	O
reconsidering	O
the	O
use	O
of	O
these	O
drugs	O
.	O

Although	O
organic	O
nitrates	O
have	O
been	O
clinically	O
used	O
for	O
more	O
than	O
a	O
century	O
,	O
findings	O
in	O
the	O
last	O
decade	O
have	O
radically	O
challenged	O
our	O
traditional	O
view	O
concerning	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
their	O
clinical	O
effects	O
and	O
implications	O
.	O

While	O
their	O
hemodynamic	O
properties	O
are	O
well	O
known	O
,	O
the	O
knowledge	O
that	O
nitrates	O
possess	O
previously	O
unexpected	O
nonhemodynamic	O
effects	O
is	O
a	O
unique	O
opportunity	O
of	O
which	O
clinicians	O
should	O
be	O
aware	O
but	O
,	O
at	O
the	O
same	O
time	O
,	O
it	O
also	O
provides	O
a	O
rationale	O
to	O
worry	O
about	O
previously	O
unanticipated	O
clinical	O
consequences	O
of	O
long	O
-	O
term	O
treatment	O
with	O
these	O
drugs	O
.	O

The	O
effect	O
of	O
QuYuHuaTanTongLuo	O
Decoction	O
on	O
the	O
non	B
-	I
alcoholic	I
steatohepatitis	I
.	O

Non	B
-	I
alcoholic	I
steatohepatitis	I
(	O
NASH	O
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
cryptogenic	B
cirrhosis	I
,	O
is	O
becoming	O
more	O
prevalent	O
in	O
China	O
.	O

However	O
,	O
there	O
is	O
as	O
yet	O
no	O
clearly	O
established	O
therapy	O
for	O
reversing	O
fatty	B
liver	I
.	O

Our	O
aim	O
is	O
to	O
explore	O
the	O
effect	O
of	O
traditional	O
Chinese	O
herbs	O
QuYuHuaTanTongLuo	O
Decoction	O
(	O
QYHTTLD	O
)	O
on	O
non	B
-	I
alcoholic	I
steatohepatitis	I
.	O

Sixty	O
-	O
nine	O
non	B
-	I
alcoholic	I
steatohepatitis	I
patients	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

One	O
group	O
of	O
35	O
patients	O
were	O
treated	O
by	O
QYHTTLD	O
,	O
another	O
group	O
of	O
34	O
patients	O
were	O
treated	O
by	O
Ursodeoxycholic	O
acid	O
(	O
UDCA	O
)	O
.	O

The	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
8	O
,	O
MDA	O
level	O
,	O
SOD	O
activity	O
and	O
liver	O
function	O
,	O
as	O
well	O
as	O
B	O
ultrasonic	O
image	O
were	O
detected	O
before	O
and	O
after	O
being	O
treated	O
.	O

The	O
results	O
showed	O
:	O
after	O
6	O
months	O
treatment	O
,	O
MBI	O
of	O
the	O
treatment	O
group	O
was	O
obviously	O
decreased	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
levels	O
of	O
TC	O
,	O
TG	O
and	O
LDL	O
-	O
C	O
were	O
significantly	O
decreased	O
whereas	O
the	O
level	O
of	O
HDL	O
-	O
C	O
increased	O
(	O
p	O
<	O
0.01	O
,	O
p	O
<	O
0.05	O
,	O
p	O
<	O
0.05	O
,	O
and	O
p	O
<	O
0.05	O
,	O
respectively	O
)	O
in	O
the	O
treatment	O
group	O
,	O
the	O
levels	O
of	O
TC	O
,	O
TG	O
,	O
LDL	O
-	O
C	O
and	O
HDL	O
-	O
C	O
had	O
no	O
significant	O
difference	O
in	O
the	O
control	O
group	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
8	O
and	O
MDA	O
were	O
significantly	O
decreased	O
whereas	O
SOD	O
activity	O
was	O
significantly	O
increased	O
(	O
p	O
<	O
0.01	O
,	O
p	O
<	O
0.05	O
,	O
p	O
<	O
0.01	O
,	O
and	O
p	O
<	O
0.01	O
,	O
respectively	O
)	O
in	O
the	O
treatment	O
group	O
,	O
the	O
level	O
of	O
MDA	O
was	O
significantly	O
decreased	O
in	O
the	O
control	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

B	O
ultrasonic	O
images	O
were	O
ameliorated	O
in	O
different	O
degree	O
(	O
p	O
<	O
0.01	O
and	O
p	O
<	O
0.01	O
,	O
respectively	O
)	O
.	O

Both	O
QYHTTLD	O
and	O
UDCA	O
had	O
the	O
effect	O
in	O
improving	O
the	O
scores	O
of	O
symptoms	O
and	O
signs	O
of	O
patients	O
,	O
however	O
,	O
the	O
difference	O
value	O
of	O
the	O
scores	O
in	O
treatment	O
group	O
were	O
significantly	O
higher	O
than	O
that	O
in	O
control	O
group	O
after	O
being	O
treated	O
for	O
6	O
months	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Conclusion	O
:	O
QYHTTLD	O
is	O
effective	O
for	O
treating	O
non	B
-	I
alcoholic	I
steatohepatitis	I
,	O
and	O
its	O
effect	O
seems	O
to	O
relate	O
with	O
the	O
ways	O
of	O
QYHTTL	O
down	O
-	O
regulating	O
inflammation	B
cytokine	O
IL	O
-	O
8	O
level	O
and	O
relieving	O
lipid	O
peroxidation	O
of	O
liver	O
.	O

Fragrance	O
material	O
review	O
on	O
sclareol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
sclareol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Fragrance	O
Material	O
Review	O
on	O
isopulegol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
isopulegol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Fragrance	O
material	O
review	O
on	O
ocimenol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
ocimenol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Topical	O
pyrethrin	B
toxicity	I
leading	O
to	O
acute	B
-	I
onset	I
stuttering	I
in	O
a	O
toddler	O
.	O

Pyrethrin	O
compounds	O
can	O
cause	O
neurotoxicity	B
when	O
used	O
in	O
an	O
excessive	O
dose	O
.	O

A	O
case	O
of	O
stuttering	B
and	O
general	O
clumsiness	B
in	O
a	O
toddler	O
associated	O
with	O
topical	O
pyrethrin	O
use	O
is	O
described	O
.	O

Antitumor	O
properties	O
of	O
a	O
sulfated	O
polysaccharide	O
from	O
the	O
red	O
seaweed	O
Champia	O
feldmannii	O
(	O
Diaz	O
-	O
Pifferer	O
)	O
.	O

In	O
recent	O
years	O
,	O
much	O
attention	O
has	O
been	O
focused	O
on	O
polysaccharides	O
isolated	O
from	O
natural	O
sources	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
antitumor	O
properties	O
of	O
a	O
sulfated	O
polysaccharide	O
isolated	O
from	O
the	O
seaweed	O
C	O
.	O

feldmannii	O
(	O
Cf	O
-	O
PLS	O
)	O
.	O

Hematological	O
,	O
biochemical	O
and	O
histopathological	O
analyses	O
were	O
performed	O
in	O
order	O
to	O
evaluate	O
the	O
toxicological	O
aspects	O
related	O
to	O
Cf	O
-	O
PLS	O
treatment	O
.	O

Its	O
effects	O
on	O
the	O
immunological	O
system	O
were	O
also	O
investigated	O
.	O

The	O
Cf	O
-	O
PLS	O
did	O
not	O
show	O
any	O
significant	O
in	O
vitro	O
cytotoxicity	B
at	O
the	O
experimental	O
exposure	O
levels	O
that	O
were	O
used	O
,	O
but	O
showed	O
in	O
vivo	O
antitumor	O
effect	O
.	O

The	O
inhibition	O
rates	O
of	O
sarcoma	B
180	O
tumor	B
development	O
were	O
48.62	O
and	O
48.16	O
%	O
at	O
the	O
doses	O
of	O
10	O
and	O
25	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
Cf	O
-	O
PLS	O
was	O
also	O
able	O
to	O
increase	O
the	O
response	O
elicited	O
by	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
from	O
48.66	O
to	O
68.32	O
%	O
.	O

The	O
histopathological	O
analysis	O
of	O
liver	O
and	O
kidney	O
showed	O
that	O
both	O
organs	O
were	O
moderately	O
affected	O
by	O
Cf	O
-	O
PLS	O
-	O
treatment	O
.	O

Neither	O
enzymatic	O
activity	O
of	O
alanine	O
aminotransferase	O
nor	O
urea	O
or	O
creatinine	O
levels	O
were	O
significantly	O
altered	O
.	O

In	O
hematological	O
analysis	O
,	O
leucopeny	B
was	O
observed	O
after	O
5	O
-	O
FU	O
treatment	O
,	O
but	O
this	O
effect	O
was	O
prevented	O
when	O
the	O
treatment	O
was	O
associated	O
with	O
the	O
Cf	O
-	O
PLS	O
.	O

It	O
was	O
also	O
demonstrated	O
that	O
Cf	O
-	O
PLS	O
acts	O
as	O
an	O
immunomodulatory	O
agent	O
,	O
raising	O
the	O
production	O
of	O
specific	O
antibodies	O
,	O
and	O
increasing	O
the	O
production	O
of	O
OVA	O
-	O
specific	O
antibodies	O
.	O

It	O
also	O
induced	O
a	O
discreet	O
hyperplasia	B
of	I
lymphoid	I
folicules	I
of	O
the	O
white	O
pulp	O
in	O
the	O
spleen	O
of	O
treated	O
mice	O
.	O

In	O
conclusion	O
,	O
Cf	O
-	O
PLS	O
has	O
some	O
interesting	O
anticancer	O
activity	O
that	O
could	O
be	O
associated	O
with	O
its	O
immunostimulating	O
properties	O
.	O

A	O
multi	O
-	O
centre	O
dose	O
-	O
escalation	O
and	O
pharmacokinetic	O
study	O
of	O
diflomotecan	O
in	O
patients	O
with	O
advanced	O
malignancy	B
.	O

PURPOSE	O
:	O
Diflomotecan	O
,	O
a	O
homocamptothecin	O
,	O
targets	O
DNA	O
topoisomerase	O
I	O
.	O

Previous	O
clinical	O
trials	O
have	O
demonstrated	O
a	O
variable	O
degree	O
of	O
dose	B
limiting	I
toxicity	I
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
further	O
evaluate	O
the	O
safety	O
and	O
pharmacokinetic	O
profile	O
of	O
a	O
range	O
of	O
diflomotecan	O
doses	O
administered	O
intravenously	O
.	O

METHODS	O
:	O
Patients	O
with	O
advanced	O
solid	O
malignant	B
tumours	I
,	O
refractory	O
to	O
standard	O
therapies	O
,	O
with	O
adequate	O
haematologic	O
,	O
renal	O
and	O
hepatic	O
function	O
,	O
received	O
diflomotecan	O
administered	O
as	O
a	O
20	O
min	O
intravenous	O
infusion	O
every	O
21	O
days	O
.	O

Cohorts	O
of	O
six	O
patients	O
were	O
recruited	O
sequentially	O
to	O
one	O
of	O
three	O
fixed	O
starting	O
dose	O
groups	O
-	O
2	O
,	O
4	O
,	O
or	O
7	O
mg	O
,	O
with	O
drug	O
administered	O
by	O
fixed	O
-	O
dose	O
rather	O
than	O
dosing	O
by	O
body	O
surface	O
area	O
.	O

Pharmacokinetic	O
analyses	O
were	O
performed	O
on	O
serial	O
blood	O
samples	O
taken	O
over	O
the	O
first	O
24	O
h	O
after	O
diflomotecan	O
administration	O
(	O
cycles	O
1	O
and	O
2	O
)	O
.	O

Cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
activity	O
was	O
determined	O
by	O
an	O
erythromycin	O
breath	O
test	O
(	O
EBT	O
)	O
prior	O
to	O
diflomotecan	O
administration	O
in	O
cycles	O
1	O
and	O
2	O
.	O

RESULTS	O
:	O
Thirteen	O
patients	O
,	O
were	O
treated	O
with	O
a	O
starting	O
dose	O
of	O
either	O
2	O
mg	O
(	O
n	O
=	O
8	O
)	O
or	O
4	O
mg	O
(	O
n	O
=	O
5	O
)	O
of	O
diflomotecan	O
.	O

Dose	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
observed	O
in	O
1	O
patient	O
in	O
the	O
2	O
mg	O
starting	O
dose	O
level	O
(	O
grade	O
4	O
neutropenia	B
which	O
lasted	O
for	O
8	O
days	O
)	O
,	O
and	O
in	O
2	O
of	O
5	O
patients	O
enrolled	O
at	O
the	O
4	O
mg	O
starting	O
dose	O
level	O
(	O
grade	O
4	O
neutropenia	B
for	O
11	O
days	O
;	O
grade	O
4	O
neutropenia	B
leading	O
to	O
withdrawal	O
from	O
the	O
study	O
)	O
,	O
and	O
no	O
further	O
dose	O
escalation	O
was	O
performed	O
.	O

Pharmacokinetic	O
analyses	O
revealed	O
a	O
less	O
than	O
dose	O
-	O
proportional	O
increase	O
in	O
diflomotecan	O
and	O
for	O
the	O
two	O
metabolites	O
BN80942	O
and	O
P	O
-	O
20	O
,	O
with	O
a	O
magnitude	O
of	O
P	O
-	O
20	O
exposure	O
similar	O
to	O
the	O
parent	O
drug	O
.	O

There	O
was	O
a	O
high	O
inter	O
-	O
patient	O
variability	O
in	O
diflomotecan	O
exposure	O
similar	O
to	O
that	O
observed	O
with	O
other	O
camptothecin	O
derivatives	O
.	O

One	O
minor	O
response	O
was	O
observed	O
in	O
a	O
patient	O
with	O
oesophageal	B
cancer	I
.	O

CONCLUSIONS	O
:	O
Diflomotecan	O
administered	O
as	O
a	O
20	O
-	O
min	O
intravenous	O
infusion	O
3	O
-	O
weekly	O
is	O
characterised	O
by	O
a	O
variable	O
pharmacokinetic	O
profile	O
.	O

Alternative	O
oral	O
dosing	O
schedules	O
of	O
diflomotecan	O
have	O
been	O
shown	O
to	O
display	O
a	O
more	O
predictable	O
PK	O
/	O
PD	O
and	O
safety	O
profile	O
and	O
should	O
be	O
selected	O
for	O
further	O
evaluation	O
in	O
Phase	O
II	O
clinical	O
trials	O
.	O

Hepatic	O
protection	O
by	O
noni	O
fruit	O
juice	O
against	O
CCl	O
(	O
4	O
)	O
-	O
induced	O
chronic	B
liver	I
damage	I
in	O
female	O
SD	O
rats	O
.	O

Morinda	O
citrifolia	O
L	O
.	O

(	O
noni	O
)	O
has	O
been	O
used	O
throughout	O
the	O
Pacific	O
,	O
Southeast	O
Asia	O
,	O
Central	O
America	O
,	O
and	O
the	O
Caribbean	O
for	O
a	O
variety	O
of	O
health	O
conditions	O
,	O
including	O
heart	O
and	O
liver	O
ailments	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
hepatoprotective	O
effects	O
of	O
TAHITIAN	O
NONI	O
Juice	O
(	O
TNJ	O
)	O
against	O
CCl	O
(	O
4	O
)	O
-	O
induced	O
chronic	B
liver	I
damage	I
in	O
female	O
Sprague	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O

Twelve	O
female	O
SD	O
rats	O
were	O
divided	O
into	O
control	O
,	O
placebo	O
and	O
TNJ	O
(	O
6	O
mL	O
/	O
rat	O
/	O
day	O
)	O
groups	O
.	O

On	O
day	O
15	O
,	O
animals	O
in	O
the	O
placebo	O
and	O
TNJ	O
groups	O
received	O
0.25	O
mL	O
/	O
kg	O
CCl	O
(	O
4	O
)	O
in	O
corn	O
oil	O
once	O
a	O
week	O
for	O
12	O
successive	O
weeks	O
.	O

All	O
animals	O
were	O
sacrificed	O
at	O
week	O
16	O
.	O

Blood	O
and	O
liver	O
were	O
collected	O
for	O
liver	O
function	O
,	O
lipid	O
panel	O
tests	O
,	O
and	O
histological	O
observation	O
.	O

Histopathological	O
examination	O
revealed	O
that	O
liver	O
sections	O
from	O
the	O
TNJ	O
+	O
CCl	O
(	O
4	O
)	O
appeared	O
similar	O
to	O
controls	O
,	O
whereas	O
typical	O
hepatic	B
steatosis	I
was	O
observed	O
in	O
the	O
placebo	O
+	O
CCl	O
(	O
4	O
)	O
group	O
.	O

Serum	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
,	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
,	O
alanine	O
transaminase	O
(	O
ALT	O
)	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
triglycerides	O
(	O
TG	O
)	O
,	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
,	O
and	O
very	O
low	O
-	O
density	O
lipoprotein	O
(	O
VLDL	O
)	O
levels	O
were	O
increased	O
in	O
the	O
placebo	O
group	O
compared	O
with	O
the	O
TNJ	O
group	O
.	O

In	O
contrast	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
was	O
increased	O
in	O
the	O
TNJ	O
group	O
and	O
decreased	O
in	O
the	O
placebo	O
group	O
.	O

Thus	O
,	O
TNJ	O
juice	O
appears	O
to	O
protect	O
the	O
liver	O
from	O
chronic	O
exogenous	O
CCl	O
(	O
4	O
)	O
exposures	O
.	O

Such	O
protective	O
mechanisms	O
are	O
supportive	O
evidence	O
for	O
the	O
utility	O
of	O
noni	O
in	O
traditional	O
medicine	O
for	O
liver	O
ailments	O
.	O

Chronopharmacology	O
and	O
antimicrobial	O
therapeutics	O
.	O

Chronobiology	O
studies	O
the	O
phenomenon	O
of	O
rhythmicity	O
in	O
living	O
organisms	O
.	O

Circadian	O
rhythms	O
are	O
genetically	O
determined	O
and	O
are	O
regulated	O
by	O
external	O
synchronizers	O
(	O
i.e.	O
light	O
/	O
day	O
cycle	O
)	O
.	O

Several	O
biological	O
processes	O
involved	O
in	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
drugs	O
are	O
subject	O
to	O
circadian	O
variations	O
.	O

Chronopharmacology	O
studies	O
how	O
biological	O
rhythms	O
impact	O
on	O
drug	O
pharmacokinetic	O
(	O
chronokinetics	O
)	O
,	O
pharmacodynamics	O
(	O
chronoesthesy	O
)	O
and	O
toxicity	O
and	O
determines	O
whether	O
time	O
of	O
day	O
administration	O
modifies	O
drug	O
's	O
pharmacological	O
characteristics	O
.	O

Chronotherapy	O
applies	O
chronopharmacological	O
studies	O
to	O
clinical	O
treatments	O
,	O
determining	O
the	O
best	O
biological	O
time	O
for	O
its	O
dosing	O
,	O
i.e.	O
when	O
beneficial	O
effects	O
are	O
maximal	O
and	O
incidence	O
and	O
/	O
or	O
intensity	O
of	O
related	O
side	O
-	O
effects	O
and	O
toxicity	O
are	O
minimal	O
.	O

Significant	O
variations	O
in	O
the	O
pharmacokinetics	O
and	O
toxicity	O
of	O
antibiotics	O
(	O
aminoglycosides	O
,	O
beta	O
-	O
lactams	O
and	O
fluoroquinolones	O
)	O
related	O
to	O
administration	O
time	O
are	O
well	O
known	O
.	O

The	O
aims	O
of	O
this	O
review	O
are	O
to	O
discuss	O
,	O
briefly	O
,	O
the	O
currently	O
accepted	O
model	O
of	O
the	O
circadian	O
system	O
that	O
substantiates	O
endogenous	O
rhythmicity	O
and	O
to	O
provide	O
an	O
update	O
on	O
the	O
knowledge	O
of	O
circadian	O
rhythms	O
applied	O
to	O
drugs	O
used	O
as	O
medicines	O
,	O
with	O
a	O
special	O
mention	O
to	O
the	O
possible	O
impact	O
on	O
antimicrobial	O
treatments	O
.	O

It	O
is	O
concluded	O
that	O
the	O
dosing	O
time	O
of	O
an	O
antimicrobial	O
agent	O
might	O
be	O
clinically	O
relevant	O
in	O
some	O
treatments	O
,	O
thus	O
,	O
clinicians	O
should	O
be	O
aware	O
that	O
the	O
dosing	O
time	O
might	O
affect	O
the	O
clinical	O
response	O
of	O
a	O
drug	O
.	O

Chemoimmunotherapy	O
reinduction	O
with	O
epratuzumab	O
in	O
children	O
with	O
acute	B
lymphoblastic	I
leukemia	I
in	O
marrow	O
relapse	O
:	O
a	O
Children	O
's	O
Oncology	O
Group	O
Pilot	O
Study	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
tolerability	O
and	O
serum	O
concentration	O
of	O
epratuzumab	O
,	O
a	O
humanized	O
monoclonal	O
antibody	O
targeting	O
CD22	O
,	O
administered	O
alone	O
and	O
in	O
combination	O
with	O
reinduction	O
chemotherapy	O
in	O
children	O
with	O
relapsed	O
acute	B
lymphoblastic	I
leukemia	I
(	O
ALL	B
)	O
,	O
and	O
to	O
preliminarily	O
assess	O
tumor	O
targeting	O
and	O
efficacy	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Therapy	O
consisted	O
of	O
a	O
single	O
-	O
agent	O
phase	O
(	O
epratuzumab	O
360	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
dose	O
intravenously	O
twice	O
weekly	O
x	O
four	O
doses	O
)	O
,	O
followed	O
by	O
four	O
weekly	O
doses	O
of	O
epratuzumab	O
in	O
combination	O
with	O
standard	O
reinduction	O
chemotherapy	O
.	O

Morphologic	O
and	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
responses	O
were	O
determined	O
at	O
the	O
end	O
of	O
this	O
6	O
-	O
week	O
period	O
.	O

Serum	O
concentrations	O
of	O
epratuzumab	O
were	O
determined	O
before	O
and	O
30	O
minutes	O
after	O
infusions	O
,	O
and	O
CD22	O
targeting	O
efficiency	O
was	O
determined	O
by	O
quantifying	O
changes	O
in	O
CD22	O
expression	O
after	O
epratuzumab	O
administration	O
.	O

RESULTS	O
:	O
Fifteen	O
patients	O
(	O
12	O
fully	O
assessable	O
for	O
toxicity	O
)	O
with	O
first	O
or	O
later	O
CD22	O
-	O
positive	O
ALL	B
marrow	O
relapse	O
enrolled	O
on	O
the	O
feasibility	O
portion	O
of	O
this	O
study	O
from	O
December	O
2005	O
to	O
June	O
2006	O
.	O

Two	O
dose	O
-	O
limiting	O
toxicities	O
occurred	O
:	O
one	O
grade	O
4	O
seizure	B
of	O
unclear	O
etiology	O
and	O
one	O
asymptomatic	O
grade	O
3	O
ALT	O
elevation	O
.	O

In	O
all	O
but	O
one	O
patient	O
,	O
surface	O
CD22	O
was	O
not	O
detected	O
by	O
flow	O
cytometry	O
on	O
peripheral	O
blood	O
leukemic	O
blasts	O
within	O
24	O
hours	O
of	O
drug	O
administration	O
,	O
indicating	O
effective	O
targeting	O
of	O
leukemic	O
cells	O
by	O
epratuzumab	O
.	O

Nine	O
patients	O
achieved	O
a	O
complete	O
remission	O
after	O
chemoimmunotherapy	O
,	O
seven	O
of	O
whom	O
were	O
MRD	O
negative	O
.	O

CONCLUSION	O
:	O
Treatment	O
with	O
epratuzumab	O
plus	O
standard	O
reinduction	O
chemotherapy	O
is	O
feasible	O
and	O
acceptably	O
tolerated	O
in	O
children	O
with	O
relapsed	O
CD22	O
-	O
positive	O
ALL	B
.	O

CD22	O
targeting	O
was	O
efficient	O
,	O
and	O
the	O
majority	O
of	O
patients	O
achieved	O
favorable	O
early	O
responses	O
.	O

Pharmacokinetic	O
interaction	O
between	O
ethinyl	O
estradiol	O
,	O
norethindrone	O
and	O
darunavir	O
with	O
low	O
-	O
dose	O
ritonavir	O
in	O
healthy	O
women	O
.	O

BACKGROUND	O
:	O
An	O
open	O
-	O
label	O
,	O
randomized	O
,	O
crossover	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
effect	O
of	O
multiple	O
doses	O
of	O
darunavir	O
co	O
-	O
administered	O
with	O
low	O
-	O
dose	O
ritonavir	O
(	O
DRV	O
/	O
r	O
)	O
on	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
the	O
oral	O
contraceptives	O
ethinyl	O
estradiol	O
(	O
EE	O
)	O
and	O
norethindrone	O
(	O
NE	O
)	O
(	O
commercial	O
name	O
of	O
the	O
combined	O
drug	O
Ortho	O
-	O
Novum	O
1	O
/	O
35	O
)	O
in	O
19	O
HIV	O
-	O
negative	O
healthy	O
women	O
.	O

METHODS	O
:	O
In	O
session	O
1	O
,	O
participants	O
received	O
35	O
microg	O
EE	O
and	O
1.0	O
mg	O
NE	O
from	O
days	O
1	O
to	O
21	O
.	O

In	O
session	O
2	O
,	O
participants	O
received	O
the	O
same	O
oral	O
contraceptive	O
treatment	O
as	O
in	O
session	O
1	O
on	O
days	O
1	O
to	O
21	O
plus	O
DRV	O
/	O
r	O
(	O
600	O
mg	O
/	O
100	O
mg	O
twice	O
daily	O
)	O
on	O
days	O
1	O
to	O
14	O
.	O

Pharmacokinetic	O
assessments	O
were	O
performed	O
on	O
day	O
14	O
for	O
each	O
session	O
.	O

RESULTS	O
:	O
Steady	O
-	O
state	O
systemic	O
exposure	O
to	O
EE	O
and	O
NE	O
decreased	O
when	O
DRV	O
/	O
r	O
was	O
co	O
-	O
administered	O
,	O
based	O
on	O
the	O
ratio	O
of	O
least	O
square	O
means	O
of	O
the	O
minimum	O
plasma	O
concentration	O
(	O
Cmin	O
)	O
,	O
the	O
maximum	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
,	O
and	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC24h	O
)	O
of	O
EE	O
(	O
which	O
decreased	O
by	O
62	O
%	O
,	O
32	O
%	O
and	O
44	O
%	O
,	O
respectively	O
)	O
and	O
NE	O
(	O
which	O
decreased	O
by	O
30	O
%	O
,	O
10	O
%	O
and	O
14	O
%	O
,	O
respectively	O
)	O
compared	O
with	O
administration	O
of	O
EE	O
and	O
NE	O
alone	O
.	O

Five	O
participants	O
discontinued	O
the	O
study	O
due	O
to	O
grade	O
2	O
cutaneous	O
events	O
,	O
as	O
required	O
per	O
protocol	O
,	O
during	O
treatment	O
with	O
EE	O
and	O
NE	O
in	O
combination	O
with	O
DRV	O
/	O
r	O
.	O

There	O
were	O
no	O
clinically	O
relevant	O
findings	O
for	O
laboratory	O
and	O
cardiovascular	O
parameters	O
.	O

CONCLUSIONS	O
:	O
The	O
pharmacokinetic	O
interaction	O
observed	O
here	O
is	O
considered	O
to	O
be	O
clinically	O
relevant	O
as	O
EE	O
concentrations	O
are	O
considerably	O
reduced	O
when	O
DRV	O
/	O
r	O
is	O
co	O
-	O
administered	O
with	O
EE	O
and	O
NE	O
.	O

Alternative	O
or	O
additional	O
contraceptive	O
measures	O
should	O
be	O
used	O
when	O
oestrogen	O
-	O
based	O
contraceptives	O
are	O
co	O
-	O
administered	O
with	O
DRV	O
/	O
r	O
.	O

Eosinophil	O
-	O
derived	O
neurotoxin	O
/	O
RNase	O
2	O
:	O
connecting	O
the	O
past	O
,	O
the	O
present	O
and	O
the	O
future	O
.	O

The	O
eosinophil	O
-	O
derived	O
neurotoxin	O
(	O
EDN	O
,	O
also	O
known	O
as	O
eosinophil	O
protein	O
-	O
X	O
)	O
is	O
best	O
-	O
known	O
as	O
one	O
of	O
the	O
four	O
major	O
proteins	O
found	O
in	O
the	O
large	O
specific	O
granules	O
of	O
human	O
eosinophilic	O
leukocytes	O
.	O

Although	O
it	O
was	O
named	O
for	O
its	O
discovery	O
and	O
initial	O
characterization	O
as	O
a	O
neurotoxin	O
,	O
it	O
is	O
also	O
expressed	O
constitutively	O
in	O
human	O
liver	O
tissue	O
and	O
its	O
expression	O
can	O
be	O
induced	O
in	O
macrophages	O
by	O
proinflammatory	O
stimuli	O
.	O

EDN	O
and	O
its	O
divergent	O
orthologs	O
in	O
rodents	O
have	O
ribonuclease	O
activity	O
,	O
and	O
are	O
members	O
of	O
the	O
extensive	O
RNase	O
A	O
superfamily	O
,	O
although	O
the	O
relationship	O
between	O
the	O
characterized	O
physiologic	O
functions	O
and	O
enzymatic	O
activity	O
remains	O
poorly	O
understood	O
.	O

Recent	O
explorations	O
into	O
potential	O
physiologic	O
functions	O
for	O
EDN	O
have	O
provided	O
us	O
with	O
some	O
insights	O
into	O
its	O
role	O
in	O
antiviral	O
host	O
defense	O
,	O
as	O
a	O
chemoattractant	O
for	O
human	O
dendritic	O
cells	O
,	O
and	O
most	O
recently	O
,	O
as	O
an	O
endogenous	O
ligand	O
for	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
2	O
.	O

Endogenous	O
alpha	O
-	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
mitigates	O
liver	B
fibrosis	I
in	O
chronic	B
hepatitis	I
induced	O
by	O
repeated	O
administration	O
of	O
concanavalin	O
A	O
.	O

BACKGROUND	O
:	O
Alpha	O
-	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
alphaCGRP	O
)	O
is	O
a	O
37	O
-	O
amino	O
acid	O
pleiotropic	O
peptide	O
that	O
we	O
previously	O
showed	O
to	O
exert	O
a	O
hepatoprotective	O
effect	O
during	O
concanavalin	O
A	B
(	I
Con	I
A	I
)	I
-	I
induced	I
acute	I
hepatitis	I
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
alphaCGRP	O
(	O
-	O
/	O
-	O
)	O
mice	O
to	O
further	O
investigate	O
the	O
antifibrogenic	O
and	O
hepatoprotective	O
effects	O
of	O
endogenous	O
alphaCGRP	O
in	O
Con	O
A	O
-	O
induced	O
chronic	B
hepatitis	I
.	O

METHODS	O
:	O
Chronic	B
hepatitis	I
was	O
induced	O
in	O
alphaCGRP	O
(	O
-	O
/	O
-	O
)	O
and	O
wild	O
-	O
type	O
mice	O
by	O
repeated	O
administration	O
of	O
Con	O
A	O
.	O

Serum	O
transaminases	O
were	O
measured	O
to	O
assess	O
hepatic	O
injury	B
.	O

The	O
severity	O
of	O
fibrosis	B
and	O
the	O
activation	O
of	O
hepatic	O
stellate	O
cells	O
(	O
HSCs	O
)	O
were	O
analysed	O
by	O
Masson	O
trichrome	O
staining	O
and	O
immunohistochemical	O
staining	O
of	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
alpha	O
-	O
SMA	O
)	O
respectively	O
.	O

Altered	O
expression	O
of	O
fibrosis	O
-	O
and	O
inflammation	O
-	O
related	O
genes	O
was	O
evaluated	O
using	O
a	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Activation	O
and	O
proliferation	O
of	O
HSCs	O
were	O
analysed	O
using	O
both	O
primary	O
cultured	O
HSCs	O
from	O
the	O
mice	O
and	O
the	O
LI90	O
HSC	O
cell	O
line	O
.	O

RESULTS	O
:	O
alphaCGRP	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
more	O
severe	O
liver	B
fibrosis	I
than	O
wild	O
-	O
type	O
mice	O
in	O
a	O
Con	O
A	O
-	O
induced	O
chronic	B
hepatitis	I
model	O
.	O

In	O
histological	O
and	O
gene	O
expression	O
analyses	O
,	O
alphaCGRP	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
greater	O
inflammatory	O
and	O
fibrotic	O
changes	O
,	O
greater	O
HSC	O
activation	O
and	O
a	O
higher	O
incidence	O
of	O
apoptosis	B
among	O
nonparenchymal	O
cells	O
than	O
wild	O
-	O
type	O
mice	O
.	O

CONCLUSIONS	O
:	O
Endogenous	O
alphaCGRP	O
mitigates	O
liver	B
fibrosis	I
in	O
chronic	B
hepatitis	I
induced	O
by	O
repeated	O
administration	O
of	O
Con	O
A	O
.	O

alphaCGRP	O
could	O
be	O
a	O
useful	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
chronic	B
hepatitis	I
.	O

Novel	O
roles	O
for	O
ceramides	O
,	O
calpains	O
and	O
caspases	O
in	O
kidney	O
proximal	O
tubule	O
cell	O
apoptosis	O
:	O
lessons	O
from	O
in	O
vitro	O
cadmium	B
toxicity	I
studies	O
.	O

Apoptosis	O
is	O
a	O
tightly	O
regulated	O
physiological	O
process	O
,	O
which	O
can	O
be	O
initiated	O
by	O
toxic	O
stimuli	O
,	O
such	O
as	O
cadmium	O
(	O
Cd2	O
+	O
)	O
.	O

Cd2	O
+	O
(	O
10	O
-	O
50	O
microM	O
)	O
induces	O
a	O
rapid	O
increase	O
in	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
(	O
>	O
or	O
=	O
30	O
min	O
)	O
in	O
a	O
cell	O
line	O
derived	O
from	O
the	O
S1	O
segment	O
of	O
rat	O
kidney	O
proximal	O
tubule	O
,	O
without	O
any	O
apparent	O
mitochondrial	O
dysfunction	O
.	O

The	O
sphingolipid	O
ceramide	O
is	O
an	O
important	O
second	O
messenger	O
in	O
apoptosis	O
.	O

Short	O
exposure	O
to	O
Cd2	O
+	O
(	O
3h	O
)	O
causes	O
an	O
increase	O
in	O
ceramides	O
,	O
which	O
occurs	O
downstream	O
of	O
ROS	O
formation	O
,	O
and	O
may	O
interact	O
with	O
cellular	O
components	O
,	O
such	O
as	O
endoplasmic	O
reticulum	O
and	O
mitochondria	O
.	O

Following	O
apoptosis	O
initiation	O
,	O
execution	O
must	O
take	O
place	O
.	O

The	O
classical	O
executioners	O
of	O
apoptosis	O
are	O
caspases	O
,	O
a	O
family	O
of	O
cysteine	O
proteases	O
.	O

However	O
,	O
increasing	O
studies	O
report	O
caspase	O
-	O
independent	O
apoptosis	O
,	O
which	O
questions	O
the	O
essentiality	O
of	O
caspases	O
for	O
apoptosis	O
implementation	O
.	O

With	O
low	O
micromolar	O
Cd2	O
+	O
concentrations	O
(	O
<	O
10	O
microM	O
)	O
,	O
caspases	O
are	O
only	O
activated	O
after	O
24h	O
and	O
not	O
at	O
earlier	O
time	O
points	O
,	O
which	O
supports	O
the	O
notion	O
of	O
caspase	O
-	O
independent	O
apoptosis	O
.	O

Due	O
to	O
increased	O
cytosolic	O
Ca	O
(	O
2	O
+	O
)	O
under	O
pathological	O
conditions	O
,	O
a	O
role	O
for	O
the	O
Ca2	O
+	O
-	O
dependent	O
proteases	O
,	O
calpains	O
,	O
has	O
emerged	O
.	O

Calpain	O
activation	O
by	O
Cd2	O
+	O
(	O
3	O
-	O
6	O
h	O
)	O
seems	O
to	O
be	O
regulated	O
by	O
ceramide	O
levels	O
,	O
in	O
order	O
to	O
induce	O
apoptosis	O
.	O

Calpain	O
and	O
caspase	O
substrates	O
overlap	O
but	O
yield	O
different	O
fragments	O
,	O
which	O
may	O
explain	O
their	O
diverse	O
downstream	O
targets	O
.	O

Furthermore	O
,	O
calpains	O
and	O
caspases	O
may	O
interact	O
with	O
one	O
another	O
to	O
enhance	O
,	O
as	O
seen	O
by	O
Cd2	O
+	O
,	O
or	O
diminish	O
apoptosis	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
novel	O
roles	O
for	O
ceramides	O
,	O
calpains	O
and	O
caspases	O
as	O
part	O
of	O
Cd2	O
+	O
-	O
induced	O
apoptotic	O
signalling	O
pathways	O
in	O
the	O
kidney	O
proximal	O
tubule	O
and	O
their	O
in	O
vivo	O
relevance	O
to	O
Cd2	O
+	O
-	O
induced	O
nephrotoxicity	B
.	O

Effect	O
of	O
darbepoetin	O
alfa	O
administered	O
once	O
monthly	O
on	O
maintaining	O
hemoglobin	O
levels	O
in	O
older	O
patients	O
with	O
chronic	B
kidney	I
disease	I
.	O

BACKGROUND	O
:	O
The	O
anemia	B
of	I
chronic	I
kidney	I
disease	I
(	O
CKD	B
)	O
is	O
associated	O
with	O
increased	O
hospitalizations	O
,	O
increased	O
cardiovascular	O
morbidity	O
and	O
mortality	O
,	O
and	O
diminished	O
quality	O
of	O
life	O
in	O
the	O
elderly	O
.	O

Darbepoetin	O
alfa	O
is	O
an	O
erythropoiesis	O
-	O
stimulating	O
agent	O
that	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
treating	O
anemia	B
in	O
patients	O
with	O
CKD	B
(	O
but	O
not	O
on	O
dialysis	O
)	O
when	O
administered	O
using	O
extended	O
-	O
dosing	O
regimens	O
.	O

OBJECTIVE	O
:	O
The	O
purpose	O
of	O
this	O
post	O
hoc	O
analysis	O
was	O
to	O
examine	O
the	O
efficacy	O
and	O
safety	O
profile	O
of	O
once	O
-	O
monthly	O
(	O
QM	O
)	O
darbepoetin	O
alfa	O
in	O
study	O
patients	O
stratified	O
according	O
to	O
age	O
(	O
ie	O
,	O
<	O
65	O
,	O
65	O
-	O
74	O
,	O
and	O
>	O
or	O
=	O
75	O
years	O
)	O
.	O

METHODS	O
:	O
Patients	O
with	O
CKD	B
but	O
not	O
on	O
dialysis	O
,	O
receiving	O
darbepoetin	O
alfa	O
every	O
other	O
week	O
(	O
Q2W	O
)	O
,	O
and	O
with	O
stable	O
hemoglobin	O
(	O
Hb	O
)	O
levels	O
between	O
11	O
and	O
13	O
g	O
/	O
dL	O
,	O
inclusive	O
,	O
were	O
enrolled	O
in	O
this	O
33	O
-	O
week	O
,	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
single	O
-	O
arm	O
study	O
.	O

The	O
study	O
was	O
carried	O
out	O
at	O
36	O
US	O
centers	O
and	O
consisted	O
of	O
a	O
24	O
-	O
week	O
QM	O
darbepoetin	O
alfa	O
dose	O
-	O
titration	O
period	O
followed	O
by	O
an	O
8	O
-	O
week	O
evaluation	O
period	O
.	O

Hb	O
levels	O
were	O
measured	O
Q2W	O
.	O

Study	O
results	O
were	O
stratified	O
according	O
to	O
patient	O
age	O
(	O
<	O
65	O
,	O
65	O
-	O
74	O
,	O
and	O
>	O
or	O
=	O
75	O
years	O
)	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
152	O
patients	O
(	O
79	O
women	O
,	O
73	O
men	O
)	O
were	O
enrolled	O
;	O
55	O
patients	O
(	O
36	O
%	O
)	O
were	O
<	O
65	O
years	O
of	O
age	O
,	O
46	O
(	O
30	O
%	O
)	O
were	O
65	O
to	O
74	O
years	O
of	O
age	O
,	O
and	O
51	O
(	O
34	O
%	O
)	O
were	O
>	O
or	O
=	O
75	O
years	O
of	O
age	O
.	O

In	O
patients	O
who	O
received	O
>	O
or	O
=	O
1	O
dose	O
of	O
darbepoetin	O
alfa	O
,	O
Hb	O
levels	O
>	O
or	O
=	O
11	O
g	O
/	O
dL	O
were	O
maintained	O
in	O
76	O
%	O
,	O
80	O
%	O
,	O
and	O
71	O
%	O
of	O
patients	O
aged	O
<	O
65	O
,	O
65	O
to	O
74	O
,	O
and	O
>	O
or	O
=	O
75	O
years	O
,	O
respectively	O
.	O

For	O
patients	O
who	O
completed	O
the	O
study	O
,	O
the	O
proportions	O
who	O
maintained	O
Hb	O
levels	O
>	O
or	O
=	O
11	O
g	O
/	O
dL	O
were	O
83	O
%	O
,	O
88	O
%	O
,	O
and	O
85	O
%	O
,	O
respectively	O
,	O
for	O
the	O
3	O
age	O
groups	O
.	O

The	O
safety	O
profile	O
of	O
QM	O
darbepoetin	O
alfa	O
in	O
this	O
study	O
was	O
consistent	O
with	O
that	O
expected	O
in	O
patients	O
with	O
CKD	B
not	O
receiving	O
dialysis	O
.	O

CONCLUSIONS	O
:	O
Darbepoetin	O
alfa	O
administered	O
QM	O
maintained	O
Hb	O
levels	O
>	O
or	O
=	O
11	O
g	O
/	O
dL	O
in	O
patients	O
with	O
CKD	B
(	O
not	O
on	O
dialysis	O
)	O
aged	O
<	O
65	O
,	O
65	O
to	O
74	O
,	O
and	O
>	O
or	O
=	O
75	O
years	O
.	O

This	O
treatment	O
regimen	O
may	O
help	O
optimize	O
anemia	B
management	O
for	O
older	O
community	O
-	O
dwelling	O
and	O
long	O
-	O
term	O
care	O
patients	O
.	O

EF24	O
,	O
a	O
novel	O
curcumin	O
analog	O
,	O
disrupts	O
the	O
microtubule	O
cytoskeleton	O
and	O
inhibits	O
HIF	O
-	O
1	O
.	O

Curcumin	O
,	O
the	O
yellow	O
pigment	O
of	O
the	O
spice	O
turmeric	O
,	O
has	O
emerged	O
as	O
a	O
promising	O
anticancer	O
agent	O
due	O
to	O
its	O
antiproliferative	O
and	O
antiangiogenic	O
properties	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
action	O
of	O
this	O
compound	O
remains	O
a	O
subject	O
of	O
debate	O
.	O

In	O
addition	O
,	O
curcumin	O
's	O
low	O
bioavailability	O
and	O
efficacy	O
profile	O
in	O
vivo	O
further	O
hinders	O
its	O
clinical	O
development	O
.	O

This	O
study	O
focuses	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
EF24	O
,	O
a	O
novel	O
curcumin	O
analog	O
with	O
greater	O
than	O
curcumin	O
biological	O
activity	O
and	O
bioavailability	O
,	O
but	O
no	O
increased	O
toxicity	O
.	O

Treatment	O
of	O
MDA	O
-	O
MB231	O
breast	O
and	O
PC3	O
prostate	B
cancer	I
cells	O
with	O
EF24	O
or	O
curcumin	O
led	O
to	O
inhibition	O
of	O
HIF	O
-	O
1alpha	O
protein	O
levels	O
and	O
,	O
consequently	O
,	O
inhibition	O
of	O
HIF	O
transcriptional	O
activity	O
.	O

This	O
drug	O
-	O
induced	O
HIF	O
inhibition	O
occurred	O
in	O
a	O
VHL	O
-	O
dependent	O
but	O
proteasome	O
-	O
independent	O
manner	O
.	O

We	O
found	O
that	O
,	O
while	O
curcumin	O
inhibited	O
HIF	O
-	O
1alpha	O
gene	O
transcription	O
,	O
EF24	O
exerted	O
its	O
activity	O
by	O
inhibiting	O
HIF	O
-	O
1alpha	O
posttranscriptionally	O
.	O

This	O
result	O
suggested	O
that	O
the	O
two	O
compounds	O
are	O
structurally	O
similar	O
but	O
mechanistically	O
distinct	O
.	O

Another	O
cellular	O
effect	O
that	O
further	O
differentiated	O
the	O
two	O
compounds	O
was	O
the	O
ability	O
of	O
EF24	O
,	O
but	O
not	O
curcumin	O
,	O
to	O
induce	O
microtubule	O
stabilization	O
in	O
cells	O
.	O

EF24	O
had	O
no	O
stabilizing	O
effect	O
on	O
tubulin	O
polymerization	O
in	O
an	O
in	O
vitro	O
assay	O
using	O
purified	O
bovine	O
brain	O
tubulin	O
,	O
suggesting	O
that	O
the	O
EF24	O
-	O
induced	O
cytoskeletal	O
disruption	O
in	O
cells	O
may	O
be	O
the	O
result	O
of	O
upstream	O
signaling	O
events	O
rather	O
than	O
EF24	O
direct	O
binding	O
to	O
tubulin	O
.	O

In	O
summary	O
,	O
our	O
study	O
identifies	O
EF24	O
as	O
a	O
novel	O
curcumin	O
-	O
related	O
compound	O
possessing	O
a	O
distinct	O
mechanism	O
of	O
action	O
,	O
which	O
we	O
believe	O
contributes	O
to	O
the	O
potent	O
anticancer	O
activity	O
of	O
this	O
agent	O
and	O
can	O
be	O
further	O
exploited	O
to	O
investigate	O
the	O
therapeutic	O
potential	O
of	O
EF24	O
.	O

How	O
can	O
biologically	O
-	O
based	O
modeling	O
of	O
arsenic	O
kinetics	O
and	O
dynamics	O
inform	O
the	O
risk	O
assessment	O
process	O
?	O

-	O
A	O
workshop	O
review	O
.	O

Quantitative	O
biologically	O
-	O
based	O
models	O
describing	O
key	O
events	O
in	O
the	O
continuum	O
from	O
arsenic	O
exposure	O
to	O
the	O
development	O
of	O
adverse	O
health	O
effects	O
provide	O
a	O
framework	O
to	O
integrate	O
information	O
obtained	O
across	O
diverse	O
research	O
areas	O
.	O

For	O
example	O
,	O
genetic	O
polymorphisms	O
in	O
arsenic	O
metabolizing	O
enzymes	O
can	O
lead	O
to	O
differences	O
in	O
target	O
tissue	O
dosimetry	O
for	O
key	O
metabolites	O
causative	O
in	O
toxic	O
and	O
carcinogenic	B
response	I
.	O

This	O
type	O
of	O
variation	O
can	O
be	O
quantitatively	O
incorporated	O
into	O
pharmacokinetic	O
(	O
PK	O
)	O
models	O
and	O
used	O
together	O
with	O
population	O
-	O
based	O
modeling	O
approaches	O
to	O
evaluate	O
the	O
impact	O
of	O
genetic	O
variation	O
in	O
methylation	O
capacity	O
on	O
dose	O
of	O
key	O
metabolites	O
to	O
target	O
tissue	O
.	O

The	O
PK	O
model	O
is	O
an	O
essential	O
bridge	O
to	O
the	O
pharmacodynamic	O
(	O
PD	O
)	O
models	O
.	O

A	O
particular	O
benefit	O
of	O
PD	O
modeling	O
for	O
arsenic	O
is	O
that	O
alternative	O
models	O
can	O
be	O
constructed	O
for	O
multiple	O
proposed	O
modes	O
of	O
action	O
for	O
arsenicals	O
.	O

Genomics	O
data	O
will	O
prove	O
useful	O
for	O
identifying	O
the	O
key	O
pathways	O
involved	O
in	O
particular	O
responses	O
and	O
aid	O
in	O
determining	O
other	O
types	O
of	O
data	O
needed	O
for	O
quantitative	O
modeling	O
.	O

These	O
models	O
,	O
when	O
linked	O
with	O
PK	O
models	O
,	O
can	O
be	O
used	O
to	O
better	O
understand	O
and	O
explain	O
dose	O
-	O
and	O
time	O
-	O
response	O
behaviors	O
.	O

This	O
in	O
turn	O
assists	O
in	O
prioritizing	O
modes	O
of	O
action	O
with	O
respect	O
to	O
their	O
risk	O
assessment	O
relevance	O
and	O
future	O
research	O
.	O

This	O
type	O
of	O
integrated	O
modeling	O
approach	O
can	O
form	O
the	O
basis	O
for	O
a	O
highly	O
informative	O
mode	O
-	O
of	O
-	O
action	O
directed	O
risk	O
assessment	O
for	O
inorganic	O
arsenic	O
(	O
iAs	O
)	O
.	O

This	O
paper	O
will	O
address	O
both	O
practical	O
and	O
theoretical	O
aspects	O
of	O
integrating	O
PK	O
and	O
PD	O
data	O
in	O
a	O
modeling	O
framework	O
,	O
including	O
practical	O
barriers	O
to	O
its	O
application	O
.	O

Enhanced	O
PDE4B	O
expression	O
augments	O
LPS	O
-	O
inducible	O
TNF	O
expression	O
in	O
ethanol	O
-	O
primed	O
monocytes	O
:	O
relevance	O
to	O
alcoholic	B
liver	I
disease	I
.	O

Increased	O
plasma	O
and	O
hepatic	O
TNF	O
-	O
alpha	O
expression	O
is	O
well	O
documented	O
in	O
patients	O
with	O
alcoholic	B
hepatitis	I
and	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
alcoholic	B
liver	I
disease	I
.	O

We	O
have	O
previously	O
shown	O
that	O
monocytes	O
from	O
patients	O
with	O
alcoholic	B
hepatitis	I
show	O
increased	O
constitutive	O
and	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	O
-	O
alpha	O
production	O
.	O

Our	O
recent	O
studies	O
showed	O
that	O
chronic	O
ethanol	O
exposure	O
significantly	O
decreased	O
cellular	O
cAMP	O
levels	O
in	O
both	O
LPS	O
-	O
stimulated	O
and	O
unstimulated	O
monocytes	O
and	O
Kupffer	O
cells	O
,	O
leading	O
to	O
an	O
increase	O
in	O
LPS	O
-	O
inducible	O
TNF	O
-	O
alpha	O
production	O
by	O
affecting	O
NF	O
-	O
kappaB	O
activation	O
and	O
induction	O
of	O
TNF	O
mRNA	O
expression	O
.	O

Accordingly	O
,	O
the	O
mechanisms	O
underlying	O
this	O
ethanol	O
-	O
induced	O
decrease	O
in	O
cellular	O
cAMP	O
leading	O
to	O
an	O
increase	O
in	O
TNF	O
expression	O
were	O
examined	O
in	O
monocytes	O
/	O
macrophages	O
.	O

In	O
this	O
study	O
,	O
chronic	O
ethanol	O
exposure	O
was	O
observed	O
to	O
significantly	O
increase	O
LPS	O
-	O
inducible	O
expression	O
of	O
cAMP	O
-	O
specific	O
phosphodiesterase	O
(	O
PDE	O
)	O
4B	O
that	O
degrades	O
cellular	O
cAMP	O
.	O

Increased	O
PDE4B	O
expression	O
was	O
associated	O
with	O
enhanced	O
NF	O
-	O
kappaB	O
activation	O
and	O
transcriptional	O
activity	O
and	O
subsequent	O
priming	O
of	O
monocytes	O
/	O
macrophages	O
leading	O
to	O
enhanced	O
LPS	O
-	O
inducible	O
TNF	O
-	O
alpha	O
production	O
.	O

Selective	O
inhibition	O
of	O
PDE4	O
by	O
rolipram	O
abrogated	O
LPS	O
-	O
mediated	O
TNF	O
-	O
alpha	O
expression	O
at	O
both	O
protein	O
and	O
mRNA	O
levels	O
in	O
control	O
and	O
ethanol	O
-	O
treated	O
cells	O
.	O

Notably	O
,	O
PDE4	O
inhibition	O
did	O
not	O
affect	O
LPS	O
-	O
inducible	O
NF	O
-	O
kappaB	O
activation	O
but	O
significantly	O
decreased	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
.	O

These	O
findings	O
strongly	O
support	O
the	O
pathogenic	O
role	O
of	O
PDE4B	O
in	O
the	O
ethanol	O
-	O
mediated	O
priming	O
of	O
monocytes	O
/	O
macrophages	O
and	O
increased	O
LPS	O
-	O
inducible	O
TNF	O
production	O
and	O
the	O
subsequent	O
development	O
of	O
alcoholic	B
liver	I
disease	I
(	O
ALD	B
)	O
.	O

Since	O
enhanced	O
TNF	O
expression	O
plays	O
a	O
significant	O
role	O
in	O
the	O
evolution	O
of	O
clinical	O
and	O
experimental	O
ALD	B
,	O
its	O
downregulation	O
via	O
selective	O
PDE4B	O
inhibitors	O
could	O
constitute	O
a	O
novel	O
therapeutic	O
approach	O
in	O
the	O
treatment	O
of	O
ALD	B
.	O

The	O
molecular	O
basis	O
of	O
class	O
side	O
effects	O
due	O
to	O
treatment	O
with	O
inhibitors	O
of	O
the	O
VEGF	O
/	O
VEGFR	O
pathway	O
.	O

Vascular	O
Endothelial	O
Growth	O
Factor	O
(	O
VEGF	O
)	O
is	O
considered	O
to	O
be	O
one	O
of	O
the	O
most	O
important	O
regulators	O
of	O
angiogenesis	O
and	O
a	O
new	O
key	O
target	O
in	O
anti	O
-	O
cancer	O
treatment	O
.	O

Various	O
clinical	O
trials	O
have	O
validated	O
the	O
clinical	O
importance	O
of	O
anti	O
-	O
VEGF	O
or	O
anti	O
-	O
VEGF	O
receptor	O
(	O
VEGFR	O
)	O
therapy	O
.	O

Currently	O
the	O
humanized	O
monoclonal	O
antibody	O
bevacizumab	O
(	O
blocks	O
VEGF	O
-	O
A	O
)	O
,	O
and	O
the	O
tyrosine	O
kinase	O
inhibitors	O
sunitinib	O
and	O
sorafenib	O
(	O
inhibit	O
VEGFRs	O
)	O
are	O
approved	O
for	O
patients	O
with	O
various	O
malignancies	B
and	O
several	O
others	O
are	O
expected	O
in	O
the	O
coming	O
years	O
.	O

Unfortunately	O
,	O
anti	O
-	O
VEGF	O
/	O
VEGFR	O
treatment	O
is	O
not	O
void	O
of	O
side	O
effects	O
.	O

An	O
array	O
of	O
unexpected	O
side	O
effects	O
is	O
now	O
seen	O
in	O
clinical	O
practice	O
.	O

Management	O
of	O
these	O
side	O
effects	O
is	O
extremely	O
important	O
in	O
the	O
development	O
of	O
the	O
various	O
anti	O
-	O
VEGF	O
/	O
VEGFR	O
therapies	O
and	O
their	O
optimal	O
use	O
.	O

This	O
review	O
provides	O
an	O
overview	O
of	O
the	O
toxicity	O
profile	O
of	O
this	O
class	O
of	O
agents	O
,	O
the	O
molecular	O
basis	O
behind	O
these	O
side	O
effects	O
and	O
indicates	O
potential	O
options	O
for	O
management	O
.	O

VEGF	O
and	O
its	O
receptors	O
play	O
an	O
important	O
role	O
in	O
normal	O
tissues	O
and	O
are	O
widely	O
expressed	O
.	O

It	O
is	O
likely	O
that	O
interference	O
with	O
this	O
pathway	O
induces	O
an	O
array	O
of	O
side	O
effects	O
due	O
to	O
the	O
lack	O
of	O
normal	O
function	O
of	O
VEGF	O
.	O

A	O
consistent	O
pattern	O
of	O
side	O
effects	O
is	O
now	O
emerging	O
.	O

Hypertension	B
,	O
gastro	B
-	I
intestinal	I
toxicity	I
,	O
hypothyroidism	B
,	O
proteinuria	B
,	O
coagulation	B
disorders	I
and	O
neurotoxicity	B
are	O
side	O
effects	O
observed	O
with	O
both	O
anti	O
-	O
VEGF	O
and	O
anti	O
-	O
VEGFR	O
inhibitors	O
.	O

For	O
these	O
side	O
effects	O
the	O
role	O
of	O
VEGF	O
/	O
VEGFR	O
pathway	O
in	O
normal	O
tissue	O
was	O
reviewed	O
in	O
order	O
to	O
provide	O
a	O
molecular	O
mechanism	O
that	O
linked	O
side	O
effect	O
with	O
physiological	O
activity	O
of	O
VEGF	O
/	O
VEGFR	O
.	O

Insight	O
into	O
the	O
molecular	O
basis	O
may	O
aid	O
specific	O
supportive	O
care	O
measures	O
to	O
ensure	O
optimal	O
use	O
of	O
this	O
class	O
of	O
agents	O
.	O

Conclusion	O
:	O
Inhibiting	O
the	O
VEGF	O
/	O
VEGFR	O
pathway	O
is	O
an	O
effective	O
approach	O
to	O
treat	O
cancer	B
.	O

It	O
has	O
also	O
provided	O
new	O
insight	O
into	O
the	O
physiological	O
role	O
of	O
this	O
pathway	O
in	O
various	O
organs	O
.	O

Integrating	O
the	O
knowledge	O
in	O
daily	O
oncological	O
practice	O
will	O
be	O
a	O
challenge	O
for	O
the	O
future	O
.	O

Safety	O
of	O
drug	O
eluting	O
stents	O
:	O
current	O
concerns	O
and	O
controversies	O
.	O

Coronary	O
artery	O
stenting	O
is	O
currently	O
the	O
most	O
frequently	O
performed	O
percutaneous	O
coronary	O
intervention	O
for	O
the	O
treatment	O
of	O
coronary	B
artery	I
disease	I
.	O

Recently	O
,	O
drug	O
-	O
eluting	O
stents	O
,	O
loaded	O
with	O
anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
migratory	O
,	O
anti	O
-	O
proliferative	O
or	O
pro	O
-	O
healing	O
drugs	O
,	O
have	O
revolutionized	O
the	O
management	O
of	O
coronary	B
artery	I
disease	I
by	O
markedly	O
reducing	O
in	O
-	O
stent	O
restenosis	O
.	O

Despite	O
the	O
excellent	O
short	O
-	O
and	O
mid	O
-	O
term	O
results	O
of	O
randomized	O
controlled	O
trials	O
observed	O
with	O
drug	O
-	O
eluting	O
stents	O
,	O
there	O
remain	O
a	O
number	O
of	O
unresolved	O
issues	O
and	O
valid	O
concerns	O
about	O
long	O
-	O
term	O
safety	O
and	O
efficacy	O
of	O
this	O
revolutionary	O
technology	O
.	O

Important	O
safety	O
issues	O
such	O
as	O
thrombosis	B
,	O
late	O
stent	B
malapposition	I
,	O
aneurysm	B
formation	O
,	O
edge	B
effect	I
,	O
late	O
inflammation	B
due	O
to	O
choice	O
of	O
polymer	O
used	O
to	O
bind	O
the	O
drug	O
,	O
the	O
release	O
of	O
toxins	O
,	O
and	O
potential	O
interactions	O
with	O
brachytherapy	O
and	O
drugs	O
have	O
not	O
been	O
completely	O
addressed	O
.	O

This	O
review	O
article	O
evaluates	O
current	O
available	O
scientific	O
evidence	O
on	O
the	O
various	O
safety	O
issues	O
related	O
to	O
the	O
use	O
of	O
drug	O
-	O
eluting	O
stents	O
.	O

Evidence	O
for	O
altered	O
hippocampal	O
volume	O
and	O
brain	O
metabolites	O
in	O
workers	O
occupationally	O
exposed	O
to	O
lead	O
:	O
a	O
study	O
by	O
magnetic	O
resonance	O
imaging	O
and	O
(	O
1	O
)	O
H	O
magnetic	O
resonance	O
spectroscopy	O
.	O

Environmental	O
and	O
occupational	O
exposure	O
to	O
lead	O
(	O
Pb	O
)	O
remains	O
to	O
be	O
a	O
major	O
public	O
health	O
issue	O
.	O

The	O
purpose	O
of	O
this	O
cross	O
-	O
sectional	O
study	O
was	O
to	O
use	O
non	O
-	O
invasive	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
proton	O
magnetic	O
resonance	O
spectroscopy	O
(	O
(	O
1	O
)	O
H	O
MRS	O
)	O
techniques	O
to	O
investigate	O
whether	O
chronic	O
exposure	O
to	O
Pb	O
in	O
an	O
occupational	O
setting	O
altered	O
brain	O
structure	O
and	O
function	O
of	O
Pb	O
-	O
exposed	O
workers	O
.	O

The	O
Pb	O
-	O
exposed	O
group	O
consisted	O
of	O
15	O
workers	O
recruited	O
from	O
either	O
a	O
Pb	O
-	O
smelting	O
factory	O
or	O
a	O
Pb	O
-	O
battery	O
manufacturer	O
.	O

The	O
control	O
group	O
had	O
19	O
healthy	O
volunteers	O
who	O
had	O
no	O
history	O
of	O
Pb	O
exposure	O
in	O
working	O
environment	O
or	O
at	O
home	O
.	O

The	O
average	O
airborne	O
Pb	O
concentrations	O
in	O
fume	O
and	O
dust	O
were	O
0.43	O
and	O
0.44	O
mg	O
/	O
m	O
(	O
3	O
)	O
,	O
respectively	O
,	O
in	O
the	O
smeltery	O
,	O
and	O
0.10	O
and	O
1.06	O
mg	O
/	O
m	O
(	O
3	O
)	O
,	O
respectively	O
,	O
in	O
the	O
Pb	O
battery	O
workshop	O
.	O

The	O
average	O
blood	O
Pb	O
concentrations	O
(	O
BPb	O
)	O
in	O
Pb	O
-	O
exposed	O
and	O
control	O
workers	O
were	O
63.5	O
and	O
8.7	O
microg	O
/	O
dL	O
,	O
respectively	O
.	O

The	O
MRI	O
examination	O
showed	O
that	O
brain	O
hippocampal	O
volume	O
among	O
Pb	O
-	O
exposed	O
workers	O
was	O
significantly	O
diminished	O
in	O
comparison	O
to	O
age	O
-	O
matched	O
control	O
subjects	O
(	O
p	O
<	O
0.01	O
)	O
,	O
although	O
the	O
extent	O
of	O
this	O
reduction	O
was	O
relatively	O
small	O
(	O
5	O
-	O
6	O
%	O
of	O
the	O
control	O
values	O
)	O
.	O

Linear	O
regression	O
analyses	O
revealed	O
significant	O
inverse	O
associations	O
between	O
BPb	O
and	O
the	O
decreased	O
hippocampal	O
volume	O
on	O
both	O
sides	O
of	O
brain	O
hemisphere	O
.	O

Among	O
five	O
brain	O
metabolites	O
investigated	O
by	O
MRS	O
,	O
i.e.	O
,	O
N	O
-	O
acetyl	O
-	O
aspartate	O
(	O
NAA	O
)	O
,	O
creatine	O
(	O
Cr	O
)	O
,	O
choline	O
(	O
Cho	O
)	O
,	O
inosine	O
(	O
mI	O
)	O
,	O
glutamate	O
/	O
glutamine	O
(	O
Glx	O
)	O
and	O
lipids	O
(	O
Lip	O
)	O
,	O
a	O
significant	O
decrease	O
in	O
NAA	O
/	O
Cr	O
ratio	O
(	O
7	O
%	O
of	O
controls	O
,	O
p	O
<	O
0.05	O
)	O
and	O
a	O
remarkable	O
increase	O
in	O
Lip	O
/	O
Cr	O
ratio	O
(	O
40	O
%	O
,	O
p	O
<	O
0.01	O
)	O
were	O
observed	O
in	O
the	O
brains	O
of	O
Pb	O
-	O
exposed	O
workers	O
as	O
compared	O
to	O
controls	O
.	O

Furthermore	O
,	O
the	O
increased	O
Lip	O
/	O
Cr	O
ratio	O
was	O
significantly	O
associated	O
with	O
BPb	O
(	O
r	O
=	O
0.46	O
,	O
p	O
<	O
0.01	O
)	O
.	O

Taken	O
together	O
,	O
this	O
study	O
suggests	O
that	O
occupational	O
exposure	O
to	O
Pb	O
may	O
cause	O
subtle	O
structural	O
and	O
functional	O
alteration	O
in	O
human	O
brains	O
.	O

The	O
MRI	O
and	O
MRS	O
brain	O
imaging	O
techniques	O
can	O
be	O
used	O
as	O
the	O
non	O
-	O
invasive	O
means	O
to	O
evaluate	O
Pb	O
-	O
induced	O
neurotoxicity	B
.	O

Anemia	B
during	O
sequential	O
induction	O
chemotherapy	O
and	O
chemoradiation	O
for	O
head	B
and	I
neck	I
cancer	I
:	O
the	O
impact	O
of	O
blood	O
transfusion	O
on	O
treatment	O
outcome	O
.	O

PURPOSE	O
:	O
Sequential	O
treatment	O
(	O
chemotherapy	O
followed	O
by	O
concomitant	O
chemoradiation	O
;	O
CCRT	O
)	O
is	O
increasingly	O
being	O
used	O
for	O
radical	O
treatment	O
of	O
squamous	B
cell	I
cancer	I
of	I
the	I
head	I
and	I
neck	I
(	O
SCCHN	B
)	O
,	O
which	O
results	O
in	O
increased	O
myelosuppression	B
.	O

In	O
this	O
study	O
,	O
we	O
review	O
the	O
incidence	O
of	O
anemia	B
and	O
the	O
effect	O
of	O
a	O
policy	O
of	O
hemoglobin	O
(	O
Hb	O
)	O
maintenance	O
by	O
blood	O
transfusion	O
on	O
disease	O
outcomes	O
in	O
these	O
patients	O
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
Retrospective	O
review	O
of	O
the	O
records	O
of	O
patients	O
with	O
SCCHN	B
treated	O
with	O
sequential	O
CCRT	O
formed	O
the	O
basis	O
of	O
this	O
study	O
.	O

The	O
incidence	O
of	O
anemia	B
and	O
statistics	O
on	O
blood	O
transfusion	O
were	O
documented	O
.	O

For	O
the	O
purpose	O
of	O
outcome	O
analyses	O
,	O
patients	O
were	O
divided	O
into	O
four	O
categories	O
by	O
(	O
1	O
)	O
transfusion	O
status	O
,	O
(	O
2	O
)	O
nadir	O
Hb	O
concentration	O
,	O
(	O
3	O
)	O
number	O
of	O
transfusion	O
episodes	O
,	O
and	O
(	O
4	O
)	O
number	O
of	O
units	O
of	O
blood	O
transfused	O
(	O
NOUT	O
)	O
.	O

Data	O
on	O
3	O
-	O
year	O
locoregional	O
control	O
(	O
LRC	O
)	O
,	O
relapse	O
-	O
free	O
survival	O
(	O
RFS	O
)	O
,	O
disease	O
-	O
specific	O
survival	O
(	O
DSS	O
)	O
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
One	O
hundred	O
and	O
sixty	O
-	O
nine	O
patients	O
were	O
identified	O
.	O

The	O
median	O
follow	O
-	O
up	O
was	O
23.6	O
months	O
.	O

The	O
RFS	O
(	O
52	O
%	O
vs.	O
41	O
%	O
,	O
p	O
=	O
0.03	O
)	O
,	O
DSS	O
(	O
71	O
%	O
vs.	O
66	O
%	O
,	O
p	O
=	O
0.02	O
)	O
,	O
and	O
OS	O
(	O
58	O
%	O
vs.	O
42	O
%	O
p	O
=	O
0.005	O
)	O
were	O
significantly	O
better	O
for	O
patients	O
who	O
did	O
not	O
have	O
a	O
transfusion	O
vs.	O
those	O
who	O
did	O
.	O

The	O
LRC	O
,	O
RFS	O
,	O
DSS	O
,	O
and	O
OS	O
were	O
also	O
significantly	O
better	O
for	O
patients	O
with	O
nadir	O
Hb	O
level	O
>	O
12	O
vs.	O
<	O
12	O
g	O
/	O
dL	O
and	O
NOUT	O
1	O
-	O
4	O
vs.	O
>	O
4	O
.	O

CONCLUSION	O
:	O
Our	O
study	O
seems	O
to	O
suggest	O
that	O
blood	O
transfusion	O
during	O
radical	O
treatment	O
for	O
SCCHN	B
might	O
be	O
detrimental	O
.	O

Further	O
research	O
should	O
be	O
undertaken	O
into	O
the	O
complex	O
interactions	O
among	O
tumor	B
hypoxia	I
,	O
anemia	B
,	O
and	O
the	O
treatment	O
of	O
anemia	B
before	O
making	O
treatment	O
recommendations	O
.	O

Disparities	O
in	O
the	O
use	O
of	O
chemotherapy	O
and	O
monoclonal	O
antibody	O
therapy	O
for	O
elderly	O
advanced	O
colorectal	B
cancer	I
patients	O
in	O
the	O
community	O
oncology	O
setting	O
.	O

BACKGROUND	O
:	O
The	O
clinical	O
trials	O
on	O
which	O
the	O
treatment	O
of	O
advanced	O
colorectal	B
(	O
CRC	B
)	O
is	O
based	O
enroll	O
few	O
elderly	O
patients	O
.	O

Furthermore	O
,	O
few	O
investigations	O
have	O
determined	O
the	O
use	O
and	O
outcomes	O
of	O
the	O
treatment	O
of	O
advanced	O
CRC	B
in	O
practice	O
.	O

This	O
study	O
evaluated	O
the	O
treatment	O
of	O
advanced	O
CRC	B
in	O
community	O
oncology	O
practices	O
,	O
focusing	O
on	O
age	O
-	O
related	O
differences	O
in	O
treatment	O
and	O
outcome	O
.	O

METHODS	O
:	O
A	O
national	O
,	O
retrospective	O
chart	O
review	O
was	O
conducted	O
to	O
evaluate	O
the	O
management	O
of	O
advanced	O
CRC	B
in	O
10	O
community	O
practices	O
across	O
the	O
U	O
.	O

S	O
.	O

All	O
medical	O
records	O
of	O
patients	O
diagnosed	O
with	O
advanced	O
CRC	B
initiating	O
chemotherapy	O
treatment	O
after	O
January	O
1	O
,	O
2003	O
through	O
2006	O
were	O
included	O
.	O

The	O
primary	O
aim	O
was	O
to	O
compare	O
the	O
proportion	O
receiving	O
doublet	O
chemotherapy	O
(	O
irinotecan	O
or	O
oxaliplatin	O
with	O
a	O
fluoropyrimidine	O
)	O
as	O
initial	O
therapy	O
in	O
young	O
(	O
age	O
<	O
or	O
=	O
65	O
years	O
)	O
and	O
elderly	O
(	O
age	O
>	O
65	O
years	O
)	O
patients	O
.	O

Additional	O
aims	O
included	O
age	O
-	O
based	O
comparisons	O
of	O
the	O
addition	O
of	O
bevacizumab	O
to	O
chemotherapy	O
,	O
overall	O
chemotherapy	O
use	O
,	O
all	O
-	O
cause	O
mortality	O
,	O
and	O
toxicity	O
-	O
related	O
events	O
.	O

RESULTS	O
:	O
Overall	O
,	O
520	O
patients	O
(	O
56	O
%	O
elderly	O
)	O
received	O
6,253	O
cycles	O
of	O
chemotherapy	O
.	O

Of	O
the	O
younger	O
patients	O
,	O
84	O
%	O
received	O
doublet	O
chemotherapy	O
first	O
-	O
line	O
,	O
compared	O
with	O
58	O
%	O
of	O
elderly	O
patients	O
(	O
p	O
<	O
.001	O
)	O
.	O

The	O
use	O
of	O
each	O
of	O
the	O
medications	O
-	O
-	O
irinotecan	O
,	O
oxaliplatin	O
,	O
and	O
bevacizumab	O
-	O
-	O
was	O
lower	O
in	O
elderly	O
patients	O
(	O
p	O
<	O
.001	O
)	O
.	O

Independent	O
predictors	O
of	O
a	O
higher	O
risk	O
for	O
mortality	O
were	O
age	O
>	O
65	O
(	O
adjusted	O
hazards	O
ratio	O
[	O
HR	O
]	O
,	O
1.19	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.02	O
-	O
1.39	O
)	O
and	O
performance	O
status	O
score	O
>	O
or	O
=	O
2	O
(	O
HR	O
,	O
1.65	O
;	O
95	O
%	O
CI	O
,	O
1.41	O
-	O
1.91	O
)	O
.	O

CONCLUSION	O
:	O
Elderly	O
patients	O
are	O
less	O
likely	O
to	O
receive	O
first	O
-	O
line	O
doublet	O
chemotherapy	O
than	O
younger	O
patients	O
.	O

Age	O
and	O
performance	O
status	O
are	O
independent	O
predictors	O
of	O
treatment	O
and	O
overall	O
survival	O
.	O

Pharmacological	O
profile	O
,	O
efficacy	O
and	O
safety	O
of	O
rupatadine	O
in	O
allergic	B
rhinitis	I
.	O

Allergic	B
rhinitis	I
(	O
AR	B
)	O
is	O
a	O
disease	O
with	O
high	O
prevalence	O
.	O

In	O
AR	B
,	O
exposure	O
to	O
airborne	O
allergens	O
elicits	O
an	O
allergic	O
response	O
which	O
involves	O
epithelial	O
accumulation	O
of	O
effector	O
cells	O
-	O
e.g.	O
mast	O
cells	O
and	O
basophils	O
-	O
and	O
subsequent	O
inflammation	B
.	O

During	O
the	O
early	O
response	O
in	O
AR	B
,	O
histamine	O
has	O
been	O
found	O
to	O
be	O
the	O
most	O
abundant	O
mediator	O
and	O
it	O
is	O
associated	O
with	O
many	O
symptoms	O
of	O
this	O
disease	O
mediated	O
through	O
the	O
histamine	O
H1	O
receptor	O
.	O

Therefore	O
,	O
anti	O
-	O
histamines	O
have	O
a	O
role	O
to	O
play	O
in	O
the	O
management	O
of	O
AR	B
.	O

However	O
,	O
the	O
available	O
antihistamines	O
have	O
certain	O
well	O
-	O
known	O
side	O
effects	O
like	O
sedation	B
and	O
potential	O
pro	B
-	I
arrythmic	I
effects	I
owing	O
to	O
their	O
interactions	O
with	O
other	O
drugs	O
,	O
as	O
well	O
as	O
having	O
poor	O
or	O
no	O
effect	O
on	O
platelet	O
activating	O
factor	O
(	O
PAF	O
)	O
which	O
also	O
plays	O
an	O
important	O
role	O
in	O
AR	B
.	O

This	O
article	O
is	O
a	O
qualitative	O
systematic	O
literature	O
review	O
on	O
the	O
pharmacological	O
profile	O
of	O
rupatadine	O
in	O
order	O
to	O
evaluate	O
its	O
safety	O
and	O
efficacy	O
in	O
AR	B
as	O
compared	O
to	O
other	O
anti	O
-	O
histamines	O
.	O

Rupatadine	O
is	O
a	O
once	O
-	O
daily	O
non	O
-	O
sedative	O
,	O
selective	O
,	O
long	O
-	O
acting	O
H1	O
anti	O
-	O
histamine	O
with	O
antagonistic	O
PAF	O
effects	O
through	O
its	O
interaction	O
with	O
specific	O
receptors	O
.	O

Rupatadine	O
significantly	O
improves	O
nasal	O
symptoms	O
in	O
patients	O
with	O
AR	B
.	O

It	O
has	O
a	O
good	O
safety	O
profile	O
and	O
is	O
devoid	O
of	O
arrythmogenic	B
effects	I
.	O

These	O
properties	O
make	O
rupatadine	O
a	O
suitable	O
first	O
line	O
anti	O
-	O
histamine	O
for	O
the	O
treatment	O
of	O
AR	B
.	O

Variability	O
in	O
platelet	O
response	O
to	O
a	O
single	O
daily	O
dose	O
of	O
150	O
mg	O
enteric	O
coated	O
aspirin	O
in	O
a	O
high	O
risk	O
population	O
.	O

PURPOSE	O
:	O
Previous	O
studies	O
have	O
reported	O
inadequate	O
anti	O
-	O
platelet	O
effect	O
in	O
0.4	O
-	O
35	O
%	O
of	O
patients	O
taking	O
aspirin	O
.	O

Such	O
studies	O
have	O
arbitrarily	O
defined	O
the	O
terms	O
""""	O
semi	O
-	O
responders	O
""""	O
,	O
""""	O
non	O
-	O
responders	O
""""	O
or	O
""""	O
resistant	O
""""	O
to	O
variable	O
doses	O
of	O
aspirin	O
on	O
the	O
basis	O
of	O
absolute	O
values	O
derived	O
from	O
different	O
ex	O
-	O
vivo	O
platelet	O
aggregation	O
(	O
PA	O
)	O
methods	O
.	O

Our	O
objective	O
was	O
to	O
define	O
response	O
to	O
150	O
-	O
mg	O
dose	O
of	O
aspirin	O
in	O
terms	O
of	O
normally	O
distributed	O
values	O
using	O
an	O
ex	O
-	O
vivo	O
measure	O
of	O
PA	O
in	O
a	O
population	O
at	O
high	O
risk	O
for	O
vascular	O
events	O
.	O

METHODS	O
:	O
We	O
prospectively	O
studied	O
high	O
risk	O
patients	O
with	O
either	O
established	O
coronary	B
artery	I
disease	I
(	O
CAD	B
)	O
or	O
stroke	B
or	O
transient	B
ischemic	I
attack	I
(	O
TIA	B
)	O
or	O
peripheral	B
vascular	I
disease	I
or	O
with	O
multiple	O
atherothrombotic	O
risk	O
factors	O
like	O
diabetes	B
plus	O
one	O
of	O
the	O
following	O
-	O
-	O
hypertension	B
,	O
increased	O
total	O
cholesterol	O
,	O
cigarette	O
smoking	O
,	O
micro	O
-	O
albuminuria	O
,	O
low	O
-	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
,	O
family	O
history	O
of	O
CAD	B
and	O
receiving	O
single	O
150	O
mg	O
dose	O
of	O
aspirin	O
daily	O
.	O

PA	O
was	O
assessed	O
by	O
chronolog	O
lumi	O
-	O
aggregometer	O
(	O
490	O
-	O
2	O
D	O
)	O
using	O
arachidonic	O
acid	O
(	O
AA	O
)	O
reagent	O
.	O

RESULTS	O
:	O
130	O
patients	O
were	O
studied	O
.	O

The	O
response	O
of	O
subjects	O
to	O
aspirin	O
followed	O
a	O
normal	O
,	O
bell	O
shaped	O
distribution	O
curve	O
with	O
a	O
mean	O
and	O
standard	O
deviation	O
(	O
S	O
.	O

D	O
.	O
)	O
of	O
13.1	O
+	O
/	O
-	O
4.4	O
%	O
.	O

3.1	O
%	O
patients	O
had	O
PA	O
values	O
more	O
than	O
2	O
S	O
.	O

D	O
.	O
of	O
the	O
mean	O
,	O
hence	O
termed	O
as	O
hypo	O
-	O
responders	O
to	O
aspirin	O
while	O
another	O
3.1	O
%	O
patients	O
had	O
PA	O
values	O
less	O
than	O
2	O
S	O
.	O

D	O
.	O
of	O
the	O
mean	O
,	O
hence	O
termed	O
as	O
hyper	O
-	O
responders	O
to	O
aspirin	O
.	O

CONCLUSION	O
:	O
There	O
is	O
minimal	O
inter	O
-	O
individual	O
variability	O
in	O
the	O
response	O
to	O
aspirin	O
when	O
tested	O
with	O
AA	O
as	O
the	O
reagent	O
.	O

The	O
response	O
to	O
aspirin	O
follows	O
a	O
normal	O
Gaussian	O
distribution	O
.	O

The	O
prevalence	O
of	O
hypo	O
-	O
responders	O
to	O
aspirin	O
in	O
high	O
risk	O
population	O
is	O
only	O
3.1	O
%	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
document	O
""""	O
hypo	O
""""	O
and	O
""""	O
hyper	O
-	O
responders	O
""""	O
to	O
single	O
daily	O
dose	O
of	O
150	O
mg	O
aspirin	O
.	O

The	O
clinical	O
relevance	O
of	O
these	O
findings	O
remains	O
to	O
be	O
determined	O
.	O

Effect	O
of	O
2	O
-	O
hydroxyethyl	O
-	O
methacrylate	O
(	O
HEMA	O
)	O
on	O
the	O
phagocytic	O
and	O
respiratory	O
burst	O
activity	O
of	O
human	O
neutrophils	O
and	O
monocytes	O
.	O

Neutrophils	O
and	O
monocytes	O
/	O
macrophages	O
(	O
M	O
?	O
)	O
,	O
found	O
in	O
oral	O
mucosa	O
and	O
gingival	O
sulcus	O
,	O
phagocytose	O
and	O
kill	O
bacteria	O
using	O
products	O
produced	O
during	O
a	O
respiratory	O
burst	O
.	O

2	O
-	O
Hydroxyethyl	O
-	O
methacrylate	O
(	O
HEMA	O
)	O
is	O
a	O
major	O
component	O
released	O
from	O
resin	O
glass	O
ionomer	O
and	O
dental	O
adhesives	O
.	O

Hence	O
,	O
in	O
pulp	O
and	O
gingiva	O
,	O
phagocytes	O
can	O
come	O
into	O
contact	O
with	O
unpolymerized	O
HEMA	O
monomers	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
exposure	O
to	O
HEMA	O
on	O
neutrophil	O
and	O
monocyte	O
bactericidal	O
function	O
.	O

Blood	O
collected	O
from	O
five	O
female	O
volunteers	O
was	O
exposed	O
in	O
vitro	O
to	O
HEMA	O
for	O
2	O
h	O
and	O
then	O
phagocytosis	O
,	O
respiratory	O
burst	O
,	O
and	O
cellular	O
integrity	O
were	O
measured	O
using	O
flow	O
cytometry	O
.	O

Respiratory	O
burst	O
was	O
quantified	O
by	O
measuring	O
fluorescent	O
rhodamine	O
123	O
generated	O
via	O
oxidation	O
of	O
dihydrorhodamine	O
123	O
.	O

Cellular	O
membrane	O
integrity	O
was	O
evaluated	O
by	O
staining	O
with	O
propidium	O
iodide	O
.	O

The	O
respiratory	O
burst	O
activity	O
of	O
the	O
neutrophils	O
was	O
significantly	O
decreased	O
by	O
exposure	O
to	O
7.5	O
and	O
15	O
mM	O
HEMA	O
.	O

No	O
significant	O
effect	O
of	O
HEMA	O
was	O
seen	O
on	O
the	O
number	O
of	O
granulocytes	O
or	O
monocytes	O
capable	O
of	O
performing	O
respiratory	O
burst	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
significant	O
effect	O
of	O
HEMA	O
on	O
the	O
phagocytic	O
activity	O
of	O
the	O
monocytes	O
or	O
the	O
granulocytes	O
.	O

In	O
conclusion	O
,	O
HEMA	O
did	O
not	O
affect	O
the	O
phagocytosis	O
activity	O
of	O
neutrophils	O
;	O
however	O
,	O
the	O
ability	O
of	O
the	O
cells	O
to	O
kill	O
internalized	O
prey	O
was	O
significantly	O
reduced	O
.	O

Methods	O
in	O
safety	O
pharmacology	O
in	O
focus	O
.	O

This	O
focused	O
issue	O
of	O
the	O
Journal	O
of	O
Pharmacological	O
and	O
Toxicological	O
Methods	O
is	O
the	O
fifth	O
to	O
highlight	O
Methods	O
in	O
Safety	O
Pharmacology	O
and	O
includes	O
a	O
number	O
of	O
articles	O
from	O
the	O
7th	O
Annual	O
Safety	O
Pharmacology	O
Society	O
(	O
SPS	O
)	O
meeting	O
that	O
was	O
held	O
in	O
Edinburgh	O
,	O
Scotland	O
,	O
September	O
19	O
-	O
21	O
,	O
2007	O
.	O

However	O
,	O
unlike	O
issues	O
of	O
the	O
past	O
,	O
in	O
which	O
content	O
predominantly	O
focused	O
on	O
cardiovascular	O
issues	O
(	O
specifically	O
QT	O
interval	O
prolongation	O
,	O
QT	O
-	O
HR	O
correction	O
methods	O
and	O
validation	O
of	O
non	O
-	O
clinical	O
cardiovascular	O
models	O
)	O
this	O
issue	O
is	O
composed	O
of	O
a	O
number	O
of	O
non	O
-	O
cardiovascular	O
methods	O
papers	O
and	O
review	O
articles	O
.	O

Of	O
particular	O
interest	O
to	O
readers	O
will	O
be	O
articles	O
related	O
to	O
CNS	O
studies	O
,	O
in	O
particular	O
neurobehavioral	O
assessments	O
in	O
non	O
-	O
human	O
primates	O
and	O
the	O
effects	O
of	O
drugs	O
in	O
juvenile	O
and	O
adult	O
rats	O
(	O
an	O
article	O
that	O
may	O
be	O
relevant	O
in	O
light	O
of	O
recent	O
EU	O
/	O
US	O
pediatric	O
legislation	O
)	O
.	O

While	O
cardiovascular	O
function	O
may	O
not	O
dominate	O
there	O
are	O
several	O
useful	O
methodological	O
papers	O
including	O
an	O
assessment	O
of	O
cardiovascular	O
sensitivity	O
of	O
drugs	O
in	O
conscious	O
and	O
anesthetized	O
non	O
-	O
human	O
primates	O
,	O
and	O
a	O
mathematical	O
model	O
(	O
fractal	O
analysis	O
)	O
applied	O
to	O
canine	O
heartbeat	O
dynamics	O
.	O

A	O
first	O
for	O
the	O
journal	O
is	O
a	O
paper	O
by	O
Vargas	O
et	O
al.	O
,	O
(	O
2008	O
-	O
this	O
issue	O
)	O
in	O
which	O
members	O
of	O
the	O
SPS	O
formed	O
a	O
working	O
group	O
in	O
order	O
to	O
assess	O
and	O
review	O
safety	O
pharmacology	O
testing	O
of	O
biological	O
therapeutic	O
agents	O
(	O
specifically	O
monoclonal	O
antibodies	O
,	O
mAbs	O
)	O
.	O

The	O
group	O
provides	O
recommendations	O
that	O
will	O
likely	O
shape	O
regulatory	O
strategy	O
and	O
discussions	O
in	O
the	O
yet	O
to	O
be	O
fully	O
discussed	O
area	O
of	O
biological	O
safety	O
testing	O
.	O

In	O
the	O
tradition	O
of	O
obtaining	O
a	O
perspective	O
on	O
industry	O
safety	O
pharmacology	O
program	O
practices	O
Lindgren	O
et	O
al.	O
,	O
(	O
2008	O
-	O
this	O
issue	O
)	O
provide	O
the	O
results	O
of	O
a	O
recent	O
SPS	O
survey	O
that	O
examines	O
ICH	O
S7A	O
and	O
S7B	O
trends	O
,	O
aspects	O
of	O
early	O
'	O
frontloading	O
'	O
safety	O
studies	O
,	O
abuse	O
and	O
dependence	O
liability	O
and	O
Contract	O
Research	O
Organization	O
(	O
CRO	O
)	O
tests	O
/	O
assays	O
used	O
in	O
safety	O
assessment	O
of	O
core	O
battery	O
and	O
supplementary	O
organ	O
systems	O
.	O

In	O
keeping	O
with	O
the	O
translation	O
track	O
aspect	O
of	O
the	O
2007	O
meeting	O
is	O
an	O
overview	O
of	O
the	O
Distinguished	O
Service	O
Award	O
lecture	O
to	O
Dr.	O
T	O
.	O

Hammond	O
that	O
discusses	O
many	O
aspects	O
of	O
safety	O
pharmacology	O
including	O
its	O
evolution	O
,	O
impact	O
,	O
value	O
and	O
translation	O
of	O
non	O
-	O
clinical	O
findings	O
to	O
humans	O
.	O

Finally	O
,	O
perspectives	O
are	O
presented	O
on	O
the	O
use	O
of	O
the	O
zebrafish	O
as	O
an	O
early	O
safety	O
pharmacology	O
-	O
screening	O
assay	O
.	O

Intensity	O
-	O
modulated	O
radiotherapy	O
in	O
postoperative	O
treatment	O
of	O
oral	B
cavity	I
cancers	I
.	O

PURPOSE	O
:	O
To	O
present	O
our	O
single	O
-	O
institution	O
experience	O
of	O
intensity	O
-	O
modulated	O
radiotherapy	O
(	O
IMRT	O
)	O
for	O
oral	B
cavity	I
cancer	I
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
Between	O
September	O
2000	O
and	O
December	O
2006	O
,	O
35	O
patients	O
with	O
histologically	O
confirmed	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
oral	I
cavity	I
underwent	O
surgery	O
followed	O
by	O
postoperative	O
IMRT	O
.	O

The	O
sites	O
included	O
were	O
buccal	O
mucosa	O
in	O
8	O
,	O
oral	O
tongue	O
in	O
11	O
,	O
floor	O
of	O
the	O
mouth	O
in	O
9	O
,	O
gingiva	O
in	O
4	O
,	O
hard	O
palate	O
in	O
2	O
,	O
and	O
retromolar	O
trigone	O
in	O
1	O
.	O

Most	O
patients	O
had	O
Stage	O
III	O
-	O
IV	O
disease	O
(	O
80	O
%	O
)	O
.	O

Ten	O
patients	O
(	O
29	O
%	O
)	O
also	O
received	O
concurrent	O
postoperative	O
chemotherapy	O
with	O
IMRT	O
.	O

The	O
median	O
prescribed	O
radiation	O
dose	O
was	O
60	O
Gy	O
.	O

RESULTS	O
:	O
The	O
median	O
follow	O
-	O
up	O
for	O
surviving	O
patients	O
was	O
28.1	O
months	O
(	O
range	O
,	O
11.9	O
-	O
85.1	O
)	O
.	O

Treatment	O
failure	O
occurred	O
in	O
11	O
cases	O
as	O
follows	O
:	O
local	O
in	O
4	O
,	O
regional	O
in	O
2	O
,	O
and	O
distant	O
metastases	O
in	O
5	O
.	O

Of	O
the	O
5	O
patients	O
with	O
distant	O
metastases	O
,	O
2	O
presented	O
with	O
dermal	O
metastases	O
.	O

The	O
2	O
-	O
and	O
3	O
-	O
year	O
estimates	O
of	O
locoregional	O
progression	O
-	O
free	O
survival	O
,	O
distant	O
metastasis	O
-	O
free	O
survival	O
,	O
disease	O
-	O
free	O
survival	O
,	O
and	O
overall	O
survival	O
were	O
84	O
%	O
and	O
77	O
%	O
,	O
85	O
%	O
and	O
85	O
%	O
,	O
70	O
%	O
and	O
64	O
%	O
,	O
and	O
74	O
%	O
and	O
74	O
%	O
,	O
respectively	O
.	O

Acute	O
Grade	O
2	O
or	O
greater	O
dermatitis	B
,	O
mucositis	B
,	O
and	O
esophageal	B
reactions	I
were	O
experienced	O
by	O
54	O
%	O
,	O
66	O
%	O
,	O
and	O
40	O
%	O
of	O
the	O
patients	O
,	O
respectively	O
.	O

Documented	O
late	O
complications	O
included	O
trismus	B
(	O
17	O
%	O
)	O
and	O
osteoradionecrosis	B
(	O
5	O
%	O
)	O
.	O

CONCLUSION	O
:	O
IMRT	O
as	O
an	O
adjuvant	O
treatment	O
after	O
surgical	O
resection	O
for	O
oral	B
cavity	I
tumors	I
is	O
feasible	O
and	O
effective	O
,	O
with	O
promising	O
results	O
and	O
acceptable	O
toxicity	O
.	O

Breakthrough	O
cryptococcosis	B
in	O
a	O
patient	O
with	O
systemic	B
lupus	I
erythematosus	I
(	O
SLE	B
)	O
receiving	O
micafungin	O
.	O

A	O
67	O
-	O
year	O
-	O
old	O
woman	O
with	O
systemic	B
lupus	I
erythematosus	I
(	O
SLE	B
)	O
was	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
lupus	B
nephritis	I
.	O

Methylprednisolone	O
minipulse	O
therapy	O
dramatically	O
reduced	O
her	O
proteinuria	B
;	O
however	O
;	O
she	O
then	O
complained	O
of	O
general	O
fatigue	B
with	O
low	O
-	O
grade	O
fever	B
.	O

Radiological	O
and	O
culture	O
studies	O
revealed	O
no	O
infectious	O
focus	O
,	O
but	O
she	O
was	O
treated	O
with	O
meropenem	O
and	O
micafungin	O
,	O
considering	O
her	O
immunosuppressive	O
state	O
.	O

Cytomegalovirus	O
antigenemia	O
was	O
later	O
determined	O
and	O
ganciclovir	O
was	O
added	O
.	O

She	O
became	O
afebrile	O
,	O
but	O
complained	O
of	O
nausea	B
and	O
headache	B
,	O
and	O
disorientation	B
,	O
without	O
meningeal	B
signs	I
.	O

Because	O
a	O
brain	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
showed	O
no	O
abnormality	O
,	O
we	O
initially	O
suspected	O
some	O
kind	O
of	O
drug	O
interaction	O
.	O

Despite	O
the	O
discontinuation	O
of	O
all	O
drugs	O
,	O
however	O
,	O
she	O
still	O
suffered	O
from	O
disturbance	O
of	O
consciousness	O
.	O

A	O
lumbar	O
puncture	O
revealed	O
yeast	O
cells	O
stained	O
by	O
India	O
ink	O
.	O

A	O
diagnosis	O
of	O
cryptococcal	B
meningitis	I
was	O
confirmed	O
.	O

Though	O
fluconazole	O
and	O
meropenem	O
were	O
administered	O
,	O
the	O
patient	O
died	O
.	O

Autopsy	O
findings	O
revealed	O
disseminated	B
cryptococcosis	I
concomitant	O
with	O
pulmonary	B
aspergillosis	I
.	O

Micafungin	O
is	O
a	O
recently	O
approved	O
echinocandin	O
-	O
class	O
antifungal	O
agent	O
that	O
is	O
now	O
widely	O
used	O
in	O
Japan	O
because	O
of	O
its	O
minimal	O
toxicity	O
and	O
broadspectrum	O
activity	O
.	O

However	O
,	O
such	O
echinocandins	O
have	O
limited	O
activity	O
against	O
a	O
number	O
of	O
fungi	O
.	O

Indeed	O
,	O
breakthrough	O
trichosporonosis	O
is	O
becoming	O
a	O
significant	O
problem	O
in	O
patients	O
with	O
hematological	B
malignancies	I
who	O
are	O
receiving	O
echinocandins	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
breakthrough	O
cryptococcosis	B
,	O
as	O
seen	O
in	O
our	O
patient	O
,	O
has	O
not	O
been	O
reported	O
previously	O
in	O
patients	O
who	O
were	O
receiving	O
micafungin	O
as	O
an	O
empiric	O
antifungal	O
therapy	O
.	O

This	O
case	O
highlights	O
that	O
cryptococcosis	B
should	O
be	O
kept	O
in	O
mind	O
as	O
a	O
possible	O
breakthrough	O
infection	B
during	O
the	O
administration	O
of	O
echinocandins	O
,	O
especially	O
in	O
patients	O
with	O
cellular	B
immunodeficiency	I
.	O

Multicenter	O
clinical	O
study	O
on	O
the	O
efficacy	O
and	O
safety	O
of	O
inhalable	O
insulin	O
aerosol	O
in	O
the	O
treatment	O
of	O
type	B
2	I
diabetes	I
.	O

BACKGROUND	O
:	O
A	O
new	O
inhalable	O
insulin	O
aerosol	O
(	O
Inh	O
-	O
Ins	O
)	O
was	O
developed	O
in	O
China	O
.	O

The	O
aim	O
of	O
this	O
multicenter	O
clinical	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
this	O
new	O
Inh	O
-	O
Ins	O
as	O
a	O
treatment	O
of	O
type	B
2	I
diabetes	I
.	O

Regular	O
porcine	O
insulin	O
(	O
RI	O
)	O
was	O
used	O
as	O
a	O
control	O
.	O

METHODS	O
:	O
This	O
study	O
is	O
a	O
prospective	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
multicenter	O
clinical	O
trial	O
in	O
which	O
253	O
qualified	O
patients	O
with	O
type	B
2	I
diabetes	I
received	O
the	O
insulin	O
Glargine	O
daily	O
at	O
bedtime	O
plus	O
either	O
a	O
pre	O
-	O
meal	O
Inh	O
-	O
Ins	O
or	O
a	O
pre	O
-	O
meal	O
subcutaneous	O
RI	O
for	O
12	O
weeks	O
.	O

HbA1c	O
,	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
,	O
the	O
1	O
-	O
hour	O
-	O
postprandial	O
blood	O
glucose	O
(	O
1hPBG	O
)	O
and	O
the	O
2	O
-	O
hour	O
-	O
postprandial	O
blood	O
glucose	O
(	O
2hPBG	O
)	O
were	O
measured	O
.	O

Events	O
were	O
monitored	O
for	O
adverse	O
effects	O
.	O

RESULTS	O
:	O
After	O
12	O
weeks	O
,	O
the	O
HbA1c	O
decreased	O
significantly	O
from	O
baseline	O
in	O
both	O
treatment	O
groups	O
,	O
with	O
no	O
significant	O
difference	O
between	O
the	O
two	O
regimens	O
.	O

In	O
the	O
Inh	O
-	O
Ins	O
group	O
,	O
FPG	O
,	O
both	O
1hPBG	O
and	O
2hPBG	O
significantly	O
declined	O
from	O
baseline	O
after	O
the	O
8th	O
-	O
and	O
12th	O
-	O
weeks	O
of	O
treatment	O
.	O

The	O
reduced	O
values	O
of	O
FPG	O
or	O
1hPBG	O
between	O
the	O
two	O
groups	O
showed	O
a	O
more	O
significant	O
hypoglycemic	O
effect	O
with	O
the	O
Inh	O
-	O
Ins	O
than	O
the	O
RI	O
.	O

After	O
12	O
weeks	O
,	O
the	O
pulmonary	O
carbon	O
monoxide	O
diffusing	O
capacity	O
(	O
DLco	O
)	O
was	O
significantly	O
lower	O
in	O
Inh	O
-	O
Ins	O
group	O
than	O
in	O
the	O
RI	O
.	O

The	O
main	O
side	O
effects	O
of	O
Inh	O
-	O
Ins	O
were	O
coughing	B
,	O
excessive	B
sputum	I
,	O
and	O
hypoglycemia	B
.	O

CONCLUSIONS	O
:	O
Inh	O
-	O
Ins	O
was	O
effective	O
in	O
decreasing	O
HbA1c	O
like	O
the	O
RI	O
.	O

It	O
was	O
better	O
in	O
lowering	O
the	O
FPG	O
and	O
the	O
1hPBG	O
than	O
the	O
RI	O
.	O

Its	O
main	O
side	O
effects	O
were	O
coughing	B
,	O
excessive	B
sputum	I
,	O
and	O
hypoglycemia	B
.	O

Also	O
,	O
Inh	O
-	O
Ins	O
slightly	O
impaired	O
DLco	O
.	O

Choosing	O
a	O
skeletal	O
muscle	O
relaxant	O
.	O

Skeletal	O
muscle	O
relaxants	O
are	O
widely	O
used	O
in	O
treating	O
musculoskeletal	O
conditions	O
.	O

However	O
,	O
evidence	O
of	O
their	O
effectiveness	O
consists	O
mainly	O
of	O
studies	O
with	O
poor	O
methodologic	O
design	O
.	O

In	O
addition	O
,	O
these	O
drugs	O
have	O
not	O
been	O
proven	O
to	O
be	O
superior	O
to	O
acetaminophen	O
or	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
for	O
low	B
back	I
pain	I
.	O

Systematic	O
reviews	O
and	O
meta	O
-	O
analyses	O
support	O
using	O
skeletal	O
muscle	O
relaxants	O
for	O
short	O
-	O
term	O
relief	O
of	O
acute	B
low	I
back	I
pain	I
when	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
or	O
acetaminophen	O
are	O
not	O
effective	O
or	O
tolerated	O
.	O

Comparison	O
studies	O
have	O
not	O
shown	O
one	O
skeletal	O
muscle	O
relaxant	O
to	O
be	O
superior	O
to	O
another	O
.	O

Cyclobenzaprine	O
is	O
the	O
most	O
heavily	O
studied	O
and	O
has	O
been	O
shown	O
to	O
be	O
effective	O
for	O
various	O
musculoskeletal	O
conditions	O
.	O

The	O
sedative	O
properties	O
of	O
tizanidine	O
and	O
cyclobenzaprine	O
may	O
benefit	O
patients	O
with	O
insomnia	B
caused	O
by	O
severe	O
muscle	B
spasms	I
.	O

Methocarbamol	O
and	O
metaxalone	O
are	O
less	O
sedating	O
,	O
although	O
effectiveness	O
evidence	O
is	O
limited	O
.	O

Adverse	O
effects	O
,	O
particularly	O
dizziness	B
and	O
drowsiness	B
,	O
are	O
consistently	O
reported	O
with	O
all	O
skeletal	O
muscle	O
relaxants	O
.	O

The	O
potential	O
adverse	O
effects	O
should	O
be	O
communicated	O
clearly	O
to	O
the	O
patient	O
.	O

Because	O
of	O
limited	O
comparable	O
effectiveness	O
data	O
,	O
choice	O
of	O
agent	O
should	O
be	O
based	O
on	O
side	O
-	O
effect	O
profile	O
,	O
patient	O
preference	O
,	O
abuse	B
potential	O
,	O
and	O
possible	O
drug	O
interactions	O
.	O

Two	O
rare	O
cases	O
of	O
methotrexate	O
-	O
induced	O
pneumonitis	B
and	O
pleurisy	B
in	O
patients	O
with	O
gestational	B
trophoblastic	I
neoplasms	I
.	O

BACKGROUND	O
:	O
Pneumonitis	B
is	O
a	O
serious	O
and	O
unpredictable	O
side	O
-	O
effect	O
of	O
treatment	O
with	O
methotrexate	O
(	O
MTX	O
)	O
that	O
may	O
result	O
in	O
a	O
life	O
-	O
threatening	O
outcome	O
.	O

Pulmonary	B
toxicity	I
of	O
methotrexate	O
in	O
patients	O
with	O
a	O
gestational	B
trophoblastic	I
neoplasm	I
(	O
GTN	B
)	O
has	O
rarely	O
been	O
reported	O
before	O
.	O

CASE	O
REPORTS	O
:	O
For	O
the	O
first	O
time	O
two	O
cases	O
of	O
methotrexate	O
-	O
induced	O
pneumonitis	B
and	O
pleurisy	B
in	O
GTN	B
patients	O
of	O
Chinese	O
ethnicity	O
are	O
presented	O
.	O

Two	O
patients	O
were	O
both	O
categorized	O
as	O
the	O
low	O
-	O
risk	O
group	O
,	O
and	O
underwent	O
a	O
single	O
regimen	O
therapy	O
of	O
methotrexate	O
.	O

Their	O
symptoms	O
,	O
such	O
as	O
fever	B
,	O
chest	B
pain	I
,	O
acute	B
nonproductive	I
cough	I
,	O
dyspnea	B
and	O
hypoxemia	B
did	O
not	O
respond	O
to	O
antibiotics	O
immediately	O
.	O

Treatment	O
with	O
corticosteroids	O
may	O
be	O
helpful	O
.	O

CONCLUSION	O
:	O
Awareness	O
of	O
pneumonitis	B
and	O
pleurisy	B
,	O
potentially	O
life	O
-	O
threatening	O
complications	O
of	O
MTX	O
,	O
is	O
very	O
necessary	O
and	O
important	O
to	O
early	O
recognition	O
and	O
treatment	O
.	O

Reduced	O
weight	O
gain	O
with	O
insulin	O
detemir	O
compared	O
to	O
NPH	O
insulin	O
is	O
not	O
explained	O
by	O
a	O
reduction	O
in	O
hypoglycemia	B
.	O

BACKGROUND	O
:	O
Weight	O
gain	O
often	O
occurs	O
when	O
insulin	O
therapy	O
is	O
initiated	O
.	O

The	O
long	O
-	O
acting	O
insulin	O
analog	O
insulin	O
detemir	O
has	O
been	O
shown	O
to	O
be	O
effective	O
and	O
well	O
tolerated	O
when	O
used	O
in	O
basal	O
-	O
bolus	O
regimens	O
or	O
as	O
an	O
add	O
-	O
on	O
to	O
oral	O
antidiabetic	O
drugs	O
(	O
OADs	O
)	O
and	O
causes	O
less	O
weight	O
gain	O
than	O
other	O
insulins	O
.	O

The	O
aim	O
of	O
this	O
exploratory	O
analysis	O
was	O
to	O
investigate	O
any	O
correlations	O
between	O
weight	O
change	O
and	O
occurrence	O
of	O
hypoglycemia	B
with	O
NPH	O
insulin	O
and	O
insulin	O
detemir	O
.	O

METHODS	O
:	O
The	O
analysis	O
was	O
based	O
on	O
a	O
26	O
-	O
week	O
,	O
randomized	O
,	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
trial	O
in	O
which	O
glycemic	O
control	O
,	O
hypoglycemia	B
,	O
and	O
weight	O
change	O
were	O
compared	O
between	O
insulin	O
detemir	O
and	O
NPH	O
insulin	O
.	O

A	O
total	O
of	O
476	O
insulin	O
-	O
naive	O
patients	O
with	O
type	B
2	I
diabetes	I
treated	O
with	O
one	O
or	O
two	O
OADs	O
added	O
insulin	O
detemir	O
(	O
n	O
=	O
237	O
)	O
or	O
NPH	O
insulin	O
(	O
n	O
=	O
239	O
)	O
morning	O
and	O
evening	O
to	O
their	O
current	O
oral	O
treatment	O
.	O

Weight	O
gain	O
data	O
from	O
this	O
study	O
were	O
analyzed	O
as	O
a	O
function	O
of	O
hypoglycemia	B
frequency	O
.	O

RESULTS	O
:	O
Both	O
groups	O
achieved	O
excellent	O
glycosylated	O
hemoglobin	O
control	O
(	O
insulin	O
detemir	O
,	O
6.6	O
%	O
;	O
NPH	O
insulin	O
,	O
6.5	O
%	O
[	O
difference	O
not	O
significant	O
]	O
)	O
.	O

Weight	O
gain	O
with	O
insulin	O
detemir	O
was	O
less	O
than	O
half	O
that	O
of	O
NPH	O
insulin	O
(	O
1.2	O
vs.	O
2.8	O
kg	O
,	O
respectively	O
[	O
P	O
<	O
0.001	O
]	O
)	O
,	O
and	O
the	O
overall	O
risk	O
of	O
hypoglycemia	B
was	O
47	O
%	O
lower	O
with	O
insulin	O
detemir	O
(	O
P	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
relationship	O
between	O
hypoglycemia	B
and	O
weight	O
gain	O
was	O
seen	O
with	O
insulin	O
detemir	O
(	O
P	O
=	O
0.2	O
)	O
,	O
while	O
a	O
statistically	O
significant	O
correlation	O
was	O
found	O
for	O
NPH	O
insulin	O
(	O
P	O
=	O
0.003	O
)	O
.	O

CONCLUSIONS	O
:	O
Hypoglycemia	B
is	O
predictive	O
of	O
weight	O
gain	O
with	O
NPH	O
insulin	O
,	O
but	O
the	O
same	O
relationship	O
is	O
not	O
seen	O
with	O
insulin	O
detemir	O
.	O

It	O
is	O
therefore	O
likely	O
that	O
the	O
weight	O
-	O
sparing	O
effect	O
of	O
insulin	O
detemir	O
involves	O
other	O
mechanisms	O
.	O

Lung	B
fibrosis	I
10	O
years	O
after	O
cessation	O
of	O
bleomycin	O
therapy	O
.	O

Bleomycin	O
(	O
BLM	O
)	O
is	O
a	O
chemotherapeutic	O
agent	O
used	O
for	O
the	O
treatment	O
of	O
several	O
types	O
of	O
malignancy	O
,	O
including	O
germ	B
cell	I
tumors	I
,	O
lymphoma	B
,	O
and	O
certain	O
types	O
of	O
squamous	B
-	I
cell	I
carcinoma	I
.	O

The	O
common	O
adverse	O
effect	O
of	O
BLM	O
is	O
interstitial	B
pneumonitis	I
,	O
followed	O
by	O
pulmonary	B
fibrosis	I
.	O

BLM	O
-	O
induced	O
pneumonitis	B
occurs	O
in	O
up	O
to	O
46	O
%	O
of	O
patients	O
treated	O
with	O
BLM	O
-	O
containing	O
chemotherapy	O
and	O
lung	B
toxicity	I
usually	O
appears	O
during	O
treatment	O
.	O

Here	O
we	O
describe	O
a	O
patient	O
with	O
lung	B
fibrosis	I
,	O
who	O
presented	O
with	O
slow	O
progressive	B
breathlessness	I
and	O
pneumothorax	B
more	O
than	O
10	O
years	O
after	O
cessation	O
of	O
BLM	O
therapy	O
.	O

A	O
15	O
year	O
-	O
old	O
girl	O
presented	O
with	O
abnormal	O
shadows	O
on	O
chest	O
X	O
-	O
ray	O
.	O

The	O
patient	O
had	O
a	O
yolk	B
sac	I
carcinoma	I
in	O
the	O
sacral	O
region	O
at	O
1	O
year	O
of	O
age	O
and	O
obtained	O
complete	O
remission	O
after	O
being	O
treated	O
with	O
tumor	B
resection	O
,	O
radiation	O
,	O
and	O
several	O
anti	O
-	O
cancer	O
drugs	O
including	O
BLM	O
.	O

There	O
were	O
no	O
abnormal	O
findings	O
in	O
chest	O
X	O
-	O
ray	O
until	O
she	O
reached	O
3	O
years	O
of	O
age	O
,	O
when	O
she	O
had	O
developed	O
respiratory	B
distress	I
that	O
worsened	O
with	O
age	O
.	O

The	O
patient	O
had	O
experienced	O
an	O
episode	O
of	O
pneumothorax	B
at	O
13	O
years	O
of	O
age	O
.	O

Chest	O
CT	O
at	O
the	O
time	O
revealed	O
interstitial	O
reticular	O
opacities	O
.	O

Radiological	O
findings	O
and	O
pathological	O
examination	O
of	O
the	O
lung	O
tissue	O
obtained	O
during	O
bullectomy	O
with	O
video	O
-	O
assisted	O
thoracic	O
surgery	O
were	O
compatible	O
with	O
BLM	O
-	O
induced	O
pneumonitis	B
.	O

The	O
present	O
study	O
suggests	O
that	O
lung	B
fibrosis	I
may	O
surface	O
more	O
than	O
10	O
years	O
after	O
cessation	O
of	O
BLM	O
therapy	O
at	O
the	O
age	O
of	O
1	O
year	O
,	O
with	O
no	O
chest	O
radiographic	O
findings	O
1	O
year	O
after	O
completion	O
of	O
chemotherapy	O
.	O

The	O
use	O
of	O
BLM	O
in	O
infants	O
requires	O
strict	O
supervision	O
and	O
observation	O
and	O
careful	O
long	O
-	O
term	O
follow	O
up	O
.	O

Riluzole	O
in	O
psychiatry	O
:	O
a	O
systematic	O
review	O
of	O
the	O
literature	O
.	O

BACKGROUND	O
:	O
The	O
glutamate	O
system	O
seems	O
to	O
be	O
an	O
important	O
contributor	O
to	O
the	O
pathophysiology	O
of	O
mood	O
and	O
anxiety	B
disorders	I
.	O

Thus	O
,	O
glutamatergic	O
modulators	O
are	O
reasonable	O
candidate	O
drugs	O
to	O
test	O
in	O
patients	O
with	O
mood	O
and	O
anxiety	B
disorders	I
.	O

Riluzole	O
,	O
a	O
neuroprotective	O
agent	O
with	O
anticonvulsant	O
properties	O
approved	O
for	O
the	O
treatment	O
of	O
amyotrophic	B
lateral	I
sclerosis	I
(	O
ALS	B
)	O
is	O
one	O
such	O
agent	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
the	O
potential	O
risks	O
and	O
benefits	O
of	O
riluzole	O
treatment	O
in	O
psychiatric	O
patients	O
.	O

METHODS	O
:	O
A	O
PubMed	O
search	O
was	O
performed	O
using	O
the	O
keywords	O
'	O
riluzole	O
'	O
,	O
'	O
inhibitor	O
of	O
glutamate	O
release	O
'	O
and	O
'	O
glutamatergic	O
modulator	O
'	O
to	O
identify	O
all	O
clinical	O
studies	O
and	O
case	O
reports	O
involving	O
riluzole	O
in	O
psychiatric	O
patients	O
.	O

RESULTS	O
/	O
CONCLUSION	O
:	O
Riluzole	O
's	O
side	O
effect	O
profile	O
is	O
favorable	O
and	O
preliminary	O
results	O
regarding	O
riluzole	O
for	O
the	O
treatment	O
of	O
severe	O
mood	O
,	O
anxiety	B
and	O
impulsive	B
disorders	I
are	O
encouraging	O
.	O

Estimates	O
of	O
cancer	B
potency	O
of	O
2,3,4,7,8	O
-	O
pentachlorodibenzofuran	O
using	O
both	O
nonlinear	O
and	O
linear	O
approaches	O
.	O

Cancer	B
potency	O
estimates	O
were	O
derived	O
for	O
2,3,4,7,8	O
-	O
pentachlorodibenzofuran	O
(	O
4	O
-	O
PeCDF	O
)	O
using	O
data	O
collected	O
from	O
the	O
recently	O
published	O
National	O
Toxicology	O
Program	O
bioassay	O
in	O
female	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

By	O
using	O
a	O
toxicokinetic	O
model	O
for	O
4	O
-	O
PeCDF	O
,	O
the	O
dose	O
-	O
response	O
relationship	O
for	O
combined	O
liver	B
tumors	I
(	O
hepatocellular	B
adenomas	I
and	O
cholangiocarcinomas	B
)	O
in	O
rats	O
was	O
assessed	O
in	O
terms	O
of	O
lifetime	O
average	O
liver	O
concentration	O
and	O
lifetime	O
average	O
adipose	O
concentration	O
with	O
data	O
from	O
both	O
the	O
lifetime	O
and	O
the	O
stop	O
-	O
exposure	O
components	O
of	O
the	O
bioassay	O
.	O

Benchmark	O
dose	O
modeling	O
was	O
performed	O
to	O
estimate	O
tissue	O
concentrations	O
at	O
two	O
points	O
of	O
departure	O
(	O
EC	O
(	O
10	O
)	O
and	O
EC	O
(	O
01	O
)	O
and	O
their	O
95	O
%	O
upper	O
and	O
lower	O
confidence	O
limits	O
)	O
.	O

The	O
same	O
toxicokinetic	O
model	O
with	O
human	O
input	O
values	O
was	O
then	O
used	O
to	O
back	O
-	O
extrapolate	O
human	O
equivalent	O
doses	O
that	O
corresponded	O
to	O
the	O
internal	O
tissue	O
concentration	O
measures	O
at	O
the	O
points	O
of	O
departure	O
.	O

Information	O
regarding	O
the	O
cancer	B
mode	O
of	O
action	O
was	O
used	O
to	O
support	O
the	O
development	O
of	O
several	O
toxicity	O
criterion	O
values	O
based	O
on	O
a	O
nonlinear	O
method	O
,	O
e.g.	O
,	O
reference	O
dose	O
or	O
tolerable	O
daily	O
intake	O
.	O

Nonlinear	O
estimates	O
of	O
toxicity	O
criteria	O
based	O
on	O
observed	O
noncancer	O
toxic	O
events	O
as	O
possible	O
precursors	O
to	O
tumor	B
formation	O
were	O
also	O
derived	O
and	O
were	O
similar	O
in	O
value	O
to	O
those	O
based	O
on	O
combined	O
liver	B
tumors	I
.	O

For	O
comparison	O
purposes	O
,	O
linear	O
estimates	O
of	O
cancer	B
potency	O
were	O
also	O
derived	O
.	O

Phase	O
II	O
preradiation	O
R115777	O
(	O
tipifarnib	O
)	O
in	O
newly	O
diagnosed	O
GBM	O
with	O
residual	O
enhancing	O
disease	O
.	O

Glioblastoma	B
multiforme	I
(	O
GBM	B
)	O
is	O
a	O
lethal	O
primary	O
malignant	B
brain	I
tumor	I
in	O
adults	O
.	O

R115777	O
(	O
tipifarnib	O
)	O
is	O
an	O
oral	O
agent	O
with	O
antiproliferative	O
effects	O
,	O
being	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
farnesyltransferase	O
.	O

This	O
multicenter	O
,	O
open	O
-	O
label	O
phase	O
II	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
R115777	O
given	O
after	O
surgery	O
and	O
prior	O
to	O
radiation	O
in	O
patients	O
with	O
newly	O
diagnosed	O
and	O
residual	O
enhancing	O
GBM	B
.	O

Following	O
surgery	O
,	O
an	O
MRI	O
confirmed	O
the	O
presence	O
of	O
residual	O
enhancing	O
tumor	O
.	O

Patients	O
on	O
enzyme	O
-	O
inducing	O
antiseizure	O
drugs	O
(	O
EIASDs	O
)	O
received	O
600	O
mg	O
twice	O
per	O
day	O
,	O
and	O
those	O
not	O
on	O
EIASDs	O
received	O
300	O
mg	O
twice	O
per	O
day	O
.	O

One	O
to	O
three	O
monthly	O
cycles	O
of	O
R115777	O
were	O
administered	O
,	O
and	O
radiation	O
was	O
initiated	O
with	O
progression	O
or	O
after	O
three	O
cycles	O
.	O

A	O
cycle	O
consisted	O
of	O
3	O
weeks	O
of	O
continuous	O
R115777	O
followed	O
by	O
a	O
1	O
-	O
week	O
rest	O
.	O

MRI	O
was	O
done	O
monthly	O
.	O

The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
;	O
secondary	O
end	O
points	O
were	O
tumor	B
response	O
rate	O
and	O
toxicity	O
.	O

A	O
total	O
of	O
28	O
confirmed	O
GBM	O
patients	O
entered	O
the	O
study	O
;	O
15	O
patients	O
(	O
54	O
%	O
)	O
were	O
on	O
EIASDs	O
.	O

The	O
overall	O
median	O
time	O
of	O
survival	O
was	O
7.7	O
months	O
.	O

There	O
were	O
no	O
tumor	B
responses	O
.	O

Eight	O
patients	O
(	O
29	O
%	O
)	O
had	O
stable	O
disease	O
as	O
the	O
best	O
response	O
.	O

The	O
study	O
was	O
stopped	O
early	O
due	O
to	O
progression	O
of	O
the	O
disease	O
in	O
12	O
patients	O
(	O
48	O
%	O
)	O
.	O

A	O
total	O
of	O
24	O
patients	O
(	O
85	O
%	O
)	O
were	O
off	O
study	O
before	O
the	O
planned	O
treatment	O
schedule	O
for	O
radiation	O
therapy	O
.	O

R115777	O
administered	O
prior	O
to	O
radiation	O
therapy	O
in	O
patients	O
with	O
newly	O
diagnosed	O
GBM	B
and	O
residual	O
enhancing	O
disease	O
did	O
not	O
result	O
in	O
any	O
measurable	O
responses	O
or	O
improvement	O
in	O
survival	O
.	O

R115777	O
administered	O
prior	O
to	O
radiation	O
therapy	O
is	O
not	O
recommended	O
for	O
patients	O
with	O
newly	O
diagnosed	O
GBM	B
.	O

Effect	O
of	O
calpain	O
and	O
proteasome	O
inhibition	O
on	O
Ca2	O
+	O
-	O
dependent	O
proteolysis	O
and	O
muscle	O
histopathology	O
in	O
the	O
mdx	O
mouse	O
.	O

Dystrophin	O
deficiency	O
is	O
the	O
underlying	O
molecular	O
cause	O
of	O
progressive	B
muscle	I
weakness	I
observed	O
in	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
.	O

Loss	O
of	O
functional	O
dystrophin	O
leads	O
to	O
elevated	O
levels	O
of	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
,	O
a	O
key	O
step	O
in	O
the	O
cellular	O
pathology	O
of	O
DMD	B
.	O

The	O
cysteine	O
protease	O
calpain	O
is	O
activated	O
in	O
dystrophin	O
-	O
deficient	O
muscle	O
,	O
and	O
its	O
inhibition	O
is	O
regarded	O
as	O
a	O
potential	O
therapeutic	O
approach	O
.	O

In	O
addition	O
,	O
previous	O
work	O
has	O
shown	O
that	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
also	O
contributes	O
to	O
muscle	O
protein	O
breakdown	O
in	O
dystrophic	O
muscle	O
and	O
,	O
therefore	O
,	O
also	O
qualifies	O
as	O
a	O
potential	O
target	O
for	O
therapeutic	O
intervention	O
in	O
DMD	B
.	O

The	O
relative	O
contribution	O
of	O
calpain	O
-	O
and	O
proteasome	O
-	O
mediated	O
proteolysis	O
induced	O
by	O
increased	O
Ca	O
(	O
2	O
+	O
)	O
levels	O
was	O
characterized	O
in	O
cultured	O
muscle	O
cells	O
and	O
revealed	O
initial	O
Ca	O
(	O
2	O
+	O
)	O
influx	O
-	O
dependent	O
calpain	O
activity	O
and	O
subsequent	O
Ca	O
(	O
2	O
+	O
)	O
-	O
independent	O
activity	O
of	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
.	O

We	O
then	O
set	O
out	O
to	O
optimize	O
novel	O
small	O
-	O
molecule	O
inhibitors	O
that	O
inhibit	O
both	O
calpain	O
as	O
well	O
as	O
the	O
20S	O
proteasome	O
in	O
a	O
cellular	O
system	O
with	O
impaired	O
Ca	O
(	O
2	O
+	O
)	O
homeostasis	O
.	O

On	O
administration	O
of	O
such	O
inhibitors	O
to	O
mdx	O
mice	O
,	O
quantitative	O
histological	O
parameters	O
improved	O
significantly	O
,	O
in	O
particular	O
with	O
compounds	O
strongly	O
inhibiting	O
the	O
20S	O
proteasome	O
.	O

To	O
investigate	O
the	O
role	O
of	O
calpain	O
inhibition	O
without	O
interfering	O
with	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
,	O
we	O
crossed	O
mdx	O
mice	O
with	O
transgenic	O
mice	O
,	O
overexpressing	O
the	O
endogenous	O
calpain	O
inhibitor	O
calpastatin	O
.	O

Although	O
our	O
data	O
show	O
that	O
proteolysis	O
by	O
calpain	O
is	O
strongly	O
inhibited	O
in	O
the	O
transgenic	O
mdx	O
mouse	O
,	O
this	O
calpain	O
inhibition	O
did	O
not	O
ameliorate	O
muscle	O
histology	O
.	O

Our	O
results	O
indicate	O
that	O
inhibition	O
of	O
the	O
proteasome	O
rather	O
than	O
calpain	O
is	O
required	O
for	O
histological	O
improvement	O
of	O
dystrophin	O
-	O
deficient	O
muscle	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
novel	O
proteasome	O
inhibitors	O
that	O
qualify	O
as	O
potential	O
candidates	O
for	O
pharmacological	O
intervention	O
in	O
muscular	B
dystrophy	I
.	O

Effects	O
of	O
in	O
vitro	O
brevetoxin	O
exposure	O
on	O
apoptosis	O
and	O
cellular	O
metabolism	O
in	O
a	O
leukemic	O
T	O
cell	O
line	O
(	O
Jurkat	O
)	O
.	O

Harmful	O
algal	O
blooms	O
(	O
HABs	O
)	O
of	O
the	O
toxic	O
dinoflagellate	O
,	O
Karenia	O
brevis	O
,	O
produce	O
red	O
tide	O
toxins	O
,	O
or	O
brevetoxins	O
.	O

Significant	O
health	O
effects	O
associated	O
with	O
red	O
tide	O
toxin	O
exposure	O
have	O
been	O
reported	O
in	O
sea	O
life	O
and	O
in	O
humans	O
,	O
with	O
brevetoxins	O
documented	O
within	O
immune	O
cells	O
from	O
many	O
species	O
.	O

The	O
objective	O
of	O
this	O
research	O
was	O
to	O
investigate	O
potential	O
immunotoxic	O
effects	O
of	O
brevetoxins	O
using	O
a	O
leukemic	O
T	O
cell	O
line	O
(	O
Jurkat	O
)	O
as	O
an	O
in	O
vitro	O
model	O
system	O
.	O

Viability	O
,	O
cell	O
proliferation	O
,	O
and	O
apoptosis	O
assays	O
were	O
conducted	O
using	O
brevetoxin	O
congeners	O
PbTx	O
-	O
2	O
,	O
PbTx	O
-	O
3	O
,	O
and	O
PbTx	O
-	O
6	O
.	O

The	O
effects	O
of	O
in	O
vitro	O
brevetoxin	O
exposure	O
on	O
cell	O
viability	O
and	O
cellular	O
metabolism	O
or	O
proliferation	O
were	O
determined	O
using	O
trypan	O
blue	O
and	O
MTT	O
(	O
1	O
-	O
(	O
4,5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
3,5	O
-	O
diphenylformazan	O
)	O
,	O
respectively	O
.	O

Using	O
MTT	O
,	O
cellular	O
metabolic	O
activity	O
was	O
decreased	O
in	O
Jurkat	O
cells	O
exposed	O
to	O
5	O
-	O
10	O
microg	O
/	O
ml	O
PbTx	O
-	O
2	O
or	O
PbTx	O
-	O
6	O
.	O

After	O
3	O
h	O
,	O
no	O
significant	O
effects	O
on	O
cell	O
viability	O
were	O
observed	O
with	O
any	O
toxin	O
congener	O
in	O
concentrations	O
up	O
to	O
10	O
microg	O
/	O
ml	O
.	O

Viability	O
decreased	O
dramatically	O
after	O
24	O
h	O
in	O
cells	O
treated	O
with	O
PbTx	O
-	O
2	O
or	O
-	O
6	O
.	O

Apoptosis	O
,	O
as	O
measured	O
by	O
caspase	O
-	O
3	O
activity	O
,	O
was	O
significantly	O
increased	O
in	O
cells	O
exposed	O
to	O
PbTx	O
-	O
2	O
or	O
PbTx	O
-	O
6	O
.	O

In	O
summary	O
,	O
brevetoxin	O
congeners	O
varied	O
in	O
effects	O
on	O
Jurkat	O
cells	O
,	O
with	O
PbTx	O
-	O
2	O
and	O
PbTx	O
-	O
6	O
eliciting	O
greater	O
cellular	O
effects	O
compared	O
to	O
PbTx	O
-	O
3	O
.	O

Influence	O
of	O
valproic	O
acid	O
on	O
outcome	O
of	O
high	O
-	O
grade	O
gliomas	O
in	O
children	O
.	O

BACKGROUND	O
:	O
Chemotherapy	O
has	O
limited	O
effects	O
in	O
the	O
treatment	O
of	O
high	O
-	O
grade	O
gliomas	B
(	O
HGGs	B
)	O
.	O

Valproic	O
acid	O
(	O
VPA	O
)	O
,	O
a	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
,	O
may	O
sensitize	O
HGGs	O
to	O
radiochemotherapy	O
.	O

As	O
the	O
drug	O
has	O
been	O
given	O
frequently	O
as	O
an	O
antiepileptic	O
drug	O
,	O
a	O
retrospective	O
analysis	O
was	O
conducted	O
to	O
ensure	O
relevant	O
information	O
was	O
not	O
missed	O
before	O
a	O
prospective	O
study	O
was	O
launched	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
An	O
analysis	O
of	O
66	O
pediatric	O
patients	O
(	O
range	O
,	O
1	O
-	O
19	O
years	O
of	O
age	O
)	O
with	O
glioblastoma	B
multiforme	I
(	O
GBM	B
)	O
(	O
n	O
=	O
40	O
)	O
or	O
anaplastic	B
astrocytoma	I
(	O
AA	B
)	O
(	O
n	O
=	O
26	O
)	O
was	O
retrospectively	O
conducted	O
for	O
predictors	O
of	O
survival	O
and	O
response	O
and	O
for	O
effects	O
of	O
VPA	O
on	O
outcome	O
or	O
toxicity	O
.	O

RESULTS	O
:	O
The	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
better	O
for	O
AA	B
(	O
p	O
=	O
0.0114	O
)	O
and	O
complete	O
resection	O
(	O
p	O
<	O
0.00005	O
)	O
and	O
event	O
-	O
free	O
survival	O
(	O
EFS	O
)	O
was	O
better	O
for	O
complete	O
resection	O
(	O
p	O
=	O
0.0049	O
)	O
.	O

Nine	O
patients	O
received	O
VPA	O
(	O
for	O
seizure	B
)	O
plus	O
further	O
oncological	O
treatment	O
.	O

The	O
most	O
severe	O
adverse	O
effect	O
was	O
a	O
pulmonary	B
embolism	I
(	O
n	O
=	O
1	O
)	O
;	O
no	O
other	O
severe	O
side	O
-	O
effects	O
were	O
noted	O
.	O

The	O
response	O
to	O
nonsurgical	O
treatment	O
after	O
8	O
weeks	O
was	O
:	O
complete	O
response	O
(	O
CR	O
)	O
:	O
0	O
,	O
partial	O
response	O
(	O
PR	O
)	O
:	O
3	O
,	O
stable	O
disease	O
(	O
SD	O
)	O
:	O
4	O
,	O
progressive	O
disease	O
(	O
PD	O
)	O
:	O
2	O
.	O

Some	O
of	O
the	O
patients	O
with	O
SD	O
responded	O
later	O
resulting	O
in	O
best	O
response	O
:	O
CR	O
:	O
0	O
,	O
PR	O
:	O
5	O
,	O
SD	O
:	O
2	O
,	O
PD	O
:	O
2	O
.	O

CONCLUSION	O
:	O
Treatment	O
with	O
VPA	O
plus	O
radiochemotherapy	O
is	O
well	O
tolerated	O
with	O
an	O
encouraging	O
response	O
rate	O
.	O

Tacrolimus	O
for	O
the	O
treatment	O
of	O
systemic	B
lupus	I
erythematosus	I
with	O
pure	O
class	O
V	O
nephritis	B
.	O

OBJECTIVES	O
:	O
The	O
treatment	O
of	O
pure	O
membranous	O
(	O
class	O
V	O
)	O
lupus	B
nephropathy	I
remains	O
unsatisfactory	O
.	O

We	O
studied	O
the	O
efficacy	O
and	O
safety	O
of	O
tacrolimus	O
in	O
the	O
treatment	O
of	O
membranous	B
nephritis	I
secondary	O
to	O
SLE	B
.	O

METHODS	O
:	O
We	O
recruited	O
18	O
consecutive	O
SLE	B
patients	O
(	O
tacrolimus	O
group	O
)	O
with	O
recently	O
confirmed	O
biopsy	O
-	O
proven	O
class	O
V	O
lupus	B
nephritis	I
.	O

They	O
were	O
treated	O
with	O
a	O
tailing	O
dose	O
of	O
oral	O
prednisolone	O
and	O
tacrolimus	O
0.1	O
-	O
0.2	O
mg	O
/	O
kg	O
/	O
day	O
for	O
6	O
months	O
,	O
followed	O
by	O
maintenance	O
prednisolone	O
and	O
AZA	O
.	O

The	O
rate	O
of	O
resolution	O
of	O
proteinuria	B
and	O
SLEDAI	O
were	O
compared	O
with	O
19	O
historical	O
controls	O
treated	O
with	O
oral	O
cyclophosphamide	O
or	O
AZA	O
(	O
control	O
group	O
)	O
.	O

All	O
patients	O
were	O
followed	O
for	O
12	O
months	O
.	O

RESULTS	O
:	O
Baseline	O
clinical	O
characteristics	O
were	O
comparable	O
between	O
the	O
groups	O
.	O

For	O
the	O
tacrolimus	O
group	O
,	O
the	O
complete	O
and	O
partial	O
remission	O
rates	O
were	O
27.8	O
and	O
50.0	O
%	O
,	O
respectively	O
at	O
12	O
weeks	O
;	O
for	O
the	O
control	O
group	O
,	O
they	O
were	O
15.8	O
and	O
47.4	O
%	O
,	O
respectively	O
(	O
overall	O
chi	O
-	O
square	O
test	O
,	O
P	O
=	O
0.5	O
)	O
.	O

However	O
,	O
tacrolimus	O
group	O
had	O
faster	O
resolution	O
of	O
proteinuria	B
than	O
the	O
control	O
group	O
by	O
the	O
general	O
linear	O
model	O
with	O
repeated	O
measures	O
(	O
P	O
=	O
0.032	O
)	O
.	O

At	O
12	O
weeks	O
,	O
proteinuria	B
was	O
reduced	O
by	O
76.2	O
+	O
/	O
-	O
17.0	O
%	O
for	O
the	O
tacrolimus	O
group	O
and	O
47.1	O
+	O
/	O
-	O
51.1	O
%	O
for	O
the	O
control	O
group	O
(	O
P	O
=	O
0.028	O
)	O
.	O

Serial	O
change	O
in	O
renal	O
function	O
and	O
SLEDAI	O
score	O
did	O
not	O
differ	O
between	O
the	O
groups	O
.	O

During	O
the	O
study	O
period	O
,	O
four	O
patients	O
of	O
the	O
tacrolimus	O
group	O
,	O
and	O
11	O
of	O
the	O
control	O
group	O
,	O
developed	O
lupus	B
flare	I
(	O
P	O
=	O
0.027	O
)	O
.	O

There	O
was	O
no	O
serious	O
adverse	O
effect	O
in	O
the	O
tacrolimus	O
group	O
.	O

CONCLUSIONS	O
:	O
A	O
6	O
-	O
month	O
course	O
of	O
tacrolimus	O
is	O
a	O
safe	O
and	O
effective	O
treatment	O
of	O
pure	O
class	O
V	O
(	O
membranous	O
)	O
lupus	B
nephritis	I
.	O

As	O
compared	O
with	O
conventional	O
cytotoxic	O
treatment	O
,	O
tacrolimus	O
possibly	O
results	O
in	O
a	O
faster	O
resolution	O
of	O
proteinuria	B
,	O
and	O
a	O
lower	O
risk	O
of	O
lupus	B
flare	I
within	O
1	O
yr	O
.	O

The	O
long	O
-	O
term	O
effect	O
and	O
optimal	O
regimen	O
of	O
tacrolimus	O
require	O
further	O
study	O
.	O

7	O
-	O
Deaza	O
-	O
6	O
-	O
benzylthioinosine	O
analogues	O
as	O
subversive	O
substrate	O
of	O
Toxoplasma	O
gondii	O
adenosine	O
kinase	O
:	O
activities	O
and	O
selective	O
toxicities	O
.	O

Toxoplasma	O
gondii	O
adenosine	O
kinase	O
(	O
EC	O
.2	O
.7	O
.1	O
.20	O
)	O
is	O
the	O
major	O
route	O
of	O
adenosine	O
metabolism	O
in	O
this	O
parasite	O
.	O

The	O
enzyme	O
is	O
significantly	O
more	O
active	O
than	O
any	O
other	O
enzyme	O
of	O
the	O
purine	O
salvage	O
in	O
T	O
.	O

gondii	O
and	O
has	O
been	O
established	O
as	O
a	O
potential	O
chemotherapeutic	O
target	O
for	O
the	O
treatment	O
of	O
toxoplasmosis	B
.	O

Certain	O
6	O
-	O
benzylthioinosines	O
act	O
as	O
subversive	O
substrates	O
of	O
T	O
.	O

gondii	O
,	O
but	O
not	O
human	O
,	O
adenosine	O
kinase	O
.	O

Therefore	O
,	O
these	O
compounds	O
are	O
preferentially	O
metabolized	O
to	O
their	O
respective	O
nucleotides	O
and	O
become	O
selectively	O
toxic	O
against	O
the	O
parasites	O
but	O
not	O
their	O
host	O
.	O

Moreover	O
,	O
7	O
-	O
deazaadenosine	O
(	O
tubercidin	O
)	O
was	O
shown	O
to	O
be	O
an	O
excellent	O
ligand	O
of	O
T	O
.	O

gondii	O
adenosine	O
kinase	O
.	O

Therefore	O
,	O
we	O
synthesized	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosine	O
,	O
and	O
analogues	O
with	O
various	O
substitutions	O
at	O
their	O
phenyl	O
ring	O
,	O
to	O
increase	O
the	O
binding	O
affinity	O
of	O
the	O
6	O
-	O
benzylthioinosines	O
to	O
T	O
.	O

gondii	O
adenosine	O
kinase	O
.	O

Indeed	O
,	O
the	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosine	O
analogues	O
were	O
better	O
ligands	O
of	O
T	O
.	O

gondii	O
adenosine	O
kinase	O
than	O
the	O
parent	O
compounds	O
,	O
6	O
-	O
benzylthioinosine	O
and	O
7	O
-	O
deazainosine	O
.	O

Herein	O
,	O
we	O
report	O
the	O
testing	O
of	O
the	O
metabolism	O
of	O
these	O
newly	O
synthesized	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosines	O
,	O
as	O
well	O
as	O
their	O
efficacy	O
as	O
anti	O
-	O
toxoplasmic	O
agents	O
in	O
cell	O
culture	O
.	O

All	O
the	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosine	O
analogues	O
were	O
metabolized	O
to	O
their	O
5	O
'	O
-	O
monophosphate	O
derivatives	O
,	O
albeit	O
to	O
different	O
degrees	O
.	O

These	O
results	O
indicate	O
that	O
these	O
compounds	O
are	O
not	O
only	O
ligands	O
but	O
also	O
substrates	O
of	O
T	O
.	O

gondii	O
adenosine	O
kinase	O
.	O

All	O
the	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosine	O
analogues	O
showed	O
a	O
selective	O
antitoxoplasmic	O
effect	O
against	O
wild	O
type	O
parasites	O
,	O
but	O
not	O
mutants	O
lacking	O
adenosine	O
kinase	O
.	O

The	O
efficacy	O
of	O
these	O
compounds	O
varied	O
with	O
the	O
position	O
and	O
nature	O
of	O
the	O
substitution	O
on	O
their	O
phenyl	O
ring	O
.	O

Moreover	O
,	O
none	O
of	O
these	O
analogues	O
exhibited	O
host	O
toxicity	O
.	O

The	O
best	O
compounds	O
were	O
7	O
-	O
deaza	O
-	O
6	O
-	O
(	O
p	O
-	O
methoxybenzylthio	O
)	O
inosine	O
(	O
IC	O
(	O
50	O
)	O
=	O
4.6	O
microM	O
)	O
,	O
7	O
-	O
deaza	O
-	O
6	O
-	O
(	O
p	O
-	O
methoxycarbonylbenzylthio	O
)	O
inosine	O
(	O
IC	O
(	O
50	O
)	O
=	O
5.0	O
microM	O
)	O
,	O
and	O
7	O
-	O
deaza	O
-	O
6	O
-	O
(	O
p	O
-	O
cyanobenzylthio	O
)	O
inosine	O
(	O
IC	O
(	O
50	O
)	O
=	O
5.3	O
microM	O
)	O
.	O

These	O
results	O
further	O
confirm	O
that	O
T	O
.	O

gondii	O
adenosine	O
kinase	O
is	O
an	O
excellent	O
target	O
for	O
chemotherapy	O
and	O
that	O
7	O
-	O
deaza	O
-	O
6	O
-	O
benzylthioinosines	O
are	O
potential	O
antitoxoplasmic	O
agents	O
.	O

INN	O
-	O
toxin	O
,	O
a	O
highly	O
lethal	O
peptide	O
from	O
the	O
venom	O
of	O
Indian	O
cobra	O
(	O
Naja	O
naja	O
)	O
venom	O
-	O
Isolation	O
,	O
characterization	O
and	O
pharmacological	O
actions	O
.	O

A	O
novel	O
toxic	O
polypeptide	O
,	O
INN	O
-	O
toxin	O
,	O
is	O
purified	O
from	O
the	O
venom	O
of	O
Naja	O
naja	O
using	O
combination	O
of	O
gel	O
-	O
permeation	O
and	O
ion	O
-	O
exchange	O
chromatography	O
.	O

It	O
has	O
a	O
molecular	O
mass	O
of	O
6951.6	O
Da	O
as	O
determined	O
by	O
MALDI	O
-	O
TOF	O
/	O
MS	O
and	O
the	O
N	O
-	O
terminal	O
sequence	O
of	O
LKXNKLVPLF	O
.	O

It	O
showed	O
both	O
neurotoxic	O
as	O
well	O
as	O
cytotoxic	B
activities	I
.	O

INN	O
-	O
toxin	O
is	O
lethal	O
to	O
mice	O
with	O
a	O
LD	O
(	O
50	O
)	O
of	O
1.2	O
mg	O
/	O
kg	O
body	O
weight	O
.	O

IgY	O
raised	O
in	O
chicks	O
against	O
basic	O
peptide	O
pool	O
neutralized	O
the	O
toxicity	O
of	O
INN	O
-	O
toxin	O
.	O

INN	O
-	O
toxin	O
did	O
not	O
inhibit	O
cholinesterase	O
activity	O
.	O

It	O
is	O
toxic	O
to	O
Ehrlich	O
ascites	O
tumor	O
(	O
EAT	O
)	O
cells	O
,	O
but	O
it	O
is	O
not	O
toxic	O
to	O
leukocyte	O
culture	O
.	O

The	O
toxin	O
appears	O
to	O
be	O
specific	O
in	O
its	O
mode	O
of	O
action	O
.	O

Interaction	O
of	O
N	O
-	O
bromosuccinamide	O
(	O
NBS	O
)	O
with	O
the	O
peptide	O
resulted	O
in	O
the	O
modification	O
of	O
tryptophan	O
residues	O
and	O
loss	O
of	O
lethal	O
toxicity	O
of	O
INN	O
-	O
toxin	O
.	O

Role	O
and	O
relevance	O
of	O
PEPT2	O
in	O
drug	O
disposition	O
,	O
dynamics	O
,	O
and	O
toxicity	O
.	O

Pept2	O
knockout	O
mice	O
are	O
an	O
important	O
tool	O
to	O
evaluate	O
the	O
evolving	O
role	O
and	O
relevance	O
of	O
this	O
proton	O
-	O
coupled	O
oligopeptide	O
transporter	O
beyond	O
drug	O
disposition	O
,	O
where	O
the	O
transporter	O
also	O
modulates	O
the	O
pharmacodynamic	O
and	O
toxicodynamic	O
effects	O
of	O
drug	O
substrates	O
.	O

Our	O
in	O
vivo	O
studies	O
with	O
glycylsarcosine	O
in	O
Pept2	O
knockout	O
mice	O
have	O
established	O
""""	O
proof	O
of	O
concept	O
""""	O
that	O
PEPT2	O
can	O
have	O
a	O
significant	O
effect	O
on	O
dipeptide	O
disposition	O
.	O

Subsequent	O
studies	O
with	O
the	O
aminocephalosporin	O
antibiotic	O
cefadroxil	O
have	O
shown	O
relevance	O
to	O
pharmacology	O
and	O
infectious	O
disease	O
.	O

Finally	O
,	O
studies	O
with	O
the	O
endogenous	O
peptidomimetic	O
5	O
-	O
aminolevulinic	O
acid	O
have	O
demonstrated	O
relevance	O
to	O
toxicology	O
in	O
the	O
framework	O
of	O
porphyria	O
-	O
and	O
lead	O
-	O
induced	O
neurotoxicity	B
.	O

These	O
studies	O
have	O
consistently	O
demonstrated	O
the	O
dual	O
action	O
of	O
PEPT2	O
with	O
respect	O
to	O
its	O
apical	O
localization	O
in	O
choroid	O
plexus	O
epithelium	O
and	O
kidney	O
in	O
:	O
1	O
)	O
effluxing	O
substrates	O
from	O
CSF	O
into	O
choroid	O
plexus	O
,	O
thereby	O
affecting	O
regional	O
pharmacokinetics	O
in	O
brain	O
;	O
and	O
2	O
)	O
reabsorbing	O
substrates	O
from	O
renal	O
tubular	O
fluid	O
into	O
proximal	O
tubules	O
,	O
thereby	O
affecting	O
systemic	O
pharmacokinetics	O
and	O
exposure	O
.	O

Moreover	O
,	O
these	O
studies	O
have	O
shown	O
that	O
the	O
regional	O
effect	O
of	O
PEPT2	O
in	O
limiting	O
substrate	O
concentrations	O
in	O
the	O
CSF	O
is	O
more	O
dramatic	O
than	O
its	O
effect	O
in	O
increasing	O
systemic	O
exposure	O
.	O

In	O
the	O
case	O
of	O
5	O
-	O
aminolevulinic	O
acid	O
,	O
such	O
regional	O
modulation	O
of	O
drug	O
disposition	O
translates	O
directly	O
into	O
significant	O
changes	O
in	O
neurotoxicity	B
.	O

Amiodarone	O
pulmonary	B
toxicity	I
after	O
lung	O
transplantation	O
.	O

Atrial	B
fibrillation	I
occurs	O
frequently	O
after	O
lung	O
transplantation	O
and	O
is	O
commonly	O
treated	O
with	O
amiodarone	O
.	O

Pulmonary	B
toxicity	I
may	O
result	O
from	O
amiodarone	O
exposure	O
and	O
is	O
characterized	O
by	O
non	O
-	O
specific	O
respiratory	O
manifestations	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
are	O
no	O
reports	O
of	O
this	O
complication	O
occurring	O
after	O
lung	O
transplantation	O
.	O

We	O
present	O
a	O
patient	O
who	O
developed	O
radiologic	O
evidence	O
of	O
amiodarone	O
deposition	O
in	O
the	O
lungs	O
after	O
bilateral	O
lung	O
transplantation	O
.	O

The	O
phenomenology	O
of	O
the	O
psychotic	O
break	O
and	O
Huxley	O
's	O
trip	O
:	O
substance	O
use	O
and	O
the	O
onset	O
of	O
psychosis	B
.	O

BACKGROUND	O
:	O
While	O
considerable	O
research	O
attention	O
has	O
been	O
devoted	O
to	O
the	O
causal	O
relationship	O
between	O
substance	O
use	O
and	O
psychosis	B
,	O
the	O
phenomenology	O
of	O
the	O
association	O
between	O
the	O
two	O
has	O
largely	O
been	O
ignored	O
.	O

This	O
is	O
a	O
significant	O
shortcoming	O
,	O
because	O
it	O
blinds	O
researchers	O
to	O
the	O
possibility	O
that	O
there	O
may	O
be	O
elements	O
of	O
the	O
subjective	O
experience	O
of	O
substance	O
use	O
and	O
psychosis	B
that	O
contribute	O
to	O
their	O
apparent	O
relationship	O
in	O
empirical	O
studies	O
.	O

SAMPLING	O
AND	O
METHODS	O
:	O
The	O
current	O
paper	O
examines	O
the	O
phenomenology	O
of	O
the	O
onset	O
of	O
psychosis	B
and	O
the	O
phenomenology	O
of	O
substance	O
intoxication	O
through	O
consideration	O
of	O
two	O
texts	O
:	O
Sass	O
's	O
account	O
of	O
the	O
phenomenology	O
of	O
psychosis	B
onset	O
and	O
Huxley	O
's	O
account	O
of	O
the	O
experience	O
of	O
hallucinogenic	B
intoxication	I
.	O

Sass	O
's	O
account	O
of	O
psychosis	B
onset	O
includes	O
four	O
components	O
:	O
Unreality	O
,	O
Fragmentation	O
,	O
Mere	O
Being	O
,	O
and	O
Apophany	O
.	O

RESULTS	O
:	O
The	O
analysis	O
reveals	O
significant	O
parallels	O
-	O
and	O
also	O
some	O
differences	O
-	O
between	O
this	O
account	O
and	O
the	O
phenomenology	O
of	O
substance	O
intoxication	O
.	O

CONCLUSIONS	O
:	O
We	O
discuss	O
the	O
implications	O
of	O
this	O
for	O
the	O
causal	O
relationship	O
between	O
psychosis	B
and	O
substance	O
use	O
and	O
suggest	O
several	O
ways	O
of	O
understanding	O
the	O
overlapping	O
phenomenologies	O
.	O

This	O
includes	O
the	O
suggestion	O
of	O
a	O
shared	O
factor	O
,	O
perhaps	O
best	O
described	O
as	O
psychotic	O
-	O
like	O
experience	O
,	O
which	O
seems	O
to	O
involve	O
a	O
breakdown	O
of	O
the	O
sign	O
-	O
referent	O
relationship	O
and	O
relationship	O
with	O
the	O
common	O
-	O
sense	O
,	O
practical	O
world	O
.	O

However	O
,	O
in	O
the	O
onset	O
of	O
psychosis	B
,	O
this	O
breakdown	O
is	O
primarily	O
experienced	O
as	O
a	O
sense	O
of	O
alienation	O
from	O
self	O
and	O
world	O
,	O
whereas	O
in	O
the	O
hallucinogenic	O
state	O
a	O
sense	O
of	O
mystical	O
union	O
and	O
revelation	O
seems	O
predominant	O
.	O

Further	O
research	O
may	O
extend	O
this	O
analysis	O
by	O
looking	O
at	O
experiences	O
with	O
other	O
drugs	O
,	O
particularly	O
cannabis	O
,	O
and	O
by	O
examining	O
the	O
phenomenology	O
of	O
psychotic	B
disorder	I
beyond	O
the	O
first	O
episode	O
.	O

Phase	O
I	O
study	O
of	O
capecitabine	O
in	O
combination	O
with	O
cisplatin	O
and	O
irinotecan	O
in	O
patients	O
with	O
advanced	O
solid	B
malignancies	I
.	O

PURPOSE	O
:	O
This	O
phase	O
I	O
trial	O
assessed	O
the	O
safety	O
and	O
the	O
maximum	O
tolerated	O
dose	O
of	O
capecitabine	O
given	O
for	O
10	O
days	O
prior	O
to	O
a	O
combination	O
of	O
cisplatin	O
and	O
irinotecan	O
in	O
patients	O
with	O
advanced	O
solid	B
malignancies	I
.	O

It	O
also	O
evaluated	O
the	O
changes	O
in	O
cisplatin	O
DNA	O
adducts	O
induced	O
by	O
capecitabine	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
refractory	O
solid	O
tumors	O
who	O
had	O
not	O
failed	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
analogs	O
or	O
topoisomerase	O
I	O
inhibitors	O
were	O
eligible	O
.	O

All	O
cohorts	O
of	O
patients	O
first	O
received	O
a	O
28	O
-	O
day	O
cycle	O
of	O
cisplatin	O
and	O
irinotecan	O
.	O

Both	O
drugs	O
were	O
given	O
at	O
a	O
dose	O
of	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
on	O
day	O
1	O
,	O
followed	O
by	O
irinotecan	O
on	O
days	O
8	O
and	O
15	O
at	O
the	O
same	O
dose	O
.	O

The	O
first	O
cycle	O
served	O
as	O
an	O
internal	O
control	O
.	O

Starting	O
from	O
the	O
second	O
cycle	O
,	O
patients	O
received	O
increasing	O
doses	O
per	O
cohort	O
of	O
capecitabine	O
from	O
day	O
1	O
to	O
10	O
of	O
each	O
cycle	O
,	O
followed	O
by	O
cisplatin	O
on	O
day	O
11	O
and	O
irinotecan	O
on	O
days	O
11	O
,	O
18	O
and	O
25	O
,	O
both	O
at	O
same	O
doses	O
as	O
the	O
first	O
cycle	O
.	O

Cycles	O
were	O
repeated	O
every	O
38	O
days	O
.	O

The	O
starting	O
dose	O
of	O
capecitabine	O
was	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
which	O
was	O
escalated	O
by	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
in	O
the	O
subsequent	O
cohort	O
of	O
patients	O
to	O
reach	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O

Later	O
,	O
additional	O
patients	O
were	O
treated	O
at	O
the	O
MTD	O
of	O
capecitabine	O
to	O
further	O
evaluate	O
the	O
safety	O
,	O
pharmacodynamics	O
,	O
and	O
tumor	O
response	O
.	O

Patients	O
blood	O
was	O
tested	O
for	O
cisplatin	O
-	O
DNA	O
adducts	O
to	O
determine	O
the	O
impact	O
of	O
capecitabine	O
on	O
cisplatin	O
-	O
based	O
therapy	O
.	O

RESULTS	O
:	O
Fifteen	O
patients	O
received	O
at	O
least	O
2	O
cycles	O
of	O
treatment	O
.	O

At	O
1,250	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
two	O
DLT	O
of	O
prolonged	O
neutropenia	B
of	O
grade	O
>	O
or	O
=	O
3	O
were	O
observed	O
.	O

The	O
MTD	O
for	O
capecitabine	O
was	O
thus	O
determined	O
to	O
be	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
.	O

Fatigue	B
and	O
diarrhea	B
of	O
grade	O
1	O
or	O
2	O
were	O
the	O
most	O
frequent	O
toxicities	O
at	O
this	O
dose	O
level	O
.	O

No	O
significant	O
hematologic	B
toxicity	I
was	O
observed	O
at	O
the	O
MTD	O
.	O

Two	O
complete	O
and	O
three	O
partial	O
remissions	O
were	O
observed	O
.	O

Four	O
of	O
the	O
responders	O
had	O
received	O
a	O
platinum	O
agent	O
and	O
/	O
or	O
5	O
-	O
FU	O
in	O
the	O
past	O
.	O

CONCLUSIONS	O
:	O
A	O
sequential	O
treatment	O
with	O
capecitabine	O
followed	O
by	O
cisplatin	O
and	O
irinotecan	O
is	O
well	O
tolerated	O
and	O
demonstrates	O
clinical	O
activity	O
in	O
patients	O
with	O
advanced	O
solid	B
malignancies	I
.	O

The	O
influence	O
of	O
capecitabine	O
,	O
if	O
any	O
,	O
on	O
the	O
efficacy	O
of	O
the	O
cisplatin	O
-	O
irinotecan	O
combination	O
is	O
not	O
related	O
to	O
a	O
variation	O
in	O
cisplatin	O
-	O
DNA	O
adducts	O
.	O

The	O
safety	O
of	O
long	O
-	O
acting	O
beta	O
-	O
agonists	O
among	O
patients	O
with	O
asthma	B
using	O
inhaled	O
corticosteroids	O
:	O
systematic	O
review	O
and	O
metaanalysis	O
.	O

RATIONALE	O
:	O
Inhaled	O
long	O
-	O
acting	O
beta	O
-	O
agonists	O
(	O
LABAs	O
)	O
,	O
when	O
used	O
as	O
monotherapy	O
in	O
asthma	B
,	O
may	O
increase	O
asthma	O
-	O
related	O
hospitalizations	O
,	O
life	O
threatening	O
events	O
requiring	O
intubation	O
/	O
mechanical	O
ventilation	O
,	O
and	O
asthma	O
-	O
related	O
deaths	O
,	O
but	O
concomitant	O
use	O
of	O
inhaled	O
corticosteroids	O
(	O
ICS	O
)	O
may	O
modify	O
this	O
effect	O
.	O

Objectives	O
:	O
To	O
determine	O
the	O
safety	O
of	O
long	O
-	O
acting	O
beta	O
-	O
agonists	O
among	O
patients	O
with	O
asthma	B
using	O
corticosteroids	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
systematic	O
review	O
and	O
metaanalysis	O
of	O
parallel	O
-	O
group	O
,	O
blinded	O
,	O
randomized	O
,	O
controlled	O
trials	O
with	O
at	O
least	O
12	O
weeks	O
of	O
treatment	O
addressing	O
the	O
impact	O
of	O
LABA	O
on	O
asthma	B
-	O
related	O
and	O
total	O
morbidity	O
and	O
mortality	O
in	O
patients	O
concomitantly	O
using	O
ICS	O
.	O

We	O
searched	O
MEDLINE	O
,	O
EMBASE	O
,	O
ACPJC	O
,	O
and	O
Cochrane	O
(	O
Central	O
)	O
databases	O
,	O
and	O
contacted	O
authors	O
and	O
sponsors	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
We	O
used	O
a	O
random	O
effects	O
model	O
to	O
pool	O
results	O
from	O
different	O
studies	O
as	O
odds	O
ratios	O
(	O
ORs	O
)	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
)	O
(	O
OR	O
<	O
1.0	O
favors	O
LABA	O
)	O
.	O

The	O
search	O
yielded	O
62	O
relevant	O
studies	O
included	O
in	O
this	O
analysis	O
.	O

Among	O
over	O
29,000	O
participants	O
(	O
15,710	O
taking	O
LABA	O
,	O
with	O
over	O
8,000	O
patient	O
-	O
years	O
observed	O
in	O
the	O
LABA	O
groups	O
)	O
,	O
there	O
were	O
three	O
asthma	B
-	O
related	O
deaths	O
and	O
two	O
asthma	B
-	O
related	O
,	O
nonfatal	O
intubations	O
(	O
all	O
in	O
LABA	O
groups	O
;	O
<	O
or	O
=	O
one	O
event	O
per	O
study	O
)	O
.	O

Differences	O
in	O
asthma	O
-	O
related	O
hospitalizations	O
(	O
OR	O
,	O
0.74	O
;	O
95	O
%	O
CI	O
,	O
0.53	O
-	O
1.03	O
)	O
and	O
asthma	O
-	O
related	O
serious	O
adverse	O
events	O
(	O
mostly	O
hospitalizations	O
;	O
OR	O
,	O
0.75	O
;	O
95	O
%	O
CI	O
,	O
0.54	O
-	O
1.03	O
)	O
failed	O
to	O
reach	O
statistical	O
significance	O
.	O

The	O
OR	O
for	O
total	O
mortality	O
was	O
1.26	O
(	O
95	O
%	O
CI	O
,	O
0.58	O
-	O
2.74	O
)	O
,	O
reflecting	O
14	O
deaths	O
in	O
LABA	O
groups	O
and	O
eight	O
deaths	O
in	O
control	O
groups	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
asthma	B
using	O
ICS	O
,	O
LABA	O
did	O
not	O
increase	O
the	O
risk	O
of	O
asthma	O
-	O
related	O
hospitalizations	O
.	O

There	O
were	O
very	O
few	O
asthma	O
-	O
related	O
deaths	O
and	O
intubations	O
,	O
and	O
events	O
were	O
too	O
infrequent	O
to	O
establish	O
LABA	O
's	O
relative	O
effect	O
on	O
these	O
outcomes	O
.	O

Adjuvant	O
treatment	O
with	O
vindesine	O
in	O
comparison	O
to	O
observation	O
alone	O
in	O
patients	O
with	O
metastasized	B
melanoma	I
after	O
complete	O
metastasectomy	O
:	O
a	O
randomized	O
multicenter	O
trial	O
of	O
the	O
German	O
Dermatologic	O
Cooperative	O
Oncology	O
Group	O
.	O

To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
vindesine	O
in	O
patients	O
with	O
metastatic	B
melanoma	I
after	O
complete	O
metastasectomy	O
.	O

One	O
hundred	O
and	O
forty	O
-	O
two	O
patients	O
with	O
metastatic	O
spread	O
to	O
regional	O
sites	O
,	O
lymph	O
nodes	O
,	O
and	O
distant	O
sites	O
after	O
complete	O
metastasectomy	O
were	O
randomized	O
to	O
receive	O
either	O
treatment	O
with	O
vindesine	O
for	O
2	O
years	O
or	O
observation	O
alone	O
.	O

Vindesine	O
3	O
mg	O
/	O
m	O
intravenously	O
was	O
administered	O
biweekly	O
for	O
the	O
first	O
26	O
weeks	O
following	O
3	O
-	O
week	O
intervals	O
for	O
an	O
additional	O
26	O
weeks	O
and	O
thereafter	O
every	O
4	O
weeks	O
for	O
52	O
weeks	O
.	O

One	O
hundred	O
and	O
thirty	O
-	O
nine	O
patients	O
were	O
eligible	O
for	O
intent	O
-	O
to	O
-	O
treat	O
analysis	O
.	O

Median	O
follow	O
-	O
up	O
time	O
was	O
46	O
months	O
.	O

Median	O
recurrence	O
free	O
survival	O
was	O
7.9	O
months	O
in	O
the	O
vindesine	O
group	O
and	O
7.6	O
months	O
in	O
the	O
observational	O
group	O
(	O
P	O
=	O
0.40	O
)	O
.	O

Three	O
-	O
year	O
overall	O
survival	O
rate	O
was	O
54.9	O
%	O
(	O
37	O
patients	O
)	O
for	O
patients	O
receiving	O
vindesine	O
in	O
comparison	O
to	O
43.6	O
%	O
(	O
31	O
patients	O
)	O
in	O
the	O
observation	O
arm	O
(	O
P	O
=	O
0.07	O
)	O
.	O

No	O
grade	O
IV	O
toxicity	O
was	O
observed	O
.	O

The	O
two	O
major	O
side	O
effects	O
in	O
the	O
vindesine	O
group	O
were	O
alopecia	B
and	O
peripheral	B
neuropathy	I
.	O

Ten	O
patients	O
went	O
off	O
treatment	O
because	O
of	O
grade	O
III	O
toxicity	O
.	O

Adjuvant	O
treatment	O
with	O
vindesine	O
did	O
not	O
significantly	O
prolong	O
disease	O
free	O
or	O
overall	O
survival	O
in	O
high	O
-	O
risk	O
melanoma	B
patients	O
.	O

Thus	O
,	O
this	O
randomized	O
trial	O
did	O
not	O
confirm	O
earlier	O
reports	O
of	O
beneficial	O
effects	O
of	O
adjuvant	O
vindesine	O
and	O
can	O
therefore	O
not	O
be	O
recommended	O
.	O

Risk	O
assessment	O
of	O
khat	O
use	O
in	O
the	O
Netherlands	O
:	O
a	O
review	O
based	O
on	O
adverse	O
health	O
effects	O
,	O
prevalence	O
,	O
criminal	O
involvement	O
and	O
public	O
order	O
.	O

In	O
preparing	O
a	O
decision	O
about	O
the	O
legal	O
status	O
of	O
khat	O
in	O
the	O
Netherlands	O
,	O
the	O
Dutch	O
Minister	O
of	O
Health	O
requested	O
CAM	O
(	O
Coordination	O
point	O
Assessment	O
and	O
Monitoring	O
new	O
drugs	O
)	O
to	O
assess	O
the	O
overall	O
risk	O
of	O
khat	O
in	O
the	O
Netherlands	O
.	O

The	O
present	O
paper	O
is	O
a	O
redraft	O
of	O
a	O
report	O
which	O
formed	O
the	O
scientific	O
basis	O
of	O
the	O
risk	O
evaluation	O
procedure	O
(	O
October	O
2007	O
)	O
.	O

This	O
report	O
reviews	O
the	O
scientific	O
data	O
about	O
khat	O
available	O
in	O
the	O
international	O
literature	O
.	O

In	O
addition	O
,	O
the	O
report	O
contains	O
some	O
information	O
specific	O
for	O
the	O
Netherlands	O
(	O
prevalence	O
,	O
availability	O
of	O
khat	O
and	O
public	O
order	O
aspects	O
)	O
.	O

The	O
main	O
psychoactive	O
compounds	O
in	O
khat	O
leaves	O
are	O
cathine	O
and	O
cathinone	O
,	O
which	O
are	O
some	O
2	O
-	O
to	O
10	O
-	O
fold	O
less	O
active	O
than	O
amphetamine	O
.	O

Acute	O
health	O
problems	O
are	O
rarely	O
seen	O
,	O
and	O
are	O
usually	O
related	O
with	O
malnutrition	O
,	O
social	O
and	O
financial	O
problems	O
.	O

Khat	O
has	O
a	O
low	O
addictive	O
potential	O
.	O

Chronic	B
toxicity	I
of	O
khat	O
is	O
modest	O
when	O
used	O
in	O
low	O
amounts	O
,	O
whereas	O
at	O
high	O
levels	O
,	O
khat	O
use	O
is	O
associated	O
with	O
adverse	O
effects	O
,	O
like	O
hypertension	B
,	O
heart	B
rhythm	I
disorders	I
,	O
insomnia	B
and	O
loss	B
of	I
appetite	I
.	O

In	O
addition	O
,	O
khat	O
users	O
show	O
a	O
higher	O
prevalence	O
of	O
cancers	B
in	O
the	O
digestive	O
tract	O
.	O

At	O
population	O
level	O
,	O
khat	O
does	O
not	O
lead	O
to	O
specific	O
health	O
risks	O
in	O
the	O
Netherlands	O
,	O
as	O
its	O
use	O
is	O
confined	O
to	O
East	O
-	O
African	O
immigrants	O
.	O

A	O
relationship	O
between	O
khat	O
use	O
and	O
psychiatric	O
disorders	O
has	O
been	O
suggested	O
,	O
but	O
the	O
reports	O
are	O
contradictory	O
,	O
and	O
such	O
studies	O
are	O
presumably	O
heavily	O
confounded	O
by	O
posttraumatic	O
and	O
social	O
stress	O
.	O

In	O
the	O
Netherlands	O
(	O
and	O
other	O
countries	O
)	O
,	O
khat	O
use	O
occasionally	O
leads	O
to	O
minor	O
disturbance	O
of	O
civil	O
order	O
in	O
the	O
public	O
domain	O
(	O
loud	O
talking	O
,	O
spitting	O
)	O
,	O
but	O
is	O
not	O
related	O
to	O
criminal	O
activities	O
.	O

Following	O
the	O
assessment	O
,	O
CAM	O
estimated	O
the	O
overall	O
risk	O
potential	O
of	O
khat	O
use	O
in	O
the	O
Netherlands	O
as	O
very	O
low	O
.	O

A	O
similar	O
conclusion	O
may	O
be	O
drawn	O
for	O
countries	O
with	O
a	O
comparable	O
prevalence	O
of	O
khat	O
use	O
and	O
khat	O
related	O
public	O
order	O
disturbance	O
.	O

High	O
-	O
dose	O
methylprednisolone	O
in	O
a	O
pregnant	O
woman	O
with	O
Crohn	B
's	I
disease	I
and	O
adrenal	B
suppression	I
in	O
her	O
newborn	O
.	O

BACKGROUND	O
:	O
The	O
synthetic	O
corticosteroid	O
methylprednisolone	O
is	O
used	O
for	O
the	O
treatment	O
of	O
acute	O
exacerbations	O
of	O
Crohn	B
's	I
disease	I
,	O
also	O
in	O
pregnancy	O
.	O

Its	O
use	O
is	O
considered	O
to	O
be	O
less	O
harmful	O
than	O
the	O
effect	O
of	O
active	O
disease	O
on	O
the	O
fetus	O
.	O

Adrenal	B
suppression	I
in	O
a	O
fetus	O
due	O
to	O
administration	O
of	O
methylprednisolone	O
has	O
hitherto	O
been	O
rarely	O
published	O
.	O

OBJECTIVE	O
:	O
To	O
present	O
a	O
case	O
of	O
neonatal	B
adrenal	I
suppression	I
due	O
to	O
the	O
use	O
of	O
high	O
-	O
dose	O
methylprednisolone	O
in	O
late	O
pregnancy	O
of	O
a	O
woman	O
with	O
Crohn	B
's	I
disease	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Clinical	O
signs	O
of	O
adrenal	B
suppression	I
were	O
observed	O
in	O
the	O
newborn	O
3	O
h	O
after	O
birth	O
.	O

After	O
hydrocortisone	O
supplementation	O
and	O
intensive	O
therapy	O
the	O
baby	O
recovered	O
completely	O
.	O

CONCLUSIONS	O
:	O
Life	O
-	O
threatening	O
adrenal	B
suppression	I
,	O
requiring	O
hydrocortisone	O
supplementation	O
and	O
intensive	O
therapy	O
,	O
was	O
observed	O
and	O
successfully	O
treated	O
in	O
a	O
newborn	O
,	O
whose	O
mother	O
had	O
received	O
high	O
-	O
dose	O
methylprednisolone	O
in	O
late	O
pregnancy	O
.	O

Effect	O
of	O
ranitidine	O
on	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
prasugrel	O
and	O
clopidogrel	O
.	O

OBJECTIVE	O
:	O
Clopidogrel	O
is	O
an	O
oral	O
thienopyridine	O
antiplatelet	O
agent	O
indicated	O
for	O
the	O
treatment	O
of	O
atherothrombotic	O
events	O
in	O
patients	O
with	O
acute	B
coronary	I
syndrome	I
(	O
ACS	O
)	O
.	O

Prasugrel	O
,	O
a	O
novel	O
oral	O
thienopyridine	O
,	O
is	O
under	O
investigation	O
for	O
the	O
reduction	O
of	O
atherothrombotic	O
events	O
in	O
patients	O
with	O
ACS	O
undergoing	O
percutaneous	O
coronary	O
intervention	O
.	O

Prasugrel	O
's	O
solubility	O
decreases	O
with	O
increasing	O
pH	O
,	O
suggesting	O
that	O
concomitantly	O
-	O
administered	O
medications	O
that	O
increase	O
gastric	O
pH	O
may	O
lower	O
the	O
rate	O
and	O
/	O
or	O
extent	O
of	O
prasugrel	O
absorption	O
.	O

This	O
study	O
evaluated	O
the	O
influence	O
of	O
ranitidine	O
coadministration	O
on	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
the	O
respective	O
active	O
metabolite	O
of	O
prasugrel	O
and	O
clopidogrel	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
In	O
this	O
open	O
-	O
label	O
,	O
two	O
-	O
period	O
,	O
two	O
-	O
treatment	O
,	O
crossover	O
study	O
,	O
47	O
healthy	O
male	O
subjects	O
were	O
randomized	O
to	O
one	O
of	O
two	O
study	O
arms	O
,	O
receiving	O
either	O
prasugrel	O
(	O
60	O
-	O
mg	O
loading	O
dose	O
[	O
LD	O
]	O
,	O
10	O
-	O
mg	O
maintenance	O
dose	O
[	O
MD	O
]	O
for	O
7	O
days	O
;	O
n	O
=	O
23	O
)	O
or	O
clopidogrel	O
(	O
600	O
-	O
mg	O
LD	O
,	O
75	O
-	O
mg	O
MD	O
for	O
7	O
days	O
;	O
n	O
=	O
24	O
)	O
.	O

In	O
one	O
treatment	O
period	O
,	O
subjects	O
received	O
prasugrel	O
or	O
clopidogrel	O
alone	O
,	O
and	O
in	O
the	O
alternate	O
period	O
received	O
the	O
same	O
thienopyridine	O
with	O
ranitidine	O
(	O
150	O
mg	O
twice	O
daily	O
,	O
starting	O
1	O
day	O
before	O
the	O
LD	O
)	O
.	O

Pharmacokinetic	O
parameter	O
estimates	O
(	O
AUC	O
(	O
0	O
-	O
t	O
last	O
)	O
,	O
C	O
(	O
max	O
)	O
,	O
and	O
t	O
(	O
max	O
)	O
)	O
and	O
inhibition	O
of	O
platelet	O
aggregation	O
(	O
IPA	O
)	O
by	O
light	O
transmission	O
aggregometry	O
were	O
assessed	O
at	O
multiple	O
time	O
points	O
after	O
the	O
LD	O
and	O
final	O
MD	O
.	O

RESULTS	O
:	O
Ranitidine	O
had	O
no	O
clinically	O
significant	O
effect	O
on	O
the	O
area	O
under	O
the	O
plasma	O
-	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
and	O
did	O
not	O
affect	O
the	O
time	O
to	O
C	O
(	O
max	O
)	O
(	O
t	O
(	O
max	O
)	O
)	O
for	O
active	O
metabolites	O
of	O
either	O
prasugrel	O
or	O
clopidogrel	O
.	O

It	O
reduced	O
the	O
geometric	O
mean	O
maximum	O
concentrations	O
of	O
active	O
metabolite	O
(	O
C	O
(	O
max	O
)	O
)	O
after	O
a	O
prasugrel	O
and	O
clopidogrel	O
LD	O
by	O
14	O
%	O
and	O
10	O
%	O
,	O
respectively	O
,	O
but	O
these	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O

When	O
coadministered	O
with	O
a	O
60	O
-	O
mg	O
prasugrel	O
LD	O
,	O
ranitidine	O
did	O
not	O
affect	O
the	O
time	O
to	O
,	O
or	O
magnitude	O
of	O
,	O
peak	O
IPA	O
,	O
but	O
did	O
result	O
in	O
a	O
modest	O
reduction	O
at	O
0.5	O
h	O
from	O
67.4	O
to	O
55.1	O
%	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Ranitidine	O
did	O
not	O
affect	O
prasugrel	O
IPA	O
during	O
MD	O
.	O

For	O
clopidogrel	O
,	O
IPA	O
was	O
not	O
affected	O
by	O
ranitidine	O
.	O

Prasugrel	O
and	O
clopidogrel	O
were	O
both	O
well	O
-	O
tolerated	O
,	O
with	O
/	O
without	O
ranitidine	O
.	O

CONCLUSIONS	O
:	O
Results	O
from	O
this	O
study	O
suggest	O
that	O
there	O
is	O
no	O
significant	O
drug	O
-	O
drug	O
interaction	B
between	O
oral	O
ranitidine	O
therapy	O
and	O
concomitantly	O
-	O
administered	O
prasugrel	O
or	O
clopidogrel	O
.	O

Dielectrophoretic	O
field	O
-	O
flow	O
fractionation	O
system	O
for	O
detection	O
of	O
aquatic	O
toxicants	O
.	O

Dielectrophoretic	O
field	O
-	O
flow	O
fractionation	O
(	O
dFFF	O
)	O
was	O
applied	O
as	O
a	O
contact	O
-	O
free	O
way	O
to	O
sense	O
changes	O
in	O
the	O
plasma	O
membrane	O
capacitances	O
and	O
conductivities	O
of	O
cultured	O
human	O
HL	O
-	O
60	O
cells	O
in	O
response	O
to	O
toxicant	O
exposure	O
.	O

A	O
micropatterned	O
electrode	O
imposed	O
electric	O
forces	O
on	O
cells	O
in	O
suspension	O
in	O
a	O
parabolic	O
flow	O
profile	O
as	O
they	O
moved	O
through	O
a	O
thin	O
chamber	O
.	O

Relative	O
changes	O
in	O
the	O
dFFF	O
peak	O
elution	O
time	O
,	O
reflecting	O
changes	O
in	O
cell	O
membrane	O
area	O
and	O
ion	O
permeability	O
,	O
were	O
measured	O
as	O
indices	O
of	O
response	O
during	O
the	O
first	O
150	O
min	O
of	O
exposure	O
to	O
eight	O
toxicants	O
having	O
different	O
single	O
or	O
mixed	O
modes	O
of	O
action	O
(	O
acrylonitrile	O
,	O
actinomycin	O
D	O
,	O
carbon	O
tetrachloride	O
,	O
endosulfan	O
,	O
N	O
-	O
nitroso	O
-	O
N	O
-	O
methylurea	O
(	O
NMU	O
)	O
,	O
paraquat	O
dichloride	O
,	O
puromycin	O
,	O
and	O
styrene	O
oxide	O
)	O
.	O

The	O
dFFF	O
method	O
was	O
compared	O
with	O
the	O
cell	O
viability	O
assay	O
for	O
all	O
toxicants	O
and	O
with	O
the	O
mitochondrial	O
potentiometric	O
dye	O
assay	O
or	O
DNA	O
alkaline	O
comet	O
assay	O
according	O
to	O
the	O
mode	O
of	O
action	O
of	O
the	O
specific	O
agents	O
.	O

Except	O
for	O
low	O
doses	O
of	O
nucleic	O
acid	O
-	O
targeting	O
agents	O
(	O
actinomycin	O
D	O
and	O
NMU	O
)	O
,	O
the	O
dFFF	O
method	O
detected	O
all	O
toxicants	O
more	O
sensitively	O
than	O
other	O
assays	O
,	O
in	O
some	O
cases	O
up	O
to	O
10	O
(	O
5	O
)	O
times	O
more	O
sensitively	O
than	O
the	O
viability	O
approach	O
.	O

The	O
results	O
suggest	O
the	O
dFFF	O
method	O
merits	O
additional	O
study	O
for	O
possible	O
applicability	O
in	O
toxicology	O
.	O

Hyperthermia	B
adds	O
to	O
chemotherapy	O
.	O

The	O
hallmarks	O
of	O
hyperthermia	B
and	O
its	O
pleotropic	O
effects	O
are	O
in	O
favour	O
of	O
its	O
combined	O
use	O
with	O
chemotherapy	O
.	O

Preclinical	O
research	O
reveals	O
that	O
for	O
heat	O
killing	O
and	O
synergistic	O
effects	O
the	O
thermal	O
dose	O
is	O
most	O
critical	O
.	O

Thermal	O
enhancement	O
of	O
drug	B
cytotoxicity	I
is	O
accompanied	O
by	O
cellular	O
death	O
and	O
necrosis	O
without	O
increasing	O
its	O
oncogenic	O
potential	O
.	O

The	O
induction	O
of	O
genetically	O
defined	O
stress	O
responses	O
can	O
deliver	O
danger	O
signals	O
to	O
activate	O
the	O
host	O
's	O
immune	O
system	O
.	O

The	O
positive	O
results	O
of	O
randomised	O
trials	O
have	O
definitely	O
established	O
hyperthermia	B
in	O
combination	O
with	O
chemotherapy	O
as	O
a	O
novel	O
clinical	O
modality	O
for	O
the	O
treatment	O
of	O
cancer	B
.	O

Hyperthermia	B
targets	O
the	O
action	O
of	O
chemotherapy	O
within	O
the	O
heated	O
tumour	B
region	O
without	O
affecting	O
systemic	B
toxicity	I
.	O

In	O
specific	O
clinical	O
settings	O
regional	B
hyperthermia	I
(	O
RHT	B
)	O
or	O
hyperthermic	O
perfusion	O
has	O
proved	O
its	O
value	O
and	O
deserve	O
a	O
greater	O
focus	O
and	O
investigation	O
in	O
other	O
malignancies	O
.	O

In	O
Europe	O
,	O
more	O
specialised	O
centres	O
should	O
be	O
created	O
and	O
maintained	O
as	O
network	O
of	O
excellence	O
for	O
hyperthermia	B
in	O
the	O
field	O
of	O
oncology	O
.	O

Multiple	O
-	O
pool	O
cell	O
lifespan	O
models	O
for	O
neutropenia	B
to	O
assess	O
the	O
population	O
pharmacodynamics	O
of	O
unbound	O
paclitaxel	O
from	O
two	O
formulations	O
in	O
cancer	B
patients	O
.	O

PURPOSE	O
:	O
Our	O
objective	O
was	O
to	O
build	O
a	O
mechanism	O
-	O
based	O
pharmacodynamic	O
model	O
for	O
the	O
time	O
course	O
of	O
neutropenia	B
in	O
cancer	B
patients	O
following	O
paclitaxel	O
treatment	O
with	O
a	O
tocopherol	O
-	O
based	O
Cremophor	O
-	O
free	O
formulation	O
(	O
Tocosol	O
Paclitaxel	O
)	O
and	O
Cremophor	O
EL	O
-	O
formulated	O
paclitaxel	O
(	O
Taxol	O
)	O
.	O

METHODS	O
:	O
A	O
randomized	O
two	O
-	O
way	O
crossover	O
trial	O
was	O
performed	O
with	O
35	O
adult	O
patients	O
who	O
received	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
paclitaxel	O
as	O
either	O
15	O
min	O
(	O
Tocosol	O
Paclitaxel	O
)	O
or	O
3	O
h	O
(	O
Taxol	O
)	O
intravenous	O
infusions	O
.	O

Paclitaxel	O
concentrations	O
were	O
measured	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
.	O

NONMEM	O
VI	O
was	O
used	O
for	O
population	O
pharmacodynamics	O
.	O

RESULTS	O
:	O
The	O
cytotoxic	B
effect	I
on	O
neutrophils	O
was	O
described	O
by	O
four	O
mechanism	O
-	O
based	O
models	O
predicated	O
on	O
known	O
properties	O
of	O
paclitaxel	O
that	O
used	O
unbound	O
concentrations	O
in	O
the	O
central	O
,	O
deep	O
peripheral	O
or	O
an	O
intracellular	O
compartment	O
as	O
forcing	O
functions	O
.	O

Tocosol	O
Paclitaxel	O
was	O
estimated	O
to	O
release	O
9.8	O
%	O
of	O
the	O
dose	O
directly	O
into	O
the	O
deep	O
peripheral	O
compartment	O
(	O
DPC	O
)	O
.	O

All	O
models	O
provided	O
reasonable	O
fitting	O
of	O
neutropenic	O
effects	O
.	O

The	O
model	O
with	O
the	O
best	O
predictive	O
performance	O
assumed	O
that	O
this	O
dose	O
fraction	O
was	O
released	O
into	O
22.5	O
%	O
of	O
the	O
DPC	O
which	O
included	O
the	O
site	O
of	O
toxicity	O
.	O

The	O
second	O
-	O
order	O
cytotoxic	O
rate	O
constant	O
was	O
0.00211	O
mL	O
/	O
ng	O
per	O
hour	O
(	O
variability	O
:	O
52	O
%	O
CV	O
)	O
.	O

The	O
relative	O
exposure	O
at	O
the	O
site	O
of	O
toxicity	O
was	O
2.21	O
+	O
/	O
-	O
0.41	O
times	O
(	O
average	O
+	O
/	O
-	O
SD	O
)	O
larger	O
for	O
Tocosol	O
Paclitaxel	O
compared	O
to	O
Taxol	O
.	O

Lifespan	O
was	O
11.0	O
days	O
for	O
progenitor	O
cells	O
,	O
1.95	O
days	O
for	O
maturating	O
cells	O
,	O
and	O
4.38	O
days	O
for	O
neutrophils	O
.	O

Total	O
drug	O
exposure	O
in	O
blood	O
explained	O
half	O
of	O
the	O
variance	O
in	O
nadir	O
to	O
baseline	O
neutrophil	O
count	O
ratio	O
.	O

CONCLUSIONS	O
:	O
The	O
relative	O
exposure	O
of	O
unbound	O
paclitaxel	O
at	O
the	O
site	O
of	O
toxicity	O
was	O
twice	O
as	O
large	O
for	O
Tocosol	O
Paclitaxel	O
compared	O
to	O
Taxol	O
.	O

The	O
proposed	O
mechanism	O
-	O
based	O
models	O
explained	O
the	O
extent	O
and	O
time	O
course	O
of	O
neutropenia	B
jointly	O
for	O
both	O
formulations	O
.	O

Effect	O
of	O
ABCG2	O
on	O
cytotoxicity	B
of	O
platinum	O
drugs	O
:	O
interference	O
of	O
EGFP	O
.	O

ATP	O
-	O
binding	O
drug	O
efflux	O
transporters	O
decrease	O
intracellular	O
concentrations	O
of	O
cytotoxic	O
drugs	O
,	O
causing	O
multidrug	O
resistance	O
in	O
cancer	B
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
possible	O
interactions	O
of	O
ABCG2	O
transporter	O
with	O
platinum	O
cytotoxic	O
drugs	O
.	O

We	O
demonstrate	O
here	O
an	O
interference	O
of	O
platinum	O
drugs	O
with	O
enhanced	O
green	O
fluorescence	O
protein	O
(	O
EGFP	O
)	O
in	O
the	O
cellular	O
models	O
,	O
where	O
EGFP	O
was	O
employed	O
as	O
a	O
reporter	O
gene	O
.	O

Cytotoxicity	B
of	O
cisplatin	O
(	O
CIP	O
)	O
,	O
carboplatin	O
(	O
CAP	O
)	O
and	O
oxaliplatin	O
(	O
OXP	O
)	O
was	O
significantly	O
lowered	O
in	O
MDCKII	O
cells	O
transfected	O
with	O
ABCG2	O
transporter	O
and	O
EGFP	O
reporter	O
.	O

The	O
IC	O
(	O
50	O
)	O
values	O
in	O
MDCKII	O
-	O
ABCG2	O
were	O
25.7	O
,	O
164	O
and	O
165	O
microM	O
for	O
CIP	O
,	O
CAP	O
and	O
OXP	O
,	O
respectively	O
,	O
whereas	O
IC	O
(	O
50	O
)	O
for	O
the	O
same	O
cytostatics	O
in	O
MDCKII	O
cells	O
were	O
as	O
follows	O
:	O
15.4	O
,	O
133	O
and	O
50.3	O
microM	O
.	O

Addition	O
of	O
fumitremorgin	O
C	O
(	O
FTC	O
)	O
,	O
a	O
potent	O
ABCG2	O
inhibitor	O
,	O
significantly	O
suppressed	O
the	O
resistance	O
of	O
MDCKII	O
-	O
ABCG2	O
to	O
OXP	O
,	O
suggesting	O
that	O
OXP	O
interacts	O
with	O
ABCG2	O
.	O

However	O
,	O
FTC	O
did	O
not	O
change	O
the	O
sensitivity	O
of	O
the	O
cells	O
to	O
CIP	O
and	O
CAP	O
.	O

We	O
assume	O
that	O
EGFP	O
rather	O
than	O
ABCG2	O
causes	O
the	O
diminished	O
toxicity	O
of	O
the	O
platinum	O
cytostatics	O
in	O
the	O
transfected	O
cells	O
.	O

This	O
hypothesis	O
was	O
confirmed	O
in	O
human	O
Hep2	O
cells	O
expressing	O
EGFP	O
:	O
using	O
MTT	O
test	O
,	O
IC	O
(	O
50	O
)	O
of	O
30.0	O
,	O
247	O
and	O
27.9	O
microM	O
were	O
obtained	O
for	O
CIP	O
,	O
CAP	O
and	O
OXP	O
,	O
respectively	O
,	O
while	O
12.3	O
,	O
106	O
and	O
20.5	O
microM	O
were	O
observed	O
in	O
the	O
parent	O
Hep2	O
cells	O
.	O

Employing	O
neutral	O
red	O
cytotoxicity	B
assay	O
,	O
similar	O
data	O
were	O
obtained	O
(	O
IC	O
(	O
50	O
)	O
7.73	O
,	O
685	O
and	O
112	O
microM	O
for	O
CIP	O
,	O
CAP	O
,	O
and	O
OXP	O
,	O
respectively	O
,	O
in	O
the	O
Hep2	O
-	O
EGFP	O
cells	O
and	O
1.65	O
,	O
79.4	O
and	O
24.5	O
microM	O
in	O
the	O
parent	O
Hep2	O
cells	O
)	O
.	O

Caspase	O
-	O
3	O
/	O
7	O
assay	O
revealed	O
lower	O
susceptibility	O
of	O
EGFP	O
expressing	O
Hep2	O
cells	O
to	O
apoptosis	O
induced	O
by	O
CIP	O
when	O
compared	O
to	O
the	O
parent	O
cell	O
line	O
.	O

We	O
therefore	O
conclude	O
that	O
EGFP	O
in	O
transfected	O
cells	O
interferes	O
with	O
cytotoxicity	B
of	O
platinum	O
drugs	O
by	O
hindering	O
the	O
drug	O
induced	O
apoptosis	O
and	O
could	O
cause	O
misinterpretation	O
of	O
results	O
obtained	O
in	O
cytotoxicity	B
studies	O
.	O

Protective	O
effects	O
of	O
asiatic	O
acid	O
on	O
rotenone	O
-	O
or	O
H2O2	O
-	O
induced	O
injury	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
is	O
a	O
progressive	B
neurodegenerative	I
disorder	I
with	O
a	O
prevalence	O
of	O
1	O
-	O
2	O
%	O
in	O
people	O
over	O
the	O
age	O
of	O
50	O
.	O

Mitochondrial	O
dysfunction	O
occurred	O
in	O
PD	B
patients	O
showing	O
a	O
15	O
-	O
30	O
%	O
loss	O
of	O
activity	O
in	O
complex	O
I	O
.	O

Asiatic	O
acid	O
(	O
AA	O
)	O
,	O
a	O
triterpenoid	O
,	O
is	O
an	O
antioxidant	O
and	O
used	O
for	O
depression	B
treatment	O
,	O
but	O
the	O
effect	O
of	O
AA	O
against	O
PD	B
-	O
like	O
damage	O
has	O
never	O
been	O
reported	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
protective	O
effects	O
of	O
AA	O
against	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
or	O
rotenone	O
-	O
induced	O
cellular	B
injury	I
and	O
mitochondrial	O
dysfunction	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Mitochondrial	O
membrane	O
potential	O
(	O
MMP	O
)	O
and	O
the	O
expression	O
of	O
voltage	O
-	O
dependent	O
anion	O
channel	O
(	O
VDAC	O
)	O
were	O
detected	O
with	O
or	O
without	O
AA	O
pretreatment	O
following	O
cellular	B
injury	I
to	O
address	O
the	O
possible	O
mechanisms	O
of	O
AA	O
neuroprotection	O
.	O

The	O
results	O
showed	O
that	O
pre	O
-	O
treatment	O
of	O
AA	O
(	O
0.01	O
-	O
100	O
nM	O
)	O
protected	O
cells	O
against	O
the	O
toxicity	O
induced	O
by	O
rotenone	O
or	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
.	O

In	O
addition	O
,	O
MMP	O
dissipation	O
occurred	O
following	O
the	O
exposure	O
of	O
rotenone	O
,	O
which	O
could	O
be	O
prevented	O
by	O
AA	O
treatment	O
.	O

More	O
interestingly	O
,	O
pre	O
-	O
administration	O
of	O
AA	O
inhibited	O
the	O
elevation	O
of	O
VDAC	O
mRNA	O
and	O
protein	O
levels	O
induced	O
by	O
rotenone	O
(	O
100	O
nM	O
)	O
or	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
(	O
300	O
microM	O
)	O
.	O

These	O
data	O
indicate	O
that	O
AA	O
could	O
protect	O
neuronal	O
cells	O
against	O
mitochondrial	O
dysfunctional	O
injury	O
and	O
suggest	O
that	O
AA	O
might	O
be	O
developed	O
as	O
an	O
agent	O
for	O
PD	O
prevention	O
or	O
therapy	O
.	O

Efficient	O
telomerase	O
inhibition	O
in	O
human	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
cells	O
by	O
liposomal	O
delivery	O
of	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
.	O

The	O
antisense	O
oligonucleotide	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
is	O
a	O
selective	O
telomerase	O
inhibitor	O
targeting	O
the	O
telomerase	O
RNA	O
component	O
and	O
represents	O
a	O
potential	O
candidate	O
for	O
anticancer	O
therapy	O
.	O

The	O
poor	O
cellular	O
uptake	O
of	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
is	O
a	O
limiting	O
factor	O
that	O
may	O
contribute	O
to	O
the	O
lack	O
of	O
functional	O
efficacy	O
.	O

To	O
improve	O
delivery	O
of	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
and	O
consequently	O
antitumoral	O
efficiency	O
in	O
human	O
lung	O
cancer	O
cells	O
,	O
we	O
have	O
investigated	O
several	O
transfection	O
reagents	O
.	O

The	O
transfection	O
reagents	O
DOTAP	O
,	O
MegaFectin	O
60	O
,	O
SuperFect	O
,	O
FuGENE	O
6	O
and	O
MATra	O
-	O
A	O
were	O
tested	O
for	O
intracellular	O
delivery	O
.	O

A	O
FAM	O
-	O
labeled	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
was	O
used	O
to	O
assess	O
the	O
intracellular	O
distribution	O
by	O
confocal	O
laser	O
scanning	O
microscopy	O
in	O
A549	O
human	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
cells	O
.	O

Telomerase	O
activity	O
was	O
measured	O
using	O
the	O
telomeric	O
repeat	O
amplification	O
protocol	O
.	O

Cell	O
viability	O
after	O
transfection	O
was	O
quantified	O
by	O
the	O
MTT	O
assay	O
.	O

All	O
transfection	O
reagents	O
enhanced	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
uptake	O
in	O
A549	O
cells	O
but	O
the	O
cationic	O
lipid	O
reagents	O
DOTAP	O
and	O
MegaFectin	O
60	O
were	O
most	O
efficient	O
in	O
the	O
delivery	O
of	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
resulting	O
in	O
telomerase	O
inhibition	O
.	O

Among	O
both	O
DOTAP	O
exhibited	O
the	O
lowest	O
cytotoxicity	B
.	O

Our	O
experiments	O
show	O
that	O
DOTAP	O
is	O
the	O
most	O
suitable	O
transfection	O
reagent	O
for	O
the	O
delivery	O
of	O
2	O
'	O
-	O
O	O
-	O
methyl	O
-	O
RNA	O
in	O
human	O
lung	O
cancer	O
cells	O
according	O
to	O
its	O
relatively	O
low	O
cytotoxicity	B
and	O
its	O
ability	O
to	O
promote	O
efficient	O
uptake	O
leading	O
to	O
the	O
inhibition	O
of	O
telomerase	O
.	O

Particulate	O
matter	O
inhibits	O
DNA	O
repair	O
and	O
enhances	O
mutagenesis	O
.	O

Exposure	O
to	O
ambient	O
air	O
pollution	O
has	O
been	O
associated	O
with	O
adverse	O
health	O
effects	O
including	O
lung	B
cancer	I
.	O

A	O
recent	O
epidemiology	O
study	O
has	O
established	O
that	O
each	O
10	O
microg	O
/	O
m3	O
elevation	O
in	O
long	O
-	O
term	O
exposure	O
to	O
average	O
PM2	O
.5	O
ambient	O
concentration	O
was	O
associated	O
with	O
approximately	O
8	O
%	O
of	O
lung	B
cancer	I
mortality	O
.	O

The	O
underlying	O
mechanisms	O
of	O
how	O
PM	O
contributes	O
to	O
lung	O
carcinogenesis	O
,	O
however	O
,	O
remain	O
to	O
be	O
elucidated	O
.	O

We	O
have	O
recently	O
found	O
that	O
transition	O
metals	O
such	O
as	O
nickel	O
and	O
chromium	O
and	O
oxidative	O
stress	O
induced	O
lipid	O
peroxidation	O
metabolites	O
such	O
as	O
aldehydes	O
can	O
greatly	O
inhibit	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
enhance	O
carcinogen	O
-	O
induced	O
mutations	O
.	O

Because	O
PM	O
is	O
rich	O
in	O
metal	O
and	O
aldehyde	O
content	O
and	O
can	O
induce	O
oxidative	O
stress	O
,	O
we	O
tested	O
the	O
effect	O
of	O
PM	O
on	O
DNA	O
repair	O
capacity	O
in	O
cultured	O
human	O
lung	O
cells	O
using	O
in	O
vitro	O
DNA	O
repair	O
synthesis	O
and	O
host	O
cell	O
reactivation	O
assays	O
.	O

We	O
found	O
that	O
PM	O
greatly	O
inhibits	O
NER	O
for	O
ultraviolet	O
(	O
UV	O
)	O
light	O
and	O
benzo	O
(	O
a	O
)	O
pyrene	O
diol	O
epoxide	O
(	O
BPDE	O
)	O
induced	O
DNA	O
damage	O
in	O
human	O
lung	O
cells	O
.	O

We	O
further	O
demonstrated	O
that	O
PM	O
exposure	O
can	O
significantly	O
increase	O
both	O
spontaneous	O
and	O
UV	O
-	O
induced	O
mutagenesis	O
.	O

These	O
results	O
together	O
suggest	O
that	O
the	O
carcinogenicity	B
of	O
PM	O
may	O
act	O
through	O
its	O
combined	O
effect	O
on	O
suppression	O
of	O
DNA	O
repair	O
and	O
enhancement	O
of	O
DNA	O
replication	O
errors	O
.	O

Nicotine	O
and	O
4	O
-	O
(	O
methylnitrosamino	O
)	O
-	O
1	O
-	O
(	O
3	O
-	O
pyridyl	O
)	O
-	O
1	O
-	O
butanone	O
induce	O
cyclooxygenase	O
-	O
2	O
activity	O
in	O
human	O
gastric	O
cancer	O
cells	O
:	O
Involvement	O
of	O
nicotinic	O
acetylcholine	O
receptor	O
(	O
nAChR	O
)	O
and	O
beta	O
-	O
adrenergic	O
receptor	O
signaling	O
pathways	O
.	O

Induction	O
of	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
associates	O
with	O
cigarette	O
smoke	O
exposure	O
in	O
many	O
malignancies	O
.	O

Nicotine	O
and	O
its	O
derivative	O
,	O
4	O
-	O
(	O
methylnitrosamino	O
)	O
-	O
1	O
-	O
(	O
3	O
-	O
pyridyl	O
)	O
-	O
1	O
-	O
butanone	O
(	O
NNK	O
)	O
,	O
are	O
the	O
two	O
important	O
components	O
in	O
cigarette	O
smoke	O
that	O
contributes	O
to	O
cancer	B
development	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
nicotine	O
or	O
NNK	O
promotes	O
gastric	O
carcinogenesis	O
remains	O
largely	O
unknown	O
.	O

We	O
found	O
that	O
nicotine	O
and	O
NNK	O
significantly	O
enhanced	O
cell	O
proliferation	O
in	O
AGS	O
cells	O
that	O
expressed	O
both	O
alpha7	O
nicotinic	O
acetylcholine	O
receptor	O
(	O
alpha7	O
nAChR	O
)	O
and	O
beta	O
-	O
adrenergic	O
receptors	O
.	O

Treatment	O
of	O
cells	O
with	O
alpha	O
-	O
bungarotoxin	O
(	O
alpha	O
-	O
BTX	O
,	O
alpha7nAChR	O
antagonist	O
)	O
or	O
propranolol	O
(	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
)	O
blocked	O
NNK	O
-	O
induced	O
COX	O
-	O
2	O
/	O
PGE	O
(	O
2	O
)	O
and	O
cell	O
proliferation	O
,	O
while	O
nicotine	O
-	O
mediated	O
cell	O
growth	O
and	O
COX	O
-	O
2	O
/	O
PGE	O
(	O
2	O
)	O
induction	O
can	O
only	O
be	O
suppressed	O
by	O
propranolol	O
,	O
but	O
not	O
alpha	O
-	O
BTX	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
the	O
dependence	O
of	O
growth	O
promoting	O
effect	O
of	O
nicotine	O
on	O
Erk	O
activation	O
,	O
inhibitor	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
repressed	O
NNK	O
-	O
induced	O
COX	O
-	O
2	O
upregulation	O
and	O
resulted	O
in	O
suppression	O
of	O
cell	O
growth	O
.	O

In	O
addition	O
,	O
nicotine	O
and	O
NNK	O
mediated	O
COX	O
-	O
2	O
induction	O
via	O
different	O
receptors	O
to	O
modulate	O
several	O
G1	O
/	O
S	O
transition	O
regulatory	O
proteins	O
and	O
promote	O
gastric	O
cancer	O
cell	O
growth	O
.	O

Selective	O
COX	O
-	O
2	O
inhibitor	O
(	O
SC	O
-	O
236	O
)	O
caused	O
G1	O
arrest	O
and	O
abrogated	O
nicotine	O
/	O
NNK	O
-	O
induced	O
cell	O
proliferation	O
.	O

Aberrant	O
expression	O
of	O
cyclin	O
D1	O
and	O
other	O
G1	O
regulatory	O
proteins	O
are	O
reversed	O
by	O
blockade	O
of	O
COX	O
-	O
2	O
.	O

These	O
results	O
pointed	O
to	O
the	O
importance	O
of	O
adrenergic	O
and	O
nicotinic	O
receptors	O
in	O
gastric	B
tumor	I
growth	O
through	O
MAPK	O
/	O
COX	O
-	O
2	O
activation	O
,	O
which	O
may	O
perhaps	O
provide	O
a	O
chemoprevention	O
strategy	O
for	O
cigarette	O
smoke	O
-	O
related	O
gastric	B
carcinogenesis	I
.	O

Selenium	O
nanoparticles	O
fabricated	O
in	O
Undaria	O
pinnatifida	O
polysaccharide	O
solutions	O
induce	O
mitochondria	O
-	O
mediated	O
apoptosis	O
in	O
A375	O
human	O
melanoma	O
cells	O
.	O

Selenium	O
nanoparticle	O
(	O
Nano	O
-	O
Se	O
)	O
is	O
a	O
novel	O
Se	O
species	O
with	O
novel	O
biological	O
activities	O
and	O
low	O
toxicity	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
a	O
simple	O
method	O
for	O
synthesis	O
of	O
size	O
-	O
controlled	O
Nano	O
-	O
Se	O
by	O
adding	O
Undaria	O
pinnatifida	O
polysaccharides	O
to	O
the	O
redox	O
system	O
of	O
selenite	O
and	O
ascorbic	O
acid	O
.	O

A	O
panel	O
of	O
four	O
human	O
cancer	O
cell	O
lines	O
was	O
shown	O
to	O
be	O
susceptible	O
to	O
Nano	O
-	O
Se	O
,	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
3.0	O
to	O
14.1	O
microM	O
.	O

Treatment	O
of	O
A375	O
human	O
melanoma	O
cells	O
with	O
the	O
Nano	O
-	O
Se	O
resulted	O
in	O
dose	O
-	O
dependent	O
cell	O
apoptosis	O
as	O
indicated	O
by	O
DNA	O
fragmentation	O
and	O
phosphatidylserine	O
translocation	O
.	O

Further	O
investigation	O
on	O
intracellular	O
mechanisms	O
found	O
that	O
Nano	O
-	O
Se	O
treatment	O
triggered	O
apoptotic	O
cell	O
death	O
in	O
A375	O
cells	O
with	O
the	O
involvement	O
of	O
oxidative	O
stress	O
and	O
mitochondrial	O
dysfunction	O
.	O

Our	O
results	O
suggest	O
that	O
Nano	O
-	O
Se	O
may	O
be	O
a	O
candidate	O
for	O
further	O
evaluation	O
as	O
a	O
chemopreventive	O
and	O
chemotherapeutic	O
agent	O
for	O
human	O
cancers	O
,	O
especially	O
melanoma	B
cancer	I
.	O

An	O
EORTC	O
phase	O
I	O
study	O
of	O
Bortezomib	O
in	O
combination	O
with	O
oxaliplatin	O
,	O
leucovorin	O
and	O
5	O
-	O
fluorouracil	O
in	O
patients	O
with	O
advanced	O
colorectal	B
cancer	I
.	O

The	O
combination	O
of	O
oxaliplatin	O
,	O
leucovorin	O
and	O
5	O
-	O
fluorouracil	O
(	O
FOLFOX	O
-	O
4	O
)	O
is	O
still	O
a	O
reference	O
regimen	O
in	O
advanced	O
colorectal	B
cancer	I
;	O
however	O
,	O
the	O
addition	O
of	O
new	O
biologic	O
compounds	O
represents	O
a	O
significant	O
way	O
forward	O
.	O

Bortezomib	O
is	O
an	O
inhibitor	O
of	O
proteasome	O
,	O
a	O
multicatalytic	O
enzyme	O
complex	O
that	O
degrades	O
several	O
intracellular	O
proteins	O
.	O

In	O
this	O
study	O
,	O
escalating	O
doses	O
of	O
Bortezomib	O
were	O
administered	O
along	O
with	O
the	O
standard	O
FOLFOX	O
-	O
4	O
doses	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
dose	B
-	I
limiting	I
toxicity	I
(	O
DLT	B
)	O
,	O
toxicity	O
profile	O
and	O
activity	O
of	O
the	O
combination	O
.	O

Patients	O
with	O
advanced	O
colorectal	B
cancer	I
,	O
unpretreated	O
for	O
metastatic	B
disease	I
,	O
were	O
enroled	O
in	O
the	O
study	O
.	O

Bortezomib	O
starting	O
dose	O
was	O
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
which	O
was	O
to	O
be	O
escalated	O
in	O
the	O
subsequent	O
steps	O
according	O
to	O
the	O
toxicities	O
observed	O
after	O
first	O
cycle	O
.	O

Exploratory	O
pharmacogenetics	O
research	O
was	O
conducted	O
by	O
analysing	O
the	O
association	O
between	O
clinical	O
outcomes	O
and	O
polymorphisms	O
in	O
candidate	O
genes	O
for	O
response	O
to	O
each	O
of	O
the	O
used	O
drugs	O
.	O

Correlation	O
between	O
tumour	O
marker	O
changes	O
and	O
response	O
was	O
also	O
investigated	O
.	O

One	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
DL	O
-	O
1	O
)	O
was	O
defined	O
as	O
being	O
the	O
maximum	O
tolerated	O
dose	O
since	O
only	O
1	O
DLT	O
was	O
observed	O
in	O
6	O
patients	O
.	O

The	O
main	O
toxicities	O
were	O
haematologic	O
,	O
neuropathy	B
,	O
diarrhoea	B
and	O
fatigue	B
.	O

Amongst	O
13	O
evaluable	O
patients	O
,	O
five	O
had	O
a	O
partial	O
response	O
,	O
five	O
had	O
a	O
stable	O
disease	O
and	O
three	O
patients	O
progressed	O
.	O

Two	O
patients	O
are	O
long	O
-	O
term	O
survivors	O
after	O
a	O
combined	O
chemosurgical	O
approach	O
.	O

Further	O
trials	O
of	O
the	O
current	O
combination	O
may	O
be	O
justified	O
.	O

Derivation	O
of	O
a	O
chronic	O
reference	O
dose	O
and	O
reference	O
concentration	O
for	O
trimethylbenzenes	O
and	O
C9	O
aromatic	O
hydrocarbon	O
solvents	O
.	O

Trimethylbenzenes	O
(	O
TMBs	O
)	O
and	O
C9	O
aromatic	O
hydrocarbon	O
solvents	O
are	O
structurally	O
similar	O
and	O
have	O
similar	O
toxicity	O
.	O

Based	O
on	O
a	O
review	O
of	O
the	O
entire	O
TMB	O
and	O
C9	O
aromatic	O
hydrocarbon	O
solvents	O
toxicology	O
database	O
,	O
oral	O
and	O
inhalation	O
studies	O
were	O
identified	O
to	O
serve	O
as	O
the	O
basis	O
for	O
a	O
Reference	O
dose	O
(	O
RfD	O
)	O
and	O
Reference	O
concentrations	O
(	O
RfC	O
)	O
.	O

The	O
RfD	O
and	O
RfC	O
were	O
derived	O
using	O
standard	O
USEPA	O
methods	O
and	O
assumptions	O
.	O

The	O
RfD	O
was	O
calculated	O
to	O
be	O
0.4	O
mg	O
/	O
kg	O
/	O
day	O
using	O
a	O
90	O
-	O
day	O
oral	O
study	O
that	O
resulted	O
in	O
a	O
NOAEL	O
of	O
600	O
mg	O
/	O
kg	O
/	O
day	O
,	O
based	O
on	O
a	O
lack	O
of	O
adverse	O
effects	O
at	O
the	O
highest	O
dose	O
level	O
(	O
reversible	O
effects	O
such	O
as	O
increased	O
serum	O
phosphorus	O
levels	O
and	O
liver	O
and	O
kidney	O
weights	O
)	O
,	O
along	O
with	O
a	O
total	O
uncertainty	O
factor	O
of	O
1000	O
.	O

For	O
the	O
RfC	O
,	O
three	O
studies	O
were	O
considered	O
based	O
on	O
different	O
study	O
designs	O
and	O
toxicological	O
endpoints	O
,	O
including	O
neurotoxicity	B
,	O
systemic	B
toxicity	I
,	O
and	O
potential	O
developmental	O
and	O
reproductive	B
toxicity	I
.	O

For	O
all	O
three	O
studies	O
,	O
as	O
the	O
calculated	O
RfCs	O
were	O
consistent	O
(	O
3	O
-	O
4	O
mg	O
/	O
m3	O
)	O
,	O
the	O
most	O
conservative	O
RfC	O
,	O
3	O
mg	O
/	O
m3	O
,	O
was	O
selected	O
.	O

The	O
C9	O
aromatic	O
hydrocarbon	O
solvents	O
referred	O
to	O
herein	O
are	O
based	O
on	O
chemistries	O
assessed	O
as	O
part	O
of	O
the	O
TSCA	O
Section	O
4	O
Test	O
Rule	O
.	O

These	O
solvents	O
contain	O
primarily	O
ethyl	O
toluene	O
and	O
tri	O
-	O
methyl	O
benzene	O
isomers	O
,	O
but	O
the	O
specific	O
compositions	O
can	O
vary	O
based	O
on	O
feedstock	O
and	O
manufacturing	O
process	O
,	O
thus	O
,	O
it	O
is	O
important	O
to	O
consider	O
the	O
composition	O
of	O
any	O
specific	O
solvent	O
to	O
assess	O
similarity	O
to	O
that	O
assessed	O
in	O
the	O
TSCA	O
Section	O
4	O
Test	O
Rule	O
program	O
.	O

Fatal	O
toxic	B
epidermal	I
necrolysis	I
and	O
severe	O
granulocytopenia	B
following	O
therapy	O
with	O
cefuroxime	O
.	O

Toxic	B
epidermal	I
necrolysis	I
(	O
TEN	B
)	O
is	O
one	O
of	O
the	O
most	O
threatening	O
adverse	O
reactions	O
to	O
various	O
drugs	O
.	O

No	O
case	O
of	O
concomitant	O
occurrence	O
TEN	B
and	O
severe	O
granulocytopenia	B
following	O
the	O
treatment	O
with	O
cefuroxime	O
has	O
been	O
reported	O
to	O
date	O
.	O

Herein	O
we	O
present	O
a	O
case	O
of	O
TEN	B
that	O
developed	O
eighteen	O
days	O
of	O
the	O
initiation	O
of	O
cefuroxime	O
axetil	O
therapy	O
for	O
urinary	B
tract	I
infection	I
in	O
a	O
73	O
-	O
year	O
-	O
old	O
woman	O
with	O
chronic	B
renal	I
failure	I
and	O
no	O
previous	O
history	O
of	O
allergic	B
diathesis	I
.	O

The	O
condition	O
was	O
associated	O
with	O
severe	O
granulocytopenia	B
and	O
followed	O
by	O
gastrointestinal	B
hemorrhage	I
,	O
severe	O
sepsis	B
and	O
multiple	B
organ	I
failure	I
syndrome	I
development	O
.	O

Despite	O
intensive	O
medical	O
treatment	O
the	O
patient	O
died	O
.	O

The	O
present	O
report	O
underlines	O
the	O
potential	O
of	O
cefuroxime	O
to	O
simultaneously	O
induce	O
life	O
threatening	O
adverse	O
effects	O
such	O
as	O
TEN	B
and	O
severe	O
granulocytopenia	B
.	O

Further	O
on	O
,	O
because	O
the	O
patient	O
was	O
also	O
taking	O
furosemide	O
for	O
chronic	B
renal	I
failure	I
,	O
the	O
possible	O
unfavorable	O
interactions	O
between	O
the	O
two	O
drugs	O
could	O
be	O
hypothesized	O
.	O

Therefore	O
,	O
awareness	O
of	O
the	O
possible	O
drug	O
interaction	O
is	O
necessary	O
,	O
especially	O
when	O
given	O
in	O
conditions	O
of	O
their	O
altered	O
pharmacokinetics	O
as	O
in	O
case	O
of	O
chronic	B
renal	I
failure	I
.	O

Spatial	O
and	O
temporal	O
aspects	O
of	O
muscle	B
hyperalgesia	I
induced	O
by	O
nerve	O
growth	O
factor	O
in	O
humans	O
.	O

Intramuscular	O
injection	O
of	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
has	O
been	O
shown	O
to	O
induce	O
long	O
-	O
term	O
sensitisation	O
and	O
time	O
-	O
dependent	O
hyperalgesia	B
indicating	O
potential	O
involvement	O
of	O
both	O
central	O
and	O
peripheral	O
pain	B
mechanisms	O
.	O

This	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
was	O
designed	O
to	O
describe	O
the	O
spatial	O
distribution	O
of	O
muscle	B
hyperalgesia	I
over	O
time	O
(	O
immediately	O
after	O
,	O
3	O
h	O
,	O
1	O
,	O
4	O
,	O
7	O
and	O
21	O
days	O
)	O
after	O
injecting	O
NGF	O
(	O
5	O
mug	O
)	O
into	O
the	O
tibialis	O
anterior	O
(	O
TA	O
)	O
muscle	O
,	O
to	O
explore	O
possibly	O
involved	O
central	O
pain	B
mechanisms	O
and	O
to	O
investigate	O
the	O
effect	O
of	O
gender	O
on	O
development	O
of	O
hyperalgesia	B
.	O

Totally	O
20	O
healthy	O
volunteers	O
(	O
10	O
men	O
and	O
10	O
women	O
)	O
participated	O
in	O
the	O
study	O
.	O

An	O
isotonic	O
saline	O
injection	O
into	O
the	O
contralateral	O
TA	O
muscle	O
served	O
as	O
a	O
control	O
condition	O
for	O
the	O
NGF	O
injection	O
.	O

Pressure	O
pain	B
thresholds	O
(	O
PPT	O
)	O
were	O
used	O
to	O
test	O
for	O
muscle	B
hyperalgesia	I
along	O
the	O
TA	O
(	O
seven	O
sites	O
)	O
muscle	O
at	O
the	O
extensor	O
digitorum	O
longus	O
and	O
at	O
the	O
web	O
between	O
1st	O
and	O
2nd	O
metatarsal	O
(	O
central	O
involvement	O
)	O
.	O

One	O
day	O
after	O
the	O
NGF	O
/	O
control	O
injections	O
,	O
hypertonic	O
saline	O
(	O
0.5	O
ml	O
,	O
5.8	O
%	O
)	O
was	O
injected	O
into	O
the	O
left	O
and	O
right	O
TA	O
to	O
study	O
the	O
pain	B
response	O
to	O
chemical	O
stimulation	O
of	O
the	O
hyperalgesic	O
muscle	O
tissue	O
.	O

Scores	O
on	O
a	O
modified	O
Likert	O
scale	O
were	O
used	O
to	O
assess	O
soreness	O
during	O
muscle	O
function	O
.	O

An	O
area	O
of	O
hyperalgesia	B
was	O
observed	O
locally	O
at	O
the	O
injected	O
site	O
3	O
h	O
after	O
injection	O
of	O
NGF	O
,	O
which	O
expanded	O
both	O
proximally	O
and	O
distally	O
on	O
day	O
1	O
;	O
this	O
effect	O
subsided	O
on	O
day	O
4	O
.	O

Decreased	O
PPT	O
was	O
also	O
found	O
between	O
1st	O
and	O
2nd	O
metatarsal	O
on	O
day	O
1	O
.	O

Hypertonic	O
saline	O
evoked	O
more	O
pain	B
in	O
men	O
when	O
injected	O
in	O
the	O
NGF	O
treated	O
TA	O
compared	O
to	O
the	O
control	O
leg	O
.	O

Injection	O
of	O
NGF	O
increased	O
muscle	B
soreness	I
during	O
muscle	O
activity	O
for	O
7	O
days	O
.	O

In	O
this	O
material	O
there	O
was	O
no	O
gender	O
effect	O
of	O
NGF	O
-	O
induced	O
muscle	B
hyperalgesia	I
.	O

The	O
expansion	O
of	O
muscle	B
hyperalgesia	I
to	O
distant	O
areas	O
indicates	O
that	O
central	O
mechanisms	O
are	O
involved	O
.	O

Occupational	O
hazard	O
:	O
treating	O
cocaine	O
body	O
packers	O
in	O
Caribbean	O
countries	O
.	O

Body	O
packing	O
is	O
a	O
common	O
method	O
of	O
smuggling	O
cocaine	O
where	O
individuals	O
ingest	O
several	O
drug	O
-	O
filled	O
parcels	O
for	O
transport	O
.	O

When	O
identified	O
by	O
the	O
authorities	O
,	O
body	O
packers	O
are	O
usually	O
taken	O
to	O
hospital	O
for	O
evaluation	O
.	O

There	O
are	O
several	O
points	O
during	O
management	O
of	O
these	O
patients	O
when	O
the	O
health	O
care	O
team	O
may	O
be	O
placed	O
at	O
risk	O
.	O

We	O
explore	O
the	O
hazards	O
encountered	O
during	O
the	O
management	O
of	O
these	O
patients	O
in	O
developing	O
Caribbean	O
nations	O
.	O

The	O
addition	O
of	O
rituximab	O
to	O
front	O
-	O
line	O
therapy	O
with	O
CHOP	O
(	O
R	O
-	O
CHOP	O
)	O
results	O
in	O
a	O
higher	O
response	O
rate	O
and	O
longer	O
time	O
to	O
treatment	O
failure	O
in	O
patients	O
with	O
lymphoplasmacytic	B
lymphoma	I
:	O
results	O
of	O
a	O
randomized	O
trial	O
of	O
the	O
German	O
Low	O
-	O
Grade	O
Lymphoma	B
Study	O
Group	O
(	O
GLSG	O
)	O
.	O

Lymphoplasmacytic	B
lymphoma	I
(	O
LPL	B
)	O
is	O
an	O
indolent	O
lymphoma	B
with	O
moderate	O
sensitivity	O
to	O
conventional	O
chemotherapy	O
.	O

This	O
study	O
investigated	O
whether	O
the	O
addition	O
of	O
rituximab	O
to	O
standard	O
chemotherapy	O
improves	O
treatment	O
outcome	O
in	O
LPL	B
and	O
the	O
subgroup	O
of	O
LPL	B
patients	O
fulfilling	O
the	O
criteria	O
of	O
Waldenstroem	B
's	I
macroglobulinemia	I
(	O
WM	B
)	O
.	O

A	O
total	O
of	O
69	O
patients	O
with	O
previously	O
untreated	O
LPL	B
were	O
enrolled	O
into	O
the	O
trial	O
;	O
64	O
patients	O
were	O
evaluable	O
for	O
treatment	O
outcome	O
.	O

In	O
all	O
,	O
48	O
of	O
the	O
64	O
LPL	B
patients	O
fulfilled	O
the	O
criteria	O
of	O
WM	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
R	O
-	O
CHOP	O
(	O
rituximab	O
,	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
vincristine	O
and	O
prednisone	O
,	O
n	O
=	O
34	O
)	O
or	O
CHOP	O
(	O
n	O
=	O
30	O
)	O
.	O

R	O
-	O
CHOP	O
resulted	O
in	O
significantly	O
higher	O
overall	O
response	O
(	O
OR	O
)	O
rate	O
(	O
94	O
vs	O
67	O
%	O
,	O
P	O
=	O
0.0085	O
)	O
in	O
the	O
LPL	B
patients	O
and	O
in	O
the	O
WM	B
subgroup	O
(	O
91	O
vs	O
60	O
%	O
,	O
P	O
=	O
0.0188	O
)	O
.	O

With	O
a	O
median	O
observation	O
time	O
of	O
42	O
months	O
,	O
R	O
-	O
CHOP	O
induced	O
a	O
significantly	O
longer	O
time	O
to	O
treatment	O
failure	O
(	O
TTF	O
)	O
with	O
a	O
median	O
of	O
63	O
months	O
for	O
R	O
-	O
CHOP	O
vs	O
22	O
months	O
in	O
the	O
CHOP	O
arm	O
in	O
the	O
LPL	B
patients	O
(	O
P	O
=	O
0.0033	O
)	O
and	O
in	O
the	O
WM	B
subgroup	O
(	O
P	O
=	O
0.0241	O
)	O
.	O

There	O
was	O
no	O
major	O
difference	O
of	O
treatment	B
-	I
associated	I
toxicity	I
between	O
both	O
treatment	O
groups	O
.	O

These	O
data	O
indicate	O
that	O
the	O
addition	O
of	O
rituximab	O
to	O
front	O
-	O
line	O
chemotherapy	O
improves	O
treatment	O
outcome	O
in	O
patients	O
with	O
LPL	B
or	O
WM	B
.	O

Novel	O
therapeutic	O
agents	O
targeting	O
the	O
glucocorticoid	O
receptor	O
for	O
inflammation	B
and	O
cancer	B
.	O

Glucocorticoids	O
,	O
through	O
their	O
interaction	O
with	O
the	O
ubiquitous	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
,	O
have	O
extensive	O
and	O
disparate	O
effects	O
on	O
different	O
cells	O
and	O
tissues	O
.	O

They	O
have	O
long	O
been	O
used	O
in	O
the	O
treatment	O
of	O
asthma	B
,	O
arthritis	B
and	O
autoimmune	B
diseases	I
based	O
on	O
their	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
effects	O
.	O

For	O
these	O
reasons	O
,	O
as	O
well	O
as	O
for	O
their	O
ability	O
to	O
induce	O
massive	O
apoptosis	O
in	O
hematological	B
malignancies	I
,	O
they	O
are	O
also	O
commonly	O
used	O
as	O
cotreatment	O
in	O
cancers	B
.	O

Despite	O
their	O
wide	O
usage	O
,	O
chronic	O
glucocorticoid	O
therapy	O
has	O
deleterious	O
side	O
effects	O
,	O
including	O
weight	O
gain	O
,	O
osteoporosis	B
and	O
diabetes	B
mellitus	I
,	O
and	O
has	O
been	O
shown	O
to	O
diminish	O
the	O
tumor	B
toxicity	I
of	O
chemotherapy	O
,	O
preventing	O
the	O
full	O
potential	O
of	O
glucocorticoid	O
treatment	O
from	O
being	O
realized	O
.	O

Technological	O
advances	O
have	O
contributed	O
to	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
glucocorticoid	O
action	O
,	O
prompting	O
the	O
development	O
of	O
tailored	O
therapeutics	O
targeting	O
the	O
desired	O
outcomes	O
of	O
GR	O
signaling	O
.	O

This	O
review	O
discusses	O
recent	O
advances	O
in	O
the	O
development	O
of	O
novel	O
therapeutic	O
agents	O
for	O
inflammation	B
and	O
cancer	B
through	O
targeting	O
the	O
GR	O
.	O

Inhibition	O
of	O
hydroxyapatite	O
dissolution	O
by	O
whole	O
casein	O
:	O
the	O
effects	O
of	O
pH	O
,	O
protein	O
concentration	O
,	O
calcium	O
,	O
and	O
ionic	O
strength	O
.	O

Formulating	O
drinks	O
with	O
reduced	O
erosive	O
potential	O
is	O
one	O
approach	O
for	O
reducing	O
dental	O
erosion	O
.	O

In	O
this	O
study	O
,	O
whole	O
casein	O
was	O
added	O
to	O
citric	O
acid	O
solutions	O
representative	O
of	O
soft	O
drinks	O
,	O
and	O
the	O
hydroxyapatite	O
dissolution	O
rate	O
was	O
assessed	O
.	O

Adding	O
0.02	O
%	O
(	O
w	O
/	O
v	O
)	O
casein	O
to	O
acid	O
solutions	O
significantly	O
reduced	O
the	O
hydroxyapatite	O
dissolution	O
rate	O
by	O
51	O
+	O
/	O
-	O
4	O
%	O
at	O
pH	O
values	O
of	O
2.80	O
,	O
3.00	O
,	O
3.20	O
,	O
3.40	O
,	O
and	O
3.60	O
,	O
although	O
the	O
baseline	O
dissolution	O
rates	O
of	O
course	O
varied	O
as	O
a	O
function	O
of	O
pH	O
.	O

The	O
protein	O
concentration	O
[	O
0.002	O
,	O
0.02	O
,	O
and	O
0.2	O
%	O
(	O
w	O
/	O
v	O
)	O
casein	O
]	O
had	O
no	O
significant	O
effect	O
on	O
dissolution	O
inhibition	O
.	O

Adding	O
both	O
casein	O
and	O
calcium	O
to	O
citric	O
acid	O
resulted	O
in	O
a	O
further	O
reduction	O
in	O
the	O
dissolution	O
rate	O
at	O
low	O
and	O
intermediate	O
calcium	O
concentrations	O
(	O
5	O
and	O
10	O
mM	O
)	O
but	O
not	O
at	O
higher	O
calcium	O
concentrations	O
(	O
20	O
and	O
50	O
mM	O
)	O
.	O

Ionic	O
strength	O
had	O
no	O
significant	O
impact	O
on	O
the	O
efficacy	O
of	O
casein	O
.	O

Casein	O
also	O
significantly	O
reduced	O
the	O
hydroxyapatite	O
dissolution	O
rate	O
when	O
the	O
hydroxyapatite	O
was	O
coated	O
with	O
a	O
salivary	O
pellicle	O
.	O

The	O
reduction	O
in	O
dissolution	O
rate	O
is	O
ascribed	O
to	O
firmly	O
adsorbed	O
casein	O
on	O
the	O
hydroxyapatite	O
surface	O
,	O
which	O
stabilizes	O
the	O
crystal	O
surface	O
and	O
inhibits	O
ion	O
detachment	O
.	O

A	O
phase	O
II	O
study	O
of	O
oxaliplatin	O
,	O
pemetrexed	O
,	O
and	O
bevacizumab	O
in	O
previously	O
treated	O
advanced	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
.	O

INTRODUCTION	O
:	O
Single	O
agent	O
chemotherapy	O
is	O
standard	O
for	O
second	O
and	O
third	O
line	O
treatment	O
of	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
(	O
NSCLC	B
)	O
.	O

Combination	O
therapy	O
to	O
date	O
has	O
not	O
proven	O
to	O
be	O
superior	O
to	O
single	O
agents	O
in	O
this	O
setting	O
,	O
often	O
adding	O
toxicity	O
without	O
any	O
additional	O
efficacy	O
.	O

We	O
investigated	O
the	O
activity	O
and	O
tolerability	O
of	O
the	O
combination	O
of	O
oxaliplatin	O
,	O
pemetrexed	O
,	O
and	O
bevacizumab	O
in	O
patients	O
with	O
previously	O
treated	O
advanced	O
NSCLC	B
.	O

METHODS	O
:	O
This	O
multicenter	O
phase	O
II	O
trial	O
evaluated	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
combination	O
of	O
pemetrexed	O
(	O
500	O
mg	O
/	O
m	O
)	O
,	O
oxaliplatin	O
(	O
120	O
mg	O
/	O
m	O
)	O
,	O
and	O
bevacizumab	O
(	O
15	O
mg	O
/	O
kg	O
)	O
,	O
given	O
every	O
21	O
days	O
,	O
in	O
patients	O
with	O
previously	O
treated	O
advanced	O
NSCLC	B
.	O

Eligibility	O
criteria	O
included	O
performance	O
status	O
0	O
to	O
1	O
,	O
nonsquamous	O
histology	O
,	O
and	O
at	O
least	O
one	O
prior	O
chemotherapy	O
regimen	O
.	O

Patients	O
with	O
treated	O
brain	B
metastases	I
were	O
allowed	O
.	O

The	O
primary	O
end	O
point	O
was	O
response	O
rate	O
,	O
with	O
secondary	O
endpoints	O
of	O
progression	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
six	O
patients	O
were	O
enrolled	O
on	O
this	O
study	O
.	O

Treatment	O
was	O
well	O
tolerated	O
;	O
the	O
most	O
common	O
grade	O
3	O
toxicity	O
was	O
hypertension	B
,	O
which	O
was	O
easily	O
managed	O
with	O
oral	O
medications	O
.	O

The	O
nine	O
(	O
25	O
%	O
)	O
patients	O
with	O
treated	O
brain	B
metastases	I
had	O
no	O
episodes	O
of	O
cerebral	B
hemorrhage	I
.	O

Of	O
the	O
34	O
patients	O
evaluable	O
for	O
tumor	B
response	O
,	O
none	O
had	O
complete	O
response	O
,	O
nine	O
(	O
27	O
%	O
)	O
had	O
partial	O
response	O
,	O
15	O
(	O
44	O
%	O
)	O
had	O
stable	O
disease	O
,	O
and	O
10	O
(	O
29	O
%	O
)	O
had	O
progressive	O
disease	O
.	O

Median	O
progression	O
-	O
free	O
survival	O
was	O
5.8	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
4.1	O
-	O
7.8	O
months	O
)	O
and	O
median	O
overall	O
survival	O
was	O
12.5	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
7.3	O
-	O
17	O
months	O
)	O
.	O

CONCLUSIONS	O
:	O
Treatment	O
with	O
oxaliplatin	O
and	O
pemetrexed	O
in	O
combination	O
with	O
the	O
targeted	O
antiangiogenic	O
agent	O
bevacizumab	O
yielded	O
promising	O
efficacy	O
with	O
manageable	O
toxicity	O
in	O
the	O
previously	O
treated	O
advanced	O
NSCLC	B
population	O
.	O

Early	O
-	O
onset	O
pancytopenia	B
and	O
skin	B
ulcer	I
following	O
low	O
-	O
dose	O
methotrexate	O
therapy	O
.	O

Pancytopenia	B
is	O
a	O
rare	O
but	O
serious	O
adverse	O
effect	O
of	O
low	O
-	O
dose	O
methotrexate	O
(	O
MTX	O
)	O
sodium	O
therapy	O
,	O
and	O
this	O
case	O
report	O
describes	O
a	O
very	O
early	O
-	O
onset	O
of	O
pancytopenia	B
and	O
cutaneous	B
lesions	I
after	O
three	O
days	O
of	O
ingestion	O
.	O

A	O
64	O
-	O
year	O
-	O
old	O
man	O
was	O
presented	O
to	O
Emergency	O
Department	O
with	O
weakness	B
,	O
fever	B
,	O
poor	B
appetite	I
,	O
nausea	B
,	O
and	O
vomiting	B
after	O
he	O
had	O
had	O
accidentally	O
ingested	O
MTX	O
tablets	O
(	O
2.5	O
mg	O
)	O
twice	O
a	O
day	O
for	O
the	O
last	O
three	O
days	O
.	O

On	O
initial	O
examination	O
,	O
several	O
painful	B
lesions	I
in	O
his	O
oral	O
mucosa	O
and	O
a	O
cutaneous	B
ulceration	I
on	O
his	O
right	O
foot	O
were	O
also	O
observed	O
.	O

He	O
had	O
severe	O
pancytopenia	B
,	O
poor	O
kidney	O
functions	O
,	O
and	O
abnormal	B
coagulation	I
parameters	O
.	O

The	O
blood	O
level	O
of	O
MTX	O
was	O
found	O
to	O
be	O
within	O
therapeutic	O
range	O
.	O

He	O
was	O
treated	O
with	O
leucovorine	O
,	O
intravenous	O
antibiotics	O
,	O
and	O
appropriate	O
blood	O
transfusions	O
;	O
he	O
was	O
discharged	O
from	O
hospital	O
without	O
any	O
sequela	O
.	O

Pancytopenia	B
associated	O
with	O
low	O
-	O
dose	O
(	O
cumulative	O
dose	O
of	O
15	O
mg	O
in	O
3	O
days	O
)	O
MTX	O
therapy	O
had	O
not	O
been	O
reported	O
previously	O
.	O

The	O
Naranjo	O
probability	O
scale	O
showed	O
pancytopenia	B
and	O
skin	B
ulcer	I
associated	O
with	O
low	O
-	O
dose	O
MTX	O
therapy	O
as	O
probable	O
adverse	O
reactions	O
.	O

Risk	O
factors	O
for	O
pancytopenia	B
such	O
as	O
renal	B
insufficiency	I
,	O
hypoalbuminemia	B
,	O
low	O
folate	O
levels	O
,	O
concomitant	B
infections	I
,	O
concomitant	O
use	O
of	O
drugs	O
,	O
and	O
folate	O
supplementation	O
were	O
not	O
identified	O
in	O
our	O
patient	O
.	O

Although	O
pancytopenia	B
associated	O
with	O
low	O
-	O
dose	O
MTX	O
therapy	O
is	O
not	O
expected	O
as	O
early	O
as	O
3	O
days	O
after	O
initiation	O
of	O
the	O
therapy	O
,	O
physicians	O
should	O
also	O
be	O
aware	O
of	O
this	O
life	O
threatening	O
adverse	O
effect	O
during	O
the	O
very	O
first	O
days	O
of	O
MTX	O
therapy	O
for	O
rheumatoid	B
arthritis	I
patients	O
.	O

Limited	O
place	O
for	O
plasma	O
monitoring	O
of	O
new	O
antiepileptic	O
drugs	O
in	O
clinical	O
practice	O
.	O

Therapeutic	O
drug	O
monitoring	O
(	O
TDM	O
)	O
has	O
been	O
recognized	O
as	O
a	O
useful	O
guide	O
in	O
the	O
clinical	O
management	O
of	O
patients	O
with	O
epilepsy	B
,	O
in	O
particular	O
those	O
on	O
therapy	O
with	O
traditional	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
.	O

The	O
demonstration	O
of	O
significant	O
drug	O
interactions	O
and	O
the	O
introduction	O
of	O
the	O
concept	O
""""	O
therapeutic	O
range	O
""""	O
have	O
also	O
contributed	O
to	O
the	O
view	O
that	O
monotherapy	O
should	O
be	O
considered	O
the	O
""""	O
gold	O
standard	O
""""	O
in	O
the	O
treatment	O
of	O
epilepsy	B
.	O

Ten	O
new	O
AEDs	O
have	O
been	O
approved	O
and	O
released	O
to	O
the	O
market	O
in	O
the	O
last	O
fifteen	O
years	O
.	O

The	O
most	O
obvious	O
consequence	O
has	O
been	O
an	O
increased	O
number	O
of	O
patients	O
on	O
polytherapy	O
.	O

In	O
general	O
,	O
newer	O
AEDs	O
have	O
better	O
and	O
more	O
predictable	O
pharmacokinetics	O
than	O
older	O
AEDs	O
and	O
usually	O
show	O
lower	O
risk	O
of	O
interactions	O
leading	O
to	O
toxicity	O
as	O
well	O
as	O
large	O
therapeutic	O
indexes	O
.	O

This	O
pragmatic	O
review	O
focuses	O
on	O
practical	O
suggestions	O
about	O
the	O
potential	O
clinical	O
usefulness	O
of	O
TDM	O
of	O
newer	O
AEDs	O
in	O
relation	O
to	O
their	O
mechanism	O
of	O
action	O
and	O
pharmacokinetic	O
characteristics	O
and	O
in	O
response	O
to	O
patient	O
-	O
specific	O
problems	O
.	O

Overall	O
,	O
the	O
usefulness	O
of	O
TDM	O
of	O
newer	O
AEDs	O
seems	O
to	O
be	O
limited	O
and	O
its	O
indiscriminate	O
use	O
is	O
not	O
justified	O
.	O

However	O
,	O
in	O
selected	O
cases	O
or	O
in	O
response	O
to	O
a	O
specific	O
clinical	O
question	O
,	O
a	O
wise	O
use	O
of	O
TDM	O
of	O
some	O
new	O
AEDs	O
could	O
represent	O
a	O
useful	O
tool	O
in	O
the	O
management	O
of	O
epileptic	O
patients	O
.	O

Exceptions	O
are	O
thus	O
represented	O
by	O
special	O
conditions	O
such	O
as	O
renal	B
failure	I
,	O
dialysis	O
,	O
ascertainment	O
of	O
non	O
-	O
compliance	O
,	O
and	O
pregnancy	O
.	O

For	O
some	O
new	O
AEDs	O
,	O
TDM	O
could	O
be	O
selectively	O
and	O
properly	O
used	O
in	O
response	O
to	O
a	O
single	O
patient	O
-	O
specific	O
pharmacokinetic	O
or	O
pharmacodynamic	O
issue	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
bile	O
acid	O
dimers	O
linked	O
with	O
1,2,3	O
-	O
triazole	O
and	O
bis	O
-	O
beta	O
-	O
lactam	O
.	O

We	O
report	O
herein	O
the	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
bile	O
acid	O
dimers	O
linked	O
through	O
1,2,3	O
-	O
triazole	O
and	O
bis	O
-	O
beta	O
-	O
lactam	O
.	O

The	O
dimers	O
were	O
synthesized	O
using	O
1,3	O
-	O
dipolar	O
cycloaddition	O
reaction	O
of	O
diazido	O
bis	O
-	O
beta	O
-	O
lactams	O
,	O
and	O
terminal	O
alkynes	O
derived	O
from	O
cholic	O
acid	O
/	O
deoxycholic	O
acid	O
in	O
the	O
presence	O
of	O
Cu	O
(	O
i	O
)	O
catalyst	O
(	O
click	O
chemistry	O
)	O
.	O

These	O
novel	O
molecules	O
were	O
evaluated	O
in	O
vitro	O
for	O
their	O
antifungal	O
and	O
antibacterial	O
activity	O
.	O

Most	O
of	O
the	O
compounds	O
exhibited	O
significant	O
antifungal	O
as	O
well	O
as	O
antibacterial	O
activity	O
against	O
all	O
the	O
tested	O
fungal	O
and	O
bacterial	O
strains	O
.	O

Moreover	O
,	O
their	O
in	O
vitro	O
cytotoxicities	B
towards	O
HEK	O
-	O
293	O
and	O
MCF	O
-	O
7	O
cells	O
were	O
also	O
established	O
.	O

Platinum	O
versus	O
non	O
-	O
platinum	O
chemotherapy	O
regimens	O
for	O
small	B
cell	I
lung	I
cancer	I
.	O

BACKGROUND	O
:	O
Small	B
cell	I
lung	I
cancer	I
(	O
SCLC	B
)	O
is	O
a	O
very	O
fast	O
growing	O
form	O
of	O
cancer	B
and	O
is	O
characterised	O
by	O
early	O
metastasis	B
.	O

As	O
a	O
result	O
,	O
chemotherapy	O
is	O
the	O
mainstay	O
of	O
treatment	O
.	O

A	O
number	O
of	O
different	O
platinum	O
-	O
based	O
chemotherapy	O
regimens	O
and	O
non	O
-	O
platinum	O
-	O
based	O
chemotherapy	O
regimens	O
have	O
been	O
used	O
for	O
the	O
treatment	O
of	O
SCLC	B
,	O
with	O
varying	O
results	O
.	O

This	O
review	O
was	O
conducted	O
to	O
analyse	O
the	O
data	O
from	O
these	O
trials	O
in	O
order	O
to	O
compare	O
their	O
effectiveness	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
effectiveness	O
of	O
platinum	O
chemotherapy	O
regimens	O
compared	O
with	O
non	O
-	O
platinum	O
chemotherapy	O
regimens	O
in	O
the	O
treatment	O
of	O
SCLC	B
with	O
respect	O
to	O
survival	O
,	O
tumour	B
response	O
,	O
toxicity	O
and	O
quality	O
of	O
life	O
.	O

SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
biomedical	O
literature	O
databases	O
CENTRAL	O
(	O
The	O
Cochrane	O
Library	O
2007	O
,	O
Issue	O
2	O
)	O
,	O
MEDLINE	O
,	O
EMBASE	O
and	O
CINAHL	O
from	O
1966	O
to	O
April	O
2007	O
.	O

In	O
addition	O
,	O
we	O
handsearched	O
reference	O
lists	O
from	O
relevant	O
resources	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
randomised	O
controlled	O
trials	O
involving	O
patients	O
with	O
pathologically	O
confirmed	O
(	O
cytological	O
or	O
histological	O
)	O
SCLC	B
and	O
the	O
use	O
of	O
a	O
platinum	O
-	O
based	O
chemotherapy	O
regimen	O
in	O
at	O
least	O
one	O
treatment	O
arm	O
and	O
a	O
non	O
-	O
platinum	O
-	O
based	O
chemotherapy	O
regimen	O
in	O
a	O
separate	O
arm	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Two	O
authors	O
independently	O
assessed	O
search	O
results	O
.	O

We	O
assessed	O
included	O
studies	O
for	O
methodological	O
quality	O
and	O
recorded	O
the	O
following	O
outcome	O
data	O
:	O
survival	O
,	O
tumour	B
response	O
,	O
toxicity	O
and	O
quality	O
of	O
life	O
.	O

We	O
combined	O
the	O
results	O
of	O
the	O
survival	O
,	O
tumour	B
response	O
and	O
toxicity	O
data	O
in	O
a	O
meta	O
-	O
analysis	O
.	O

MAIN	O
RESULTS	O
:	O
A	O
total	O
of	O
29	O
trials	O
involving	O
5530	O
patients	O
were	O
included	O
in	O
this	O
systematic	O
review	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
treatment	O
groups	O
in	O
terms	O
of	O
survival	O
at	O
6	O
months	O
,	O
12	O
months	O
and	O
24	O
months	O
.	O

There	O
was	O
also	O
no	O
statistically	O
significant	O
difference	O
in	O
terms	O
of	O
overall	O
tumour	B
response	O
.	O

However	O
,	O
platinum	O
-	O
based	O
treatment	O
regimens	O
did	O
have	O
a	O
significantly	O
higher	O
rate	O
of	O
complete	O
response	O
.	O

Platinum	O
-	O
based	O
chemotherapy	O
regimens	O
had	O
significantly	O
higher	O
rates	O
of	O
nausea	B
and	O
vomiting	B
,	O
anaemia	B
and	O
thrombocytopenia	B
toxicity	O
.	O

Three	O
trials	O
presented	O
quality	O
of	O
life	O
data	O
but	O
the	O
data	O
presented	O
were	O
not	O
complete	O
and	O
therefore	O
could	O
not	O
be	O
combined	O
in	O
a	O
meta	O
-	O
analysis	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
Platinum	O
-	O
based	O
chemotherapy	O
regimens	O
did	O
not	O
offer	O
a	O
statistically	O
significant	O
benefit	O
in	O
survival	O
or	O
overall	O
tumour	B
response	O
compared	O
with	O
non	O
-	O
platinum	O
-	O
based	O
regimens	O
.	O

However	O
,	O
platinum	O
-	O
based	O
chemotherapy	O
regimens	O
did	O
increase	O
complete	O
response	O
rates	O
,	O
at	O
the	O
cost	O
of	O
higher	O
adverse	O
events	O
including	O
nausea	B
and	O
vomiting	B
,	O
anaemia	B
and	O
thrombocytopenia	B
toxicity	O
.	O

These	O
data	O
suggest	O
non	O
-	O
platinum	O
chemotherapy	O
regimens	O
have	O
a	O
more	O
advantageous	O
risk	O
-	O
benefit	O
profile	O
.	O

This	O
systematic	O
review	O
highlights	O
the	O
lack	O
of	O
quality	O
of	O
life	O
data	O
in	O
trials	O
involving	O
chemotherapy	O
treatment	O
for	O
SCLC	B
.	O

With	O
poor	O
long	O
-	O
term	O
survival	O
associated	O
with	O
both	O
treatment	O
groups	O
,	O
the	O
issue	O
of	O
the	O
quality	O
of	O
the	O
survival	O
period	O
takes	O
on	O
even	O
more	O
significance	O
.	O

It	O
would	O
be	O
beneficial	O
for	O
future	O
trials	O
in	O
this	O
area	O
to	O
include	O
a	O
quality	O
of	O
life	O
assessment	O
.	O

Blood	O
pressure	B
lowering	O
efficacy	O
of	O
renin	O
inhibitors	O
for	O
primary	B
hypertension	I
.	O

BACKGROUND	O
:	O
Hypertension	B
is	O
a	O
chronic	O
condition	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
mortality	O
and	O
morbidity	O
.	O

The	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
is	O
an	O
important	O
target	O
site	O
for	O
five	O
antihypertensive	O
drug	O
classes	O
:	O
beta	O
blockers	O
,	O
renin	O
inhibitors	O
,	O
ACE	O
inhibitors	O
,	O
angiotensin	O
receptor	O
blockers	O
(	O
ARBs	O
)	O
and	O
aldosterone	O
inhibitors	O
.	O

Renin	O
is	O
the	O
enzyme	O
responsible	O
for	O
converting	O
angiotensinogen	O
to	O
angiotensin	O
I	O
,	O
which	O
is	O
then	O
converted	O
to	O
angiotensin	O
II	O
.	O

Renin	O
inhibitors	O
prevent	O
the	O
formation	O
of	O
both	O
angiotensin	O
I	O
and	O
angiotensin	O
II	O
.	O

Renin	O
inhibitors	O
do	O
not	O
affect	O
kinin	O
metabolism	O
and	O
may	O
produce	O
fewer	O
adverse	O
effects	O
than	O
ACE	O
inhibitors	O
such	O
as	O
dry	B
cough	I
or	O
angioedema	B
.	O

OBJECTIVES	O
:	O
To	O
quantify	O
the	O
dose	O
-	O
related	O
blood	O
pressure	B
lowering	O
efficacy	O
of	O
renin	O
inhibitors	O
versus	O
placebo	O
in	O
the	O
treatment	O
of	O
primary	B
hypertension	I
.	O

SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
following	O
databases	O
for	O
randomised	O
,	O
double	O
blind	B
,	O
placebo	O
-	O
controlled	O
trials	O
of	O
renin	O
inhibitors	O
:	O
Medline	O
(	O
1966	O
-	O
March	O
2008	O
)	O
,	O
EMBASE	O
(	O
1988	O
-	O
March	O
2008	O
)	O
,	O
Cochrane	O
CENTRAL	O
,	O
and	O
bibliographic	O
citations	O
from	O
retrieved	O
references	O
.	O

No	O
language	O
restrictions	O
were	O
applied	O
.	O

SELECTION	O
CRITERIA	O
:	O
Study	O
design	O
had	O
to	O
meet	O
the	O
following	O
criteria	O
:	O
double	O
-	O
blinded	O
,	O
placebo	O
-	O
controlled	O
;	O
random	O
allocation	O
to	O
a	O
specific	O
dose	O
of	O
renin	O
inhibitor	O
group	O
and	O
parallel	O
placebo	O
group	O
;	O
duration	O
of	O
follow	O
-	O
up	O
of	O
at	O
least	O
three	O
weeks	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Two	O
reviewers	O
independently	O
extracted	O
data	O
and	O
assessed	O
trial	O
quality	O
using	O
risk	O
of	O
bias	O
tables	O
.	O

Disagreements	O
were	O
resolved	O
by	O
discussion	O
or	O
a	O
third	O
reviewer	O
.	O

Data	O
synthesis	O
and	O
analyses	O
were	O
done	O
using	O
the	O
Cochrane	O
Review	O
Manager	O
software	O
,	O
RevMan	O
5	O
.	O

Data	O
for	O
continuous	O
variables	O
were	O
combined	O
using	O
a	O
weighted	O
mean	O
difference	O
method	O
.	O

Dichotomous	O
variables	O
were	O
analysed	O
using	O
relative	O
risk	O
.	O

MAIN	O
RESULTS	O
:	O
Six	O
trials	O
(	O
N	O
=	O
3694	O
)	O
met	O
the	O
inclusion	O
criteria	O
for	O
this	O
review	O
.	O

Aliskiren	O
was	O
the	O
only	O
renin	O
inhibitor	O
studied	O
in	O
these	O
studies	O
.	O

The	O
meta	O
-	O
analysis	O
shows	O
that	O
aliskiren	O
has	O
a	O
dose	O
-	O
related	O
both	O
systolic	O
/	O
diastolic	O
blood	O
pressure	B
lowering	O
effect	O
as	O
compared	O
to	O
placebo	O
:	O
aliskiren	O
75	O
mg	O
-	O
2.9	O
/	O
-	O
2.3	O
mmHg	O
,	O
aliskiren	O
150	O
mg	O
-	O
5.5	O
/	O
-	O
3.0	O
mmHg	O
,	O
aliskiren	O
300	O
mg	O
-	O
8.7	O
/	O
-	O
5.0	O
,	O
aliskiren	O
600	O
mg	O
-	O
11.4	O
/	O
-	O
6.6	O
mmHg	O
.	O

Aliskiren	O
300	O
mg	O
significantly	O
lowered	O
both	O
SBP	O
and	O
DBP	O
as	O
compared	O
to	O
aliskiren	O
150	O
mg	O
(	O
SBP	O
:	O
-	O
2.97	O
(	O
95	O
%	O
CI	O
-	O
3.99	O
,	O
-	O
1.95	O
)	O
and	O
DBP	O
:	O
-	O
1.66	O
(	O
95	O
%	O
CI	O
-	O
2.32	O
,	O
-	O
1.0	O
)	O
.	O

Aliskiren	O
has	O
no	O
effect	O
on	O
blood	O
pressure	B
variability	O
.	O

No	O
data	O
was	O
available	O
to	O
assess	O
the	O
effect	O
of	O
aliskiren	O
on	O
heart	O
rate	O
and	O
pulse	O
pressure	B
.	O

This	O
review	O
found	O
weak	O
evidence	O
that	O
with	O
short	O
-	O
term	O
use	O
,	O
aliskiren	O
does	O
not	O
increase	O
withdrawals	O
due	O
to	O
adverse	O
effects	O
as	O
compared	O
to	O
placebo	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
Aliskiren	O
has	O
a	O
dose	O
-	O
related	O
blood	O
pressure	B
lowering	O
effect	O
better	O
than	O
placebo	O
.	O

This	O
effect	O
is	O
similar	O
to	O
that	O
determined	O
for	O
ACE	O
inhibitors	O
and	O
ARBs	O
.	O

Fragrance	O
material	O
review	O
on	O
tricyclodecanyl	O
acetate	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
tricyclodecanyl	O
acetate	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

NRF2	O
as	O
a	O
determinant	O
of	O
cellular	O
resistance	O
in	O
retinoic	O
acid	O
cytotoxicity	B
.	O

Clinical	O
use	O
of	O
retinoic	O
acids	O
(	O
RA	O
)	O
is	O
hindered	O
by	O
toxicity	O
possibly	O
related	O
to	O
oxidative	O
stress	O
.	O

Recently	O
,	O
RA	O
at	O
relatively	O
low	O
concentrations	O
was	O
shown	O
to	O
inhibit	O
NRF2	O
and	O
the	O
expression	O
of	O
its	O
target	O
antioxidative	O
genes	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
RA	B
toxicity	I
may	O
result	O
from	O
cellular	O
inability	O
to	O
cope	O
with	O
resultant	O
oxidative	O
stress	O
.	O

Using	O
in	O
vitro	O
cell	O
and	O
in	O
vivo	O
mouse	O
models	O
,	O
we	O
report	O
that	O
RA	O
,	O
specifically	O
all	O
-	O
trans	O
-	O
RA	O
(	O
atRA	O
)	O
at	O
concentrations	O
implicated	O
in	O
toxicity	O
,	O
can	O
activate	O
NRF2	O
and	O
induce	O
NRF2	O
target	O
genes	O
,	O
particularly	O
the	O
subunits	O
of	O
the	O
rate	O
-	O
limiting	O
enzyme	O
of	O
glutathione	O
biosynthesis	O
,	O
glutamate	O
cysteine	O
ligase	O
(	O
GCLM	O
/	O
GCLC	O
)	O
.	O

RNA	O
interference	O
-	O
mediated	O
silencing	O
of	O
NRF2	O
,	O
but	O
not	O
of	O
retinoid	O
X	O
receptor	O
-	O
alpha	O
and	O
-	O
beta	O
,	O
reduced	O
basal	O
and	O
atRA	O
-	O
induced	O
GCLM	O
/	O
GCLC	O
gene	O
expression	O
.	O

Moreover	O
,	O
RA	O
increased	O
nuclear	O
accumulation	O
of	O
NRF2	O
,	O
antioxidant	O
response	O
element	O
(	O
ARE	O
)	O
reporter	O
activity	O
,	O
and	O
NRF2	O
occupancy	O
at	O
AREs	O
.	O

4	O
-	O
Hydroxynonenal	O
,	O
a	O
lipid	O
peroxidation	O
product	O
,	O
was	O
increased	O
by	O
RA	O
.	O

Inhibition	O
of	O
MEK1	O
/	O
ERK	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
significantly	O
suppressed	O
atRA	O
-	O
induced	O
NRF2	O
activation	O
and	O
ARE	O
-	O
regulated	O
gene	O
expression	O
,	O
reducing	O
cell	O
resistance	O
against	O
toxic	O
concentrations	O
of	O
RA	O
.	O

NRF2	O
-	O
silenced	O
cells	O
were	O
vulnerable	O
to	O
atRA	O
-	O
induced	O
mitochondrial	B
toxicity	I
and	O
apoptosis	O
.	O

In	O
conclusion	O
,	O
toxic	O
RA	O
activates	O
NRF2	O
,	O
thereby	O
triggering	O
an	O
adaptive	O
response	O
against	O
the	O
resultant	O
oxidative	O
stress	O
.	O

NRF2	O
enhancement	O
as	O
a	O
therapeutic	O
target	O
of	O
retinoid	O
toxicity	O
awaits	O
further	O
investigation	O
.	O

Renin	O
-	O
angiotensin	O
-	O
aldosterone	O
responsiveness	O
to	O
low	O
sodium	O
and	O
blood	O
pressure	O
reactivity	O
to	O
angiotensin	O
-	O
II	O
are	O
unrelated	O
to	O
cholesteryl	O
ester	O
transfer	O
protein	O
mass	O
in	O
healthy	O
subjects	O
.	O

BACKGROUND	O
:	O
The	O
blood	O
pressure	O
increase	O
associated	O
with	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
inhibitor	O
,	O
torcetrapib	O
is	O
probably	O
attributable	O
to	O
an	O
off	O
-	O
target	O
effect	O
but	O
it	O
is	O
unknown	O
whether	O
activation	O
of	O
the	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
(	O
RAAS	O
)	O
may	O
be	O
related	O
to	O
variation	O
in	O
the	O
plasma	O
CETP	O
level	O
.	O

We	O
questioned	O
whether	O
the	O
plasma	O
CETP	O
level	O
would	O
affect	O
RAAS	O
responsiveness	O
to	O
low	O
sodium	O
diet	O
and	O
the	O
blood	O
pressure	O
response	O
to	O
angiotensin	O
-	O
II	O
infusion	O
in	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
RAAS	O
parameters	O
and	O
blood	O
pressure	O
were	O
determined	O
during	O
liberal	O
sodium	O
diet	O
(	O
200	O
mmol	O
/	O
24	O
h	O
)	O
and	O
low	O
sodium	O
diet	O
(	O
50	O
mmol	O
/	O
24	O
h	O
)	O
in	O
67	O
healthy	O
men	O
.	O

Blood	O
pressure	O
response	O
to	O
incremental	O
angiotensin	O
-	O
II	O
infusion	O
was	O
assessed	O
in	O
34	O
subjects	O
during	O
liberal	O
sodium	O
diet	O
.	O

Correlation	O
analysis	O
was	O
performed	O
to	O
test	O
whether	O
RAAS	O
responsiveness	O
and	O
blood	O
pressure	O
were	O
related	O
to	O
plasma	O
CETP	O
mass	O
,	O
high	O
-	O
density	O
lipoprotein	O
-	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
and	O
apolipoprotein	O
A	O
-	O
I	O
measured	O
during	O
liberal	O
sodium	O
diet	O
.	O

RESULTS	O
:	O
CETP	O
mass	O
ranged	O
from	O
1.29	O
to	O
2.95	O
mg	O
/	O
l	O
.	O

No	O
significant	O
differences	O
in	O
(	O
changes	O
)	O
in	O
mean	O
arterial	O
pressure	O
,	O
aldosterone	O
and	O
active	O
plasma	O
renin	O
concentration	O
in	O
response	O
to	O
low	O
sodium	O
were	O
observed	O
between	O
the	O
lowest	O
and	O
highest	O
tertiles	O
of	O
CETP	O
mass	O
,	O
HDL	O
-	O
C	O
and	O
apolipoprotein	O
A	O
-	O
I	O
.	O

These	O
outcome	O
variables	O
were	O
also	O
not	O
significantly	O
correlated	O
with	O
CETP	O
,	O
HDL	O
-	O
C	O
and	O
apolipoprotein	O
A	O
-	O
I	O
,	O
except	O
for	O
a	O
modest	O
relation	O
of	O
aldosterone	O
measured	O
during	O
low	O
sodium	O
with	O
apolipoprotein	O
A	O
-	O
I	O
(	O
r	O
=	O
0.28	O
,	O
p	O
=	O
0.022	O
)	O
.	O

Blood	O
pressure	O
response	O
to	O
angiotensin	O
-	O
II	O
was	O
similar	O
between	O
CETP	O
tertiles	O
.	O

CONCLUSIONS	O
:	O
Mineralocorticoid	O
and	O
blood	O
pressure	O
responsiveness	O
to	O
dietary	O
salt	O
intake	O
are	O
not	O
significantly	O
related	O
to	O
physiological	O
interindividual	O
differences	O
in	O
plasma	O
CETP	O
.	O

We	O
suggest	O
that	O
a	O
lower	O
CETP	O
mass	O
does	O
not	O
exert	O
adverse	O
effects	O
on	O
blood	O
pressure	O
regulation	O
.	O

D	O
-	O
chiro	O
-	O
inositol	O
-	O
enriched	O
tartary	O
buckwheat	O
bran	O
extract	O
lowers	O
the	O
blood	O
glucose	O
level	O
in	O
KK	O
-	O
Ay	O
mice	O
.	O

D	O
-	O
chiro	O
-	O
inositol	O
(	O
DCI	O
)	O
is	O
an	O
active	O
compound	O
in	O
tartary	O
buckwheat	O
[	O
Fagopyrum	O
tataricum	O
(	O
L	O
.	O
)	O

Gaench	O
]	O
with	O
an	O
insulin	O
-	O
like	O
bioactivity	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
(	O
i	O
)	O
prepare	O
DCI	O
-	O
enriched	O
tartary	O
buckwheat	O
bran	O
extract	O
(	O
TBBE	O
)	O
,	O
(	O
ii	O
)	O
evaluate	O
its	O
acute	B
toxicity	I
in	O
mice	O
,	O
and	O
(	O
iii	O
)	O
examine	O
its	O
blood	O
glucose	O
lowering	O
activity	O
in	O
diabetic	O
mice	O
.	O

It	O
was	O
found	O
that	O
steaming	O
buckwheat	O
bran	O
in	O
an	O
autoclave	O
at	O
1.6	O
MPa	O
and	O
120	O
degrees	O
C	O
for	O
60	O
min	O
could	O
significantly	O
enrich	O
the	O
DCI	O
level	O
in	O
TBBE	O
from	O
0.03	O
to	O
0.22	O
%	O
and	O
further	O
to	O
22	O
%	O
after	O
passage	O
of	O
the	O
TBBE	O
through	O
activated	O
carbon	O
and	O
ion	O
exchange	O
resins	O
.	O

An	O
acute	B
toxicity	I
test	O
demonstrated	O
that	O
the	O
LD	O
50	O
of	O
TBBE	O
was	O
>	O
20	O
g	O
/	O
kg	O
of	O
body	O
weight	O
in	O
mice	O
,	O
suggesting	O
that	O
TBBE	O
was	O
in	O
general	O
nontoxic	O
and	O
safe	O
in	O
mice	O
.	O

Male	O
KK	O
-	O
A	O
(	O
y	O
)	O
mice	O
(	O
type	B
2	I
diabetic	I
)	O
and	O
C57BL	O
/	O
6	O
mice	O
(	O
the	O
control	O
)	O
were	O
used	O
to	O
investigate	O
the	O
antidiabetic	O
activity	O
of	O
TBBE	O
.	O

In	O
KK	O
-	O
A	O
(	O
y	O
)	O
mice	O
,	O
the	O
blood	O
glucose	O
,	O
plasma	O
C	O
-	O
peptide	O
,	O
glucagon	O
,	O
total	O
cholesterol	O
,	O
triglyceride	O
,	O
and	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
levels	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
C57BL	O
/	O
6	O
mice	O
.	O

In	O
addition	O
,	O
KK	O
-	O
A	O
(	O
y	O
)	O
mice	O
showed	O
an	O
obvious	O
decrease	O
in	O
insulin	O
immunoreactivity	O
in	O
the	O
pancreas	O
.	O

The	O
present	O
study	O
clearly	O
demonstrated	O
that	O
oral	O
administration	O
of	O
DCI	O
-	O
enriched	O
TBBE	O
could	O
lower	O
plasma	O
glucose	O
,	O
C	O
-	O
peptide	O
,	O
glucagon	O
,	O
triglyceride	O
,	O
and	O
BUN	O
,	O
improve	O
glucose	O
tolerance	B
,	O
and	O
enhance	O
insulin	O
immunoreactivity	O
in	O
KK	O
-	O
A	O
(	O
y	O
)	O
mice	O
.	O

Optimal	O
timing	O
for	O
adjuvant	O
radiation	O
therapy	O
in	O
breast	B
cancer	I
:	O
a	O
comprehensive	O
review	O
and	O
perspectives	O
.	O

PURPOSE	O
:	O
The	O
optimal	O
sequence	O
of	O
modalities	O
involved	O
in	O
breast	B
cancer	I
treatment	O
with	O
respect	O
to	O
radiotherapy	O
and	O
the	O
maximum	O
acceptable	O
interval	O
between	O
radiotherapy	O
and	O
surgery	O
need	O
to	O
be	O
determined	O
.	O

DESIGN	O
:	O
This	O
review	O
attempts	O
a	O
critical	O
reading	O
of	O
the	O
literature	O
.	O

RESULTS	O
:	O
A	O
delay	O
of	O
radiotherapy	O
more	O
than	O
8	O
-	O
12	O
weeks	O
after	O
surgery	O
adversely	O
affects	O
local	O
recurrence	O
.	O

Radiotherapy	O
should	O
be	O
administered	O
within	O
7	O
months	O
after	O
surgery	O
,	O
when	O
chemotherapy	O
is	O
administered	O
first	O
.	O

Several	O
chemotherapy	O
regimens	O
can	O
be	O
safely	O
administered	O
concurrently	O
with	O
radiotherapy	O
.	O

The	O
concurrent	O
use	O
of	O
tamoxifen	O
with	O
chemotherapy	O
should	O
be	O
avoided	O
,	O
but	O
not	O
with	O
radiotherapy	O
.	O

Data	O
is	O
insufficient	O
with	O
regard	O
to	O
concurrent	O
use	O
of	O
aromatase	O
inhibitors	O
with	O
radiotherapy	O
.	O

The	O
use	O
of	O
trastuzumab	O
concomitantly	O
with	O
radiotherapy	O
may	O
enhance	O
toxicities	O
but	O
may	O
also	O
improve	O
its	O
efficacy	O
.	O

CONCLUSIONS	O
:	O
Although	O
the	O
issue	O
of	O
radiotherapy	O
delay	O
and	O
that	O
of	O
sequence	O
with	O
chemotherapy	O
or	O
tamoxifen	O
are	O
clarified	O
,	O
the	O
sequence	O
of	O
radiotherapy	O
with	O
aromatase	O
inhibitors	O
and	O
trastuzumab	O
needs	O
to	O
be	O
defined	O
.	O

Individual	O
radiosensitivity	O
may	O
influence	O
toxicity	O
.	O

New	O
biologic	O
markers	O
have	O
to	O
be	O
determined	O
in	O
the	O
future	O
for	O
tailoring	O
radiotherapy	O
in	O
breast	B
cancer	I
.	O

Determinants	O
of	O
negative	O
white	O
-	O
coat	O
effect	O
in	O
treated	O
hypertensive	O
patients	O
:	O
the	O
Jichi	O
Morning	O
Hypertension	B
Research	O
(	O
J	O
-	O
MORE	O
)	O
study	O
.	O

BACKGROUND	O
:	O
The	O
negative	O
white	O
-	O
coat	O
effect	O
(	O
WCE	O
)	O
,	O
a	O
phenomenon	O
in	O
which	O
out	O
-	O
of	O
-	O
office	O
blood	O
pressure	O
(	O
BP	O
)	O
is	O
higher	O
than	O
clinic	O
BP	O
,	O
has	O
not	O
been	O
well	O
examined	O
,	O
unlike	O
the	O
WCE	O
.	O

METHODS	O
:	O
As	O
part	O
of	O
the	O
Jichi	O
Morning	O
Hypertension	B
Research	O
study	O
,	O
in	O
which	O
clinic	O
and	O
home	O
BP	O
were	O
measured	O
in	O
969	O
hypertensive	O
outpatients	O
,	O
405	O
patients	O
with	O
normal	O
clinic	O
BP	O
were	O
separately	O
analyzed	O
.	O

Clinic	O
BP	O
was	O
measured	O
on	O
two	O
different	O
occasions	O
,	O
and	O
home	O
BP	O
was	O
measured	O
twice	O
in	O
the	O
morning	O
and	O
twice	O
in	O
the	O
evening	O
for	O
three	O
consecutive	O
days	O
.	O

Clinic	O
and	O
home	O
BP	O
were	O
each	O
averaged	O
from	O
all	O
readings	O
,	O
and	O
negative	O
WCE	O
was	O
defined	O
as	O
clinic	O
systolic	O
BP	O
(	O
SBP	O
)	O
lower	O
than	O
home	O
SBP	O
.	O

RESULTS	O
:	O
Negative	O
WCE	O
was	O
observed	O
in	O
324	O
(	O
33	O
%	O
)	O
of	O
the	O
patients	O
overall	O
and	O
in	O
173	O
(	O
42	O
%	O
)	O
of	O
the	O
patients	O
with	O
controlled	O
BP	O
(	O
clinic	O
BP	O
<	O
140	O
/	O
90	O
mm	O
Hg	O
)	O
.	O

In	O
multiple	O
logistic	O
regression	O
analysis	O
adjusting	O
for	O
covariates	O
including	O
home	O
SBP	O
and	O
pulse	O
rate	O
,	O
negative	O
WCE	O
was	O
correlated	O
with	O
older	O
age	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
1.03	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.01	O
-	O
1.06	O
)	O
and	O
male	O
gender	O
(	O
OR	O
1.08	O
,	O
95	O
%	O
CI	O
1.01	O
-	O
1.14	O
)	O
in	O
overall	O
subjects	O
.	O

Among	O
patients	O
with	O
well	O
-	O
controlled	O
clinic	O
BP	O
,	O
negative	O
WCE	O
was	O
significantly	O
correlated	O
with	O
the	O
presence	O
of	O
ischemic	B
heart	I
disease	I
(	O
OR	O
1.17	O
,	O
95	O
%	O
CI	O
1.04	O
-	O
1.31	O
)	O
.	O

The	O
association	O
of	O
negative	O
WCE	O
with	O
age	O
and	O
male	O
gender	O
remained	O
significant	O
under	O
stringent	O
criteria	O
(	O
negative	O
WCE	O
<	O
-	O
10.2	O
mm	O
Hg	O
(	O
the	O
mean	O
-	O
1	O
s	O
.	O

d	O
.	O
)	O
)	O
.	O

CONCLUSIONS	O
:	O
Negative	O
WCE	O
remaining	O
even	O
after	O
clinic	O
BP	O
is	O
controlled	O
may	O
be	O
related	O
to	O
cardiovascular	O
risk	O
factors	O
such	O
as	O
older	O
age	O
,	O
male	O
gender	O
,	O
and	O
a	O
history	O
of	O
ischemic	B
heart	I
disease	I
.	O

Addition	O
of	O
sildenafil	O
to	O
long	O
-	O
term	O
intravenous	O
epoprostenol	O
therapy	O
in	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
:	O
a	O
randomized	O
trial	O
.	O

BACKGROUND	O
:	O
Oral	O
sildenafil	O
and	O
intravenous	O
epoprostenol	O
have	O
independently	O
been	O
shown	O
to	O
be	O
effective	O
in	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
adding	O
oral	O
sildenafil	O
to	O
long	O
-	O
term	O
intravenous	O
epoprostenol	O
in	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
.	O

DESIGN	O
:	O
A	O
16	O
-	O
week	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
group	O
study	O
.	O

SETTING	O
:	O
Multinational	O
study	O
at	O
41	O
centers	O
in	O
11	O
countries	O
from	O
3	O
July	O
2003	O
to	O
27	O
January	O
2006	O
.	O

PATIENTS	O
:	O
267	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
(	O
idiopathic	O
,	O
associated	O
anorexigen	O
use	O
or	O
connective	B
tissue	I
disease	I
,	O
or	O
corrected	O
congenital	B
heart	I
disease	I
)	O
who	O
were	O
receiving	O
long	O
-	O
term	O
intravenous	O
epoprostenol	O
therapy	O
.	O

INTERVENTION	O
:	O
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	O
or	O
sildenafil	O
,	O
20	O
mg	O
three	O
times	O
daily	O
,	O
titrated	O
to	O
40	O
mg	O
and	O
80	O
mg	O
three	O
times	O
daily	O
,	O
as	O
tolerated	O
,	O
at	O
4	O
-	O
week	O
intervals	O
.	O

Of	O
265	O
patients	O
who	O
received	O
treatment	O
,	O
256	O
(	O
97	O
%	O
)	O
patients	O
(	O
123	O
in	O
the	O
placebo	O
group	O
and	O
133	O
in	O
the	O
sildenafil	O
group	O
)	O
completed	O
the	O
study	O
.	O

MEASUREMENTS	O
:	O
Change	O
from	O
baseline	O
in	O
exercise	O
capacity	O
measured	O
by	O
6	O
-	O
minute	O
walk	O
distance	O
(	O
primary	O
end	O
point	O
)	O
and	O
hemodynamic	O
measurements	O
,	O
time	O
to	O
clinical	O
worsening	O
,	O
and	O
Borg	O
dyspnea	B
score	O
(	O
secondary	O
end	O
points	O
)	O
.	O

RESULTS	O
:	O
A	O
placebo	O
-	O
adjusted	O
increase	O
of	O
28.8	O
meters	O
(	O
95	O
%	O
CI	O
,	O
13.9	O
to	O
43.8	O
meters	O
)	O
in	O
the	O
6	O
-	O
minute	O
walk	O
distance	O
occurred	O
in	O
patients	O
in	O
the	O
sildenafil	O
group	O
;	O
these	O
improvements	O
were	O
most	O
prominent	O
among	O
patients	O
with	O
baseline	O
distances	O
of	O
325	O
meters	O
or	O
more	O
.	O

Relative	O
to	O
epoprostenol	O
monotherapy	O
,	O
addition	O
of	O
sildenafil	O
resulted	O
in	O
a	O
greater	O
change	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
by	O
-	O
3.8	O
mm	O
Hg	O
(	O
CI	O
,	O
-	O
5.6	O
to	O
-	O
2.1	O
mm	O
Hg	O
)	O
;	O
cardiac	O
output	O
by	O
0.9	O
L	O
/	O
min	O
(	O
CI	O
,	O
0.5	O
to	O
1.2	O
L	O
/	O
min	O
)	O
;	O
and	O
longer	O
time	O
to	O
clinical	O
worsening	O
,	O
with	O
a	O
smaller	O
proportion	O
of	O
patients	O
experiencing	O
a	O
worsening	O
event	O
in	O
the	O
sildenafil	O
group	O
(	O
0.062	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
0.195	O
)	O
by	O
week	O
16	O
(	O
P	O
=	O
0.002	O
)	O
.	O

Health	O
-	O
related	O
quality	O
of	O
life	O
also	O
improved	O
in	O
patients	O
who	O
received	O
combined	O
therapy	O
compared	O
with	O
those	O
who	O
received	O
epoprostenol	O
monotherapy	O
.	O

There	O
was	O
no	O
effect	O
on	O
the	O
Borg	O
dyspnea	O
score	O
.	O

Of	O
the	O
side	O
effects	O
generally	O
associated	O
with	O
sildenafil	O
treatment	O
,	O
the	O
most	O
commonly	O
reported	O
in	O
the	O
placebo	O
and	O
sildenafil	O
groups	O
,	O
respectively	O
,	O
were	O
headache	B
(	O
34	O
%	O
and	O
57	O
%	O
;	O
difference	O
,	O
23	O
percentage	O
points	O
[	O
CI	O
,	O
12	O
to	O
35	O
percentage	O
points	O
]	O
)	O
,	O
dyspepsia	B
(	O
2	O
%	O
and	O
16	O
%	O
;	O
difference	O
,	O
13	O
percentage	O
points	O
[	O
CI	O
,	O
7	O
to	O
20	O
percentage	O
points	O
]	O
)	O
,	O
pain	B
in	O
extremity	O
(	O
18	O
%	O
and	O
25	O
%	O
;	O
difference	O
,	O
8	O
percentage	O
points	O
[	O
CI	O
,	O
-	O
2	O
to	O
18	O
percentage	O
points	O
]	O
)	O
,	O
and	O
nausea	B
(	O
18	O
%	O
and	O
25	O
%	O
;	O
difference	O
,	O
8	O
percentage	O
points	O
[	O
CI	O
,	O
-	O
2	O
to	O
18	O
percentage	O
points	O
]	O
)	O
.	O

LIMITATIONS	O
:	O
The	O
study	O
excluded	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
associated	O
with	O
other	O
causes	O
.	O

There	O
was	O
an	O
imbalance	O
in	O
missing	O
data	O
between	O
groups	O
,	O
with	O
8	O
placebo	O
recipients	O
having	O
no	O
postbaseline	O
walk	O
assessment	O
compared	O
with	O
1	O
sildenafil	O
recipient	O
.	O

These	O
patients	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O

CONCLUSION	O
:	O
In	O
some	O
patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
,	O
the	O
addition	O
of	O
sildenafil	O
to	O
long	O
-	O
term	O
intravenous	O
epoprostenol	O
therapy	O
improves	O
exercise	O
capacity	O
,	O
hemodynamic	O
measurements	O
,	O
time	O
to	O
clinical	O
worsening	O
,	O
and	O
quality	O
of	O
life	O
,	O
but	O
not	O
Borg	O
dyspnea	B
score	O
.	O

Increased	O
rates	O
of	O
headache	B
and	O
dyspepsia	B
occurred	O
with	O
the	O
addition	O
of	O
sildenafil	O
.	O

Capecitabine	O
:	O
have	O
we	O
got	O
the	O
dose	O
right	O
?	O

In	O
the	O
past	O
5	O
-	O
10	O
years	O
there	O
has	O
been	O
a	O
growing	O
trend	O
for	O
substituting	O
conventional	O
5	O
-	O
fluorouracil	O
with	O
the	O
oral	O
prodrug	O
of	O
5	O
-	O
fluorouracil	O
,	O
capecitabine	O
,	O
in	O
chemotherapy	O
regimens	O
.	O

This	O
regimen	O
change	O
is	O
based	O
on	O
evidence	O
of	O
the	O
efficacy	O
equivalence	O
of	O
these	O
two	O
drugs	O
and	O
the	O
lack	O
of	O
an	O
increase	O
in	O
overall	O
toxic	O
effects	O
when	O
capecitabine	O
is	O
used	O
.	O

Many	O
investigators	O
in	O
different	O
parts	O
of	O
the	O
world	O
have	O
determined	O
their	O
own	O
starting	O
dose	O
for	O
capecitabine	O
,	O
usually	O
based	O
on	O
their	O
experience	O
of	O
toxic	O
events	O
within	O
the	O
population	O
of	O
patients	O
they	O
treat	O
.	O

This	O
starting	O
dose	O
is	O
usually	O
between	O
1,000	O
-	O
1,250	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
which	O
is	O
generally	O
administered	O
twice	O
daily	O
for	O
14	O
days	O
followed	O
by	O
7	O
days	O
rest	O
.	O

This	O
Review	O
summarizes	O
why	O
there	O
may	O
indeed	O
not	O
be	O
a	O
universally	O
applicable	O
starting	O
dose	O
for	O
capecitabine	O
because	O
of	O
interpatient	O
differences	O
in	O
basic	O
physiology	O
,	O
pharmacogenomics	O
and	O
diet	O
.	O

This	O
article	O
also	O
explores	O
which	O
of	O
these	O
factors	O
contribute	O
to	O
the	O
observed	O
inter	O
-	O
regional	O
geographical	O
variation	O
in	O
capecitabine	O
toxicity	O
,	O
and	O
explains	O
why	O
even	O
within	O
a	O
region	O
various	O
factors	O
should	O
prompt	O
a	O
clinician	O
to	O
modify	O
the	O
starting	O
dose	O
.	O

Predicting	O
and	O
preventing	O
acute	B
kidney	I
injury	I
after	O
cardiac	O
surgery	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
Acute	B
kidney	I
injury	I
(	O
AKI	B
)	O
after	O
cardiac	O
surgery	O
is	O
associated	O
with	O
significant	O
morbidity	O
and	O
mortality	O
.	O

Despite	O
the	O
proliferation	O
of	O
predictive	O
clinical	O
scoring	O
models	O
of	O
renal	O
risk	O
after	O
cardiac	O
surgery	O
,	O
limitations	O
in	O
preventing	O
AKI	O
through	O
the	O
use	O
of	O
pharmacological	O
agents	O
remain	O
.	O

Here	O
we	O
review	O
the	O
evolution	O
of	O
predictive	O
models	O
of	O
renal	O
risk	O
after	O
cardiac	O
surgery	O
,	O
and	O
highlight	O
the	O
important	O
gains	O
made	O
in	O
preventing	O
its	O
occurrence	O
.	O

RECENT	O
FINDINGS	O
:	O
Simple	O
risk	O
indices	O
predicting	O
AKI	O
after	O
cardiac	O
surgery	O
have	O
been	O
developed	O
and	O
can	O
now	O
be	O
readily	O
applied	O
clinically	O
.	O

However	O
,	O
studies	O
focusing	O
on	O
preventing	O
AKI	O
after	O
surgery	O
have	O
yet	O
to	O
demonstrate	O
any	O
consistent	O
renoprotective	O
effect	O
.	O

SUMMARY	O
:	O
Clinical	O
scoring	O
systems	O
predicting	O
AKI	O
risk	O
after	O
cardiac	O
surgery	O
are	O
available	O
and	O
should	O
be	O
employed	O
in	O
the	O
preoperative	O
assessment	O
.	O

Elucidation	O
of	O
beneficial	O
preventive	O
strategies	O
of	O
AKI	O
after	O
cardiac	O
surgery	O
requires	O
ongoing	O
research	O
.	O

Transient	O
gene	O
delivery	O
for	O
functional	O
enrichment	O
of	O
differentiating	O
embryonic	O
stem	O
cells	O
.	O

There	O
is	O
a	O
critical	O
need	O
for	O
new	O
sources	O
of	O
hepatocytes	O
,	O
both	O
clinically	O
to	O
provide	O
support	O
for	O
patients	O
with	O
liver	B
failure	I
and	O
in	O
drug	O
discovery	O
for	O
toxicity	O
,	O
metabolic	O
and	O
pharmacokinetic	O
screening	O
of	O
new	O
drug	O
entities	O
.	O

We	O
have	O
reported	O
previously	O
a	O
variety	O
of	O
methods	O
for	O
differentiating	O
murine	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
into	O
hepatocyte	O
-	O
like	O
cells	O
.	O

One	O
major	O
challenge	O
of	O
our	O
work	O
and	O
others	O
in	O
the	O
field	O
has	O
been	O
the	O
ability	O
to	O
selectively	O
purify	O
and	O
enrich	O
these	O
cells	O
from	O
a	O
heterogeneous	O
population	O
.	O

Traditional	O
approaches	O
for	O
inserting	O
new	O
genes	O
(	O
e.g.	O
,	O
stable	O
transfection	O
,	O
knock	O
-	O
in	O
,	O
retroviral	O
transduction	O
)	O
involve	O
permanent	O
alterations	O
in	O
the	O
genome	O
.	O

These	O
approaches	O
can	O
lead	O
to	O
mutations	O
and	O
involve	O
the	O
extra	O
costs	O
and	O
time	O
of	O
developing	O
,	O
validating	O
and	O
maintaining	O
new	O
cell	O
lines	O
.	O

We	O
have	O
developed	O
a	O
transient	O
gene	O
delivery	O
system	O
that	O
uses	O
fluorescent	O
gene	O
reporters	O
for	O
purification	O
of	O
the	O
cells	O
.	O

Following	O
a	O
transient	O
transfection	O
,	O
the	O
cells	O
are	O
purified	O
through	O
a	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
(	O
FACS	O
)	O
,	O
re	O
-	O
plated	O
in	O
secondary	O
culture	O
and	O
subsequent	O
phenotypic	O
analysis	O
is	O
performed	O
.	O

In	O
an	O
effort	O
to	O
test	O
the	O
ability	O
of	O
the	O
reporters	O
to	O
work	O
in	O
a	O
transient	O
environment	O
for	O
our	O
differentiation	O
system	O
,	O
we	O
engineered	O
two	O
non	O
-	O
viral	O
plasmid	O
reporters	O
,	O
the	O
first	O
driven	O
by	O
the	O
mouse	O
albumin	O
enhancer	O
/	O
promoter	O
and	O
the	O
second	O
by	O
the	O
mouse	O
cytochrome	O
P450	O
7A1	O
(	O
Cyp7A1	O
)	O
promoter	O
.	O

We	O
optimized	O
the	O
transfection	O
efficiency	O
of	O
delivering	O
these	O
genes	O
into	O
spontaneously	O
differentiated	O
ES	O
cells	O
and	O
sorted	O
independent	O
fractions	O
positive	O
for	O
each	O
reporter	O
17	O
days	O
after	O
inducing	O
differentiation	O
.	O

We	O
found	O
that	O
cells	O
sorted	O
based	O
on	O
the	O
Cyp7A1	O
promoter	O
showed	O
significant	O
enrichment	O
in	O
terms	O
of	O
albumin	O
secretion	O
,	O
urea	O
secretion	O
and	O
cytochrome	O
P450	O
1A2	O
detoxification	O
activity	O
as	O
compared	O
to	O
enrichment	O
garnered	O
by	O
the	O
albumin	O
promoter	O
-	O
based	O
cell	O
sort	O
.	O

Development	O
of	O
gene	O
reporter	O
systems	O
that	O
allow	O
us	O
to	O
identify	O
,	O
purify	O
and	O
assess	O
homogeneous	O
populations	O
of	O
cells	O
is	O
important	O
in	O
better	O
understanding	O
stem	O
cell	O
differentiation	O
pathways	O
.	O

And	O
engineering	O
cellular	O
systems	O
without	O
making	O
permanent	O
gene	O
changes	O
will	O
be	O
critical	O
for	O
the	O
generation	O
of	O
clinically	O
acceptable	O
cellular	O
material	O
in	O
the	O
future	O
.	O

